<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants - Jasani, B - 2022 | Cochrane Library</title> <meta content="Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants - Jasani, B - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010061.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants - Jasani, B - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010061.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010061.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants" name="citation_title"/> <meta content="Bonny Jasani" name="citation_author"/> <meta content="Hospital for Sick Children" name="citation_author_institution"/> <meta content="Souvik Mitra" name="citation_author"/> <meta content="Dalhousie University &amp; IWK Health Centre" name="citation_author_institution"/> <meta content="Prakeshkumar S Shah" name="citation_author"/> <meta content="University of Toronto Mount Sinai Hospital" name="citation_author_institution"/> <meta content="prakeshkumar.shah@sinaihealth.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD010061.pub5" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/12/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010061.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010061.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010061.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Acetaminophen [adverse effects]; Drug Therapy, Combination [adverse effects]; *Ductus Arteriosus, Patent [drug therapy]; Ibuprofen [therapeutic use]; Indomethacin [therapeutic use]; Infant, Low Birth Weight; Infant, Premature; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010061.pub5&amp;doi=10.1002/14651858.CD010061.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="qy4lqFNF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010061\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010061\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","th","ms","ja","id","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010061.pub5",title:"Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants",firstPublishedDate:"Dec 15, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010061.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010061.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010061.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010061.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010061.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010061.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010061.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010061.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010061.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010061.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8585 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010061.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-sec-0157"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-sec-0151"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/appendices#CD010061-sec-0162"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/supinfo/CD010061StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/supinfo/CD010061StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information#CD010061-cr-0004">Bonny Jasani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information#CD010061-cr-0005">Souvik Mitra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information#CD010061-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Prakeshkumar S Shah</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information/en#CD010061-sec-0184">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 December 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010061.pub5">https://doi.org/10.1002/14651858.CD010061.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010061-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010061-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010061-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010061-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010061-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010061-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD010061-abs-0006">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010061-abs-0001" lang="en"> <section id="CD010061-sec-0001"> <h3 class="title" id="CD010061-sec-0001">Background</h3> <p>The different management strategies for patent ductus arteriosus (PDA) in preterm infants are expectant management, surgery, or medical treatment with non‐selective cyclo‐oxygenase inhibitors. Randomized controlled trials (RCTs) have suggested that paracetamol may be an effective and safe agent for the closure of a PDA. </p> </section> <section id="CD010061-sec-0002"> <h3 class="title" id="CD010061-sec-0002">Objectives</h3> <p>To determine the efficacy and safety of paracetamol as monotherapy or as part of combination therapy via any route of administration, compared with placebo, no intervention, or another prostaglandin inhibitor, for prophylaxis or treatment of an echocardiographically‐diagnosed PDA in preterm or low birth weight infants. </p> </section> <section id="CD010061-sec-0003"> <h3 class="title" id="CD010061-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, and three trials registers on 13 October 2021, and one other database on 1 March 2022. We also checked references and contacted study authors to identify additional studies. </p> </section> <section id="CD010061-sec-0004"> <h3 class="title" id="CD010061-sec-0004">Selection criteria</h3> <p>We included RCTs and quasi‐RCTs in which paracetamol (single‐agent or combination therapy) was compared to no intervention, placebo, or other agents used for closure of PDA, irrespective of dose, duration, and mode of administration in preterm infants. Two independent authors reviewed the search results and made a final selection of potentially eligible articles through discussion. </p> </section> <section id="CD010061-sec-0005"> <h3 class="title" id="CD010061-sec-0005">Data collection and analysis</h3> <p>We performed data collection and analyses in accordance with the methods of Cochrane Neonatal. We used the GRADE approach to assess the certainty of evidence for the following outcomes: failure of ductal closure after the first course of treatment; all‐cause mortality during initial hospital stay; and necrotizing enterocolitis (NEC). </p> </section> <section id="CD010061-sec-0006"> <h3 class="title" id="CD010061-sec-0006">Main results</h3> <p>For this update, we included 27 studies enrolling 2278 infants. We considered the overall risk of bias in the 27 studies to vary from low to unclear. We identified 24 ongoing studies. </p> <p><b>Paracetamol versus ibuprofen</b>  </p> <p>There was probably little to no difference between paracetamol and ibuprofen for failure of ductal closure after the first course (risk ratio (RR) 1.02, 95% confidence interval (CI) 0.88 to 1.18; 18 studies, 1535 infants; moderate‐certainty evidence). There was likely little to no difference between paracetamol and ibuprofen for all‐cause mortality during hospital stay (RR 1.09, 95% CI 0.80 to 1.48; 8 studies, 734 infants; moderate‐certainty evidence), and for NEC (RR 1.30, 95% CI 0.87 to 1.94; 10 studies, 1015 infants; moderate‐certainty evidence). </p> <p><b>Paracetamol versus indomethacin</b> </p> <p>There was little to no difference between paracetamol and indomethacin for failure of ductal closure after the first course (RR 1.02, 95% CI 0.78 to 1.33; 4 studies, 380 infants; low‐certainty evidence). There was little to no difference between paracetamol and indomethacin for all‐cause mortality during hospital stay (RR 0.86, 95% CI 0.39 to 1.92; 2 studies, 114 infants; low‐certainty evidence). The rate of NEC may be lower in the paracetamol group (3.7%) versus the indomethacin group(9.2%) (RR 0.42, 95% CI 0.19 to 0.96; 4 studies, 384 infants; low‐certainty evidence).  </p> <p><b>Prophylactic paracetamol versus placebo/no intervention</b> </p> <p>Prophylactic paracetamol (17%) compared to placebo/no intervention (61%) may reduce failure of ductal closure after one course (RR 0.27, 95% CI 0.18 to 0.42; 3 studies, 240 infants; low‐certainty evidence). There was little to no difference between prophylactic paracetamol and placebo/no intervention for all‐cause mortality during hospital stay (RR 0.59, 95% CI 0.24 to 1.44; 3 studies, 240 infants; low‐certainty evidence). No studies reported on NEC.  </p> <p><b>Early paracetamol treatment versus placebo/no intervention</b> </p> <p>Early paracetamol treatment (28%) compared to placebo/no intervention (79%) may reduce failure of ductal closure after one course when used before 14 days' postnatal age (RR 0.35, 95% CI 0.23 to 0.53; 2 studies, 127 infants; low‐certainty evidence). No studies reported on all‐cause mortality during hospital stay or NEC.  </p> <p><b>Late paracetamol treatment versus placebo/no intervention </b> </p> <p>There was little to no difference between late paracetamol and placebo for failure of ductal closure after one course of treatment when used at or after 14 days' postnatal age (RR 0.85, 95% CI 0.72 to 1.01; 1 study, 55 infants; low‐certainty evidence) or NEC (RR 1.04, 95% CI 0.07 to 15.76; 1 study, 55 infants; low‐certainty evidence). No data were reported for all‐cause mortality during hospital stay.  </p> <p><b>Paracetamol combined with ibuprofen versus ibuprofen combined with placebo or no intervention</b> </p> <p>There was little to no difference between paracetamol plus ibuprofen compared to ibuprofen plus placebo or no intervention for failure of ductal closure after the first course (RR 0.77, 95% CI 0.43 to 1.36; 2 studies, 111 infants; low‐certainty evidence). There was little to no difference between paracetamol plus ibuprofen compared to ibuprofen plus placebo or no intervention for NEC (RR 0.33, 95% CI 0.01 to 7.45; 1 study, 24 infants; low‐certainty evidence). No data were reported for all‐cause mortality during hospital stay.  </p> </section> <section id="CD010061-sec-0007"> <h3 class="title" id="CD010061-sec-0007">Authors' conclusions</h3> <p>Moderate‐certainty evidence suggests that there is probably little or no difference in effectiveness between paracetamol and ibuprofen; low‐certainty evidence suggests that there is probably little or no difference in effectiveness between paracetamol and indomethacin; low‐certainty evidence suggests that prophylactic paracetamol may be more effective than placebo/no intervention; low‐certainty evidence suggests that early paracetamol treatment may be more effective than placebo/no intervention; low‐certainty evidence suggests that there is probably little or no difference between late paracetamol treatment and placebo, and probably little or no difference in effectiveness between the combination of paracetamol plus ibuprofen versus ibuprofen alone for the closure of PDA after the first course of treatment. The majority of neonates included in these studies were of moderate preterm gestation. Thus, establishing the efficacy and safety of paracetamol for PDA treatment in extremely low birth weight (ELBW: birth weight &lt; 1000 grams) and extremely low gestational age neonates (ELGANs &lt; 28 weeks' gestation) requires further studies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010061-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010061-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010061-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010061-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010061-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/id#CD010061-abs-0010">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010061-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010061-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010061-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD010061-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010061-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010061-abs-0002" lang="en"> <h3>What are the benefits and risks of paracetamol (acetaminophen) for patent ductus arteriosus (PDA, a blood vessel necessary for fetal survival) in preterm and low birth weight infants? </h3> <p><b>Background</b>  </p> <p>A common complication for preterm (premature) or small babies is a patent ductus arteriosus (PDA). Blood circulation to the (as yet) non‐functioning lungs is unnecessary before birth. This is because the placenta delivers oxygen to the fetal blood supply. The PDA is a temporary fetal blood vessel that connects the pulmonary artery (the vessel that, after birth, takes blood depleted of oxygen from the heart to the lungs) to the aorta (the vessel that takes freshly oxygenated blood, returned from the lungs to the heart by the pulmonary vein, away from the heart and on the beginning of its journey around the body). In other words, the PDA ‘short‐circuits’ the fetal circulation of blood through the lungs. It is necessary to sustain life in the womb, but it should close after birth. Sometimes the PDA remains open because of the baby's immature stage of development. </p> <p>A PDA in preterm babies is associated with life‐threatening complications. The usual treatment for PDA has been the medicines indomethacin or ibuprofen, which inhibit the production of prostaglandins and promote the closure of the PDA. Prostaglandins are chemical compounds made throughout the body (i.e. not in any one particular organ), particularly wherever soft tissues are damaged. Their production (or 'synthesis') plays a key role in healing processes. They are known to play an important role in keeping the ductus arteriosus open (or 'patent'), so lowering their production would encourage closure of the ductus arteriosus. </p> <p>Recently, paracetamol (acetaminophen) – a commonly used medicine to treat fever or pain in infants, children, and adults – has been suggested as an alternative to ibuprofen, with potentially fewer side effects. A number of clinical trials have suggested that paracetamol may be an alternative for the closure of a PDA. Exactly how paracetamol works to close the PDA is not known, but probably involves inhibition of prostaglandin synthesis. </p> <p><b>What did we want to find out?</b> </p> <p>How effective and safe is paracetamol, which has weak anti‐inflammatory properties, compared with placebo (a substance with no active therapeutic effect), or no intervention, or non‐steroidal anti‐inflammatory medicines (indomethacin and ibuprofen), for closure of a PDA in preterm or low birth weight infants? </p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at short‐term (benefit and safety) and long‐term (neurodevelopmental) effects of paracetamol used either alone or in combination with ibuprofen compared to ibuprofen, indomethacin, placebo, or no intervention for prevention or treatment of a significant PDA in preterm or small babies. We subclassified treatment into early (&lt; 14 days of age) and late (≥ 14 days of age) treatment. </p> <p><b>What did we find?</b>  </p> <p>We identified 27 studies that enrolled 2278 preterm infants. These studies compared the efficacy and safety of paracetamol alone or in combination with ibuprofen versus ibuprofen, indomethacin, placebo, or no intervention for preventive treatment (prophylaxis) or treatment of a PDA. We identified 24 ongoing studies on this topic. </p> <p>When the results of the included studies were combined, we found:</p> <p>‐ the success rate for paracetamol to close a PDA was probably higher than that of placebo and likely similar to that of ibuprofen and indomethacin;<br/>‐ paracetamol appears to have fewer harmful effects on the kidney and intestine;<br/>‐ in two small studies that followed children to 24 months and five years of age, there was little to no difference in neurodevelopmental disability between the children given paracetamol and those given the non‐experimental medicine or placebo. </p> <p>For the key outcome of the closure of a PDA after the first course of treatment, we found: </p> <p>‐ moderate‐certainty evidence that there is probably little or no difference in effectiveness between paracetamol and ibuprofen; <br/>‐ low‐certainty evidence that there is probably little or no difference in effectiveness between paracetamol and indomethacin; <br/>‐ low‐certainty evidence that prophylactic paracetamol may be more effective than placebo/no intervention; <br/>‐ low‐certainty evidence that early paracetamol treatment may be more effective than placebo/no intervention; <br/>‐ low‐certainty evidence that there is probably little or no difference between late paracetamol treatment and placebo, <br/>‐ low‐certainty evidence that there is probably little or no difference in effectiveness between the combination of ibuprofen plus paracetamol and ibuprofen alone. </p> <p>The majority of infants included in these studies were of moderate preterm gestation. Thus, establishing the efficacy and safety of paracetamol for PDA treatment in extremely low gestational age babies (ELGANs: less than 28 weeks' gestation) or extremely low birth weight babies (ELBW: birth weight less than 1000 grams) requires further studies. </p> <p>The healthcare providers were not always 'blinded' (unaware of which drug the infants received) in the studies. Thus, we judged the quality (certainty) of the evidence to be moderate or low. </p> <p><b>How up to date is this evidence?</b> </p> <p>This review updates our previous review. The evidence is up to date to October 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010061-sec-0157" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010061-sec-0157"></div> <h3 class="title" id="CD010061-sec-0158">Implications for practice</h3> <section id="CD010061-sec-0158"> <p>For the closure of patent ductus arteriosus (PDA) after the first course of treatment: moderate‐certainty evidence suggests that there is probably little or no difference in effectiveness between paracetamol and ibuprofen; low‐certainty evidence suggests that there is probably little or no difference in effectiveness between paracetamol and indomethacin; low‐certainty evidence suggests that prophylactic paracetamol may be more effective than placebo/no intervention; low‐certainty evidence suggests early paracetamol treatment may be more effective than placebo/no intervention; low‐certainty evidence suggests that there is probably little or no difference between late paracetamol treatment and placebo, and probably little or no difference in effectiveness between combination of ibuprofen plus paracetamol and ibuprofen alone. </p> <p>The majority of neonates included in these studies were of moderate preterm gestation. Thus, the efficacy and safety of paracetamol for PDA treatment in extremely low gestational age neonates (ELGANs) and extremely low birth weight (ELBW) infants are not clearly established. Currently, there are at least 24 ongoing trials on this topic, and their published results may shed further light on these questions to produce firmer implications for practice. </p> </section> <h3 class="title" id="CD010061-sec-0159">Implications for research</h3> <section id="CD010061-sec-0159"> <p>In this review, we identified the following research gaps.</p> <p> <ul id="CD010061-list-0016"> <li> <p>Larger trials are required to increase the precision of the point estimates for the primary and secondary outcomes included in this review and improve the certainty of the evidence. </p> </li> <li> <p>In view of a report in mice of adverse effects on the developing brain from paracetamol (<a href="./references#CD010061-bbs2-0112" title="VibergH , ErikssonP , GordhT , FredrikssonA . Paracetamol (acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice. Toxicological Sciences2014;138(1):139-47. [DOI: 10.1093/toxsci/kft329] [PMID: 24361869]">Viberg 2014</a>), the association between postnatal use of paracetamol and autism and autism spectrum disorder (ASD) (<a href="./references#CD010061-bbs2-0059" title="BauerAZ , KriebelD . Prenatal and perinatal analgesic exposure and autism: an ecological link. Environmental Health2013;12:41. [DOI: 10.1186/1476-069X-12-41] [PMID: 23656698]">Bauer 2013</a>), and prenatal exposure to paracetamol and language delay in girls at 30 months (<a href="./references#CD010061-bbs2-0062" title="BornehagCG , ReichenbergA , HallerbackMU , WikstromS , KochHM , JonssonBA , et al. Prenatal exposure to acetaminophen and children's language development at 30 months. European Psychiatry2018;51:98-103. [DOI: 10.1016/j.eurpsy.2017.10.007] [PMID: 29331486]">Bornehag 2017</a>), the long‐term follow‐up to 18 to 24 months' postnatal age and preferably to school age should be incorporated in any studies of paracetamol to close a PDA or to prevent or treat pain. </p> </li> <li> <p>The majority of neonates studied in current trials included neonates of moderate preterm gestation; the efficacy and safety of paracetamol in ELGANs and ELBW neonates needs to be studied. </p> </li> <li> <p>The pharmacokinetics and pharmacodynamics of optimal dose and duration that would be effective in ductal constriction is not known; further studies are needed to establish these values. </p> </li> <li> <p>There is ongoing debate as to “whether to treat PDA or not” in the neonatal community and many units have adopted “treat all” or “treat none” approaches. This alteration in practice has stemmed from the fact that despite improvement in closure of PDA rates in placebo/no intervention trials, there was no change in any of the secondary outcomes questioning the efficacy of closure of PDA. This would mean that future trials of comparison with active pharmacological agents are as welcome as trials of comparison with placebo control. </p> </li> <li> <p>Combination therapy needs to be studied in larger trials to evaluate efficacy and safety in the short and long term. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010061-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010061-sec-0008"></div> <div class="table" id="CD010061-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paracetamol versus ibuprofen for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol (oral or IV) versus ibuprofen (oral or IV) for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm or low birth weight infants with PDA<br/><b>Settings:</b> hospitals in China, Egypt, Jordan, Iran, India, Italy, and Turkey<br/><b>Intervention:</b> paracetamol<br/><b>Comparison:</b> ibuprofen </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty  of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral/IV ibuprofen</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral/IV paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(assessed by post‐treatment ECHO)<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b><br/>(0.88 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1535<br/>(18 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>299 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b><br/>(266 to 355) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality during initial hospital stay</b><br/>(by clinical assessment) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.09</b><br/>(0.80 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>734<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>166 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b><br/>(133 to 245) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Necrotizing enterocolitis</b> <b>during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> <p>(61 to 136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.30</b><br/>(0.87 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1015<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>For all three key critical outcomes, we downgraded the evidence by one level to moderate certainty, due to concerns regarding blinding of personnel and outcome assessment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010061-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Paracetamol versus indomethacin for PDA in preterm or low birth weight infants </span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol (oral or IV) versus indomethacin (IV) for PDA in preterm or low birth weight infants </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with PDA </p> <p><b>Settings:</b> neonatal intensive care unit in India, Egypt, and the USA  </p> <p><b>Intervention:</b> paracetamol </p> <p><b>Comparison:</b> indomethacin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Indomethacin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(assessed by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b> (0.78 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>380<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>297 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>303 per 1000</b><br/>(232 to 395) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> <p>(73 to 358)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> (0.39 to 1.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>93 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> </p> <p>(18 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.42</b> (0.19 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded evidence by two levels to low certainty due to concerns regarding blinding of personnel and outcome assessment, and high heterogeneity.<br/><sup>b</sup>We downgraded evidence by two levels to low certainty due to concerns regarding blinding of personnel and outcome assessment, and imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010061-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prophylactic administration of paracetamol versus placebo or no intervention for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylactic administration of paracetamol (oral or IV) versus placebo (IV) or no intervention for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with PDA </p> <p><b>Settings:</b> neonatal intensive care units in Finland and Iran </p> <p><b>Intervention:</b> paracetamol </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of PDA closure after first course </b> </p> <p>(assessed by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.27</b> (0.18 to 0.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>612 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>165 per 1000</b><br/>(110 to 257) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.59</b> (0.24 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b><br/>(22 to 131) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Data not available</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the evidence by two levels to low certainty due to concerns regarding selection bias, blinding of personnel, and high heterogeneity.<br/><sup>b</sup>We downgraded the evidence by two levels to low certainty due to concerns regarding selection bias, blinding of personnel, and imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010061-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Early paracetamol versus placebo/no intervention for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Early paracetamol (oral or IV, &lt; 14 days postnatal age) versus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm or low birth weight infants with PDA<br/><b>Settings:</b> hospitals in Iran and Australia<br/><b>Intervention:</b> paracetamol<br/><b>Comparison:</b> placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty  of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral/IV paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.35</b> </p> <p>(0.23 TO 0.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>790 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>277 per 1000 </b> </p> <p>(182 to 419)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the evidence by two levels to low certainty due to concerns regarding selection bias, blinding of personnel and outcome assessors, and high heterogeneity. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010061-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Late paracetamol versus placebo/no intervention for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Late paracetamol (oral or IV, ≥ 14 days postnatal age) versus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm or low birth weight infants with PDA<br/><b>Settings:</b> hospital in Australia<br/><b>Intervention:</b> paracetamol<br/><b>Comparison:</b> placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty  of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oral/IV paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(assessed by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.85</b> </p> <p>(0.72 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>850 per 1000</b> </p> <p>(720 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> <p>(3 to 563)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> </p> <p>(0.07 to 15.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the evidence for both failure of PDA closure after first course of treatment and NEC by two levels to low certainty due to concerns regarding indirectness and imprecision.  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010061-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm or low birth weight infants with PDA<br/><b>Settings:</b> hospitals in Israel and Iran<br/><b>Intervention:</b> paracetamol plus ibuprofen<br/><b>Comparison:</b> ibuprofen plus placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ibuprofen plus placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Paracetamol plus ibuprofen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(assessed by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> <p>(134 to 425)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77</p> <p>(0.43 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> <p>(1 to 621)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.33</p> <p>(0.01 to 7.45)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the evidence for both failure of PDA closure after first course of treatment and NEC by two levels to low certainty due to concerns regarding selection bias, blinding of personnel, outcome assessment, and imprecision.  </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010061-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010061-sec-0009"></div> <section id="CD010061-sec-0010"> <h3 class="title" id="CD010061-sec-0010">Description of the condition</h3> <p>The ductus arteriosus connects the pulmonary artery to the descending aorta (<a href="./references#CD010061-bbs2-0065" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). Normal fetal circulation is dependent on the placenta and the patency of the ductus arteriosus (<a href="./references#CD010061-bbs2-0088" title="MathewR . Development of the pulmonary circulation: metabolic aspects. In: PolinRA , FoxWW , editors(s). Fetal and Neonatal Physiology. Vol. 1. Philadelphia (PA): W.B. Saunders, 1998:924-9.">Mathew 1998</a>). During fetal life, the ductus arteriosus diverts most of the combined ventricular output away from the lungs (<a href="./references#CD010061-bbs2-0065" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). Following birth, and with the separation of the placenta and initiation of breathing, the circulation changes and the ductus closes (<a href="./references#CD010061-bbs2-0088" title="MathewR . Development of the pulmonary circulation: metabolic aspects. In: PolinRA , FoxWW , editors(s). Fetal and Neonatal Physiology. Vol. 1. Philadelphia (PA): W.B. Saunders, 1998:924-9.">Mathew 1998</a>). In full‐term newborns, this happens within 24 to 48 hours after birth (<a href="./references#CD010061-bbs2-0065" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). In preterm newborns, the ductus frequently fails to close. The failure of the ductus arteriosus to constrict after birth is due to lower intrinsic tone, less ductal muscle fibre, and fewer subendothelial cushions in preterm as compared to term infants (<a href="./references#CD010061-bbs2-0073" title="HammermanC . Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clinics in Perinatology1995;22(2):457-79. [PMID: 7671547]">Hammerman 1995</a>). The immature ductus arteriosus has higher sensitivity to the vasodilating effects of prostaglandins and nitric oxide (<a href="./references#CD010061-bbs2-0073" title="HammermanC . Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clinics in Perinatology1995;22(2):457-79. [PMID: 7671547]">Hammerman 1995</a>). This is aggravated by hemodynamic derangements due to respiratory distress syndrome and surfactant therapy (<a href="./references#CD010061-bbs2-0073" title="HammermanC . Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clinics in Perinatology1995;22(2):457-79. [PMID: 7671547]">Hammerman 1995</a>). The clinical consequences of a PDA are related to the degree of left to right shunting through the ductus. Despite the ability of the left ventricle, in preterm infants, to increase its output in the face of a left to right shunt, blood flow distribution to vital organs is altered due to a drop in diastolic pressure and localised vasoconstriction (<a href="./references#CD010061-bbs2-0065" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). The presence of a PDA is associated with reduced middle cerebral artery blood flow velocity (<a href="./references#CD010061-bbs2-0114" title="WeirFJ , OhlssonA , MyhrTL , FongK , RyanML . A patent ductus arteriosus is associated with reduced middle cerebral artery blood flow velocity. European Journal of Pediatrics1999;158(6):484-7. [DOI: 10.1007/s004310051125] [PMID: 10378397]">Weir 1999</a>). The hemodynamic instability caused by the left to right shunt has been associated with gastrointestinal, cerebral, and renal effects, including spontaneous intestinal perforation and necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), decreased kidney function, and bronchopulmonary dysplasia (BPD) and, if not managed, may lead to death. To date, intervention studies with the intention of treatment and closure of PDA have failed to show a decrease in incidence in morbidity or mortality when the PDA is treated. Furthermore, many centers follow a conservative approach without an increase in morbidity or mortality (<a href="./references#CD010061-bbs2-0109" title="SungSI , ChangYS , ChunJY , YoonSA , YooHS , AhnSY , et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. Journal of Pediatrics2016;177:66-71. [DOI: 10.1016/j.jpeds.2016.06.046]">Sung 2016</a>).  </p> <p>In the two published Cochrane Reviews of prophylactic use of ibuprofen and indomethacin to close a PDA in preterm infants, the spontaneous closure rates in the control groups were 58% and 57%, respectively (<a href="./references#CD010061-bbs2-0070" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD000174. [DOI: 10.1002/14651858.CD000174.pub2]">Fowlie 2010</a>; <a href="./references#CD010061-bbs2-0094" title="OhlssonA , ShahSS . Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD004213. [DOI: 10.1002/14651858.CD004213.pub5]">Ohlsson 2020a</a>). </p> </section> <section id="CD010061-sec-0011"> <h3 class="title" id="CD010061-sec-0011">Description of the intervention</h3> <p>A PDA can be treated with expectant management (<a href="./references#CD010061-bbs2-0109" title="SungSI , ChangYS , ChunJY , YoonSA , YooHS , AhnSY , et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. Journal of Pediatrics2016;177:66-71. [DOI: 10.1016/j.jpeds.2016.06.046]">Sung 2016</a>), surgically, or medically with one of two prostaglandin inhibitors: indomethacin or ibuprofen. Surgical closure of a symptomatic PDA improves hemodynamics and lung compliance (<a href="./references#CD010061-bbs2-0090" title="NaultyCM , HornS , ConryJ , AveryGB . Improved lung compliance after ligation of patent ductus arteriosus in hyaline membrane disease. Journal of Pediatrics1978;93(4):682-4. [DOI: 10.1016/s0022-3476(78)80917-2] [PMID: 702251]">Naulty 1978</a>). However, medical treatment is still considered the treatment of choice because of the risks related to the surgery. In a large Canadian cohort (n = 3779) of very low birth weight infants, 28% received treatment for a PDA: 75% were treated with indomethacin alone, 8% with surgical ligation alone, and 17% received both indomethacin and surgical ligation (<a href="./references#CD010061-bbs2-0083" title="LeeSK , McMillanDD , OhlssonA , PendrayM , SynnesA , WhyteR , et al. Variations in practice and outcomes in the Canadian NICU network 1996-1997. Pediatrics2000;106(5):1070-9. [DOI: 10.1542/peds.106.5.1070] [PMID: 11061777]">Lee 2000</a>). Infants with lower birth weights were more likely to be treated surgically (<a href="./references#CD010061-bbs2-0083" title="LeeSK , McMillanDD , OhlssonA , PendrayM , SynnesA , WhyteR , et al. Variations in practice and outcomes in the Canadian NICU network 1996-1997. Pediatrics2000;106(5):1070-9. [DOI: 10.1542/peds.106.5.1070] [PMID: 11061777]">Lee 2000</a>). Prostaglandins play a significant role in keeping the ductus arteriosus patent (<a href="./references#CD010061-bbs2-0088" title="MathewR . Development of the pulmonary circulation: metabolic aspects. In: PolinRA , FoxWW , editors(s). Fetal and Neonatal Physiology. Vol. 1. Philadelphia (PA): W.B. Saunders, 1998:924-9.">Mathew 1998</a>). Inhibiting prostaglandin synthesis with non‐selective blockers of both cyclo‐oxygenase (COX) 1 and 2 is effective for the non‐surgical closure of PDA (<a href="./references#CD010061-bbs2-0065" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). However, indomethacin use is associated with transient or permanent derangement of renal function, NEC, gastrointestinal hemorrhage or perforation, alteration of platelet function, and impairment of cerebral blood flow or cerebral blood flow velocity (<a href="./references#CD010061-bbs2-0067" title="EdwardsAD , WyattJS , RichardsonC , PotterA , CopeM , DelpyDT , et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet1990;335(8704):1491-5. [DOI: 10.1016/0140-6736(90)93030-s] [PMID: 1972434]">Edwards 1990</a>; <a href="./references#CD010061-bbs2-0093" title="OhlssonA , BottuJ , GovanJ , RyanML , FongK , MyhrT . Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with patent ductus arteriosus. Developmental Pharmacology and Therapeutics1993;20(1-2):100-6. [DOI: 10.1159/000457546] [PMID: 7924757]">Ohlsson 1993</a>; <a href="./references#CD010061-bbs2-0105" title="SeyberthHW , RascherW , HackenthalR , WilleL . Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus. Journal of Pediatrics1993;103(6):979-84. [DOI: 10.1016/s0022-3476(83)80736-7] [PMID: 6358443]">Seyberth 1983</a>; <a href="./references#CD010061-bbs2-0115" title="WolfWM , SnoverDC , LeonardAS . Localized intestinal perforation following intravenous indomethacin in premature infants. Journal of Pediatric Surgery1989;24(4):409-10. [DOI: 10.1016/s0022-3468(89)80284-2] [PMID: 2732888]">Wolf 1989</a>). </p> <p>Ibuprofen, a propionic acid derivative and non‐selective COX inhibitor, is as effective as indomethacin in closing a PDA and reduces the risk of NEC (<a href="./references#CD010061-bbs2-0095" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>). There is less evidence of transient renal insufficiency following treatment with ibuprofen compared to indomethacin (<a href="./references#CD010061-bbs2-0095" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>). </p> <p>Another non‐steroidal anti‐inflammatory drug (NSAID), mefenamic acid, has been reported to close a PDA (<a href="./references#CD010061-bbs2-0103" title="SakhalkarVS , MerchantRH . Therapy of symptomatic patent ductus arteriosus in preterms with mefenemic acid and indomethacin. Indian Pediatrics1992;29(3):313-8. [PMID: 1612672]">Sakhalkar 1992</a>), but no randomized controlled trials have been reported (<a href="./references#CD010061-bbs2-0094" title="OhlssonA , ShahSS . Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD004213. [DOI: 10.1002/14651858.CD004213.pub5]">Ohlsson 2020a</a>; <a href="./references#CD010061-bbs2-0095" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>). </p> <p>In the sheep fetus, Peterson showed that acetaminophen has potent activity on the ductus arteriosus and produces a constriction in therapeutic analgesic quantities (<a href="./references#CD010061-bbs2-0099" title="PetersonRG . Consequences associated with nonnarcotic analgesics in the fetus and newborn. Federation Proceedings1985;44(7):2309-13. [PMID: 3884385]">Peterson 1985</a>). In humans, <a href="./references#CD010061-bbs2-0106" title="SimbiKA , SecchieriS , RinaldoM , DemiM , ZanardoV . In utero ductal closure following near-term maternal self-medication with nimesulide and acetaminophen. Journal of Obstetrics and Gynaecology2002;22(4):440-1. [DOI: 10.1080/01443610220141489] [PMID: 12521476]">Simbi 2002</a> reported on a pregnant woman near term who took nimesulide 400 mg and acetaminophen 500 mg twice daily for three days as a medication for pain. The woman noticed diminished fetal movements and, one day later, ultrasound confirmed lack of fetal movements and breathing. A constricted ductus arteriosus was confirmed by fetal echocardiography. Following caesarean section, the male infant presented with severe mixed acidosis. An echocardiogram showed an almost completely constricted ductus arteriosus. Following intensive care, the infant improved and was discharged home on day 12 after birth. At three months' follow‐up, the infant was doing well. Either nimesulide or acetaminophen, or both, could be responsible for ductal closure in this case. </p> <p>The complications associated with the use of indomethacin and possibly ibuprofen have encouraged the search for an alternative drug to treat a PDA. In 2011, paracetamol was suggested as an alternative (<a href="./references#CD010061-bbs2-0074" title="HammermanC , Bin-NunA , MarkovitchE , SchimmelMS , KaplanM , FinkD . Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics2011;128(6):e1618-21. [DOI: 10.1542/peds.2011-0359] [PMID: 22065264]">Hammerman 2011</a>). Hammerman and colleagues reported on five preterm infants (postmenstrual age (PMA) 26 to 32 weeks at birth and postnatal age of 3 to 35 days) with large, hemodynamically significant PDAs (<a href="./references#CD010061-bbs2-0074" title="HammermanC , Bin-NunA , MarkovitchE , SchimmelMS , KaplanM , FinkD . Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics2011;128(6):e1618-21. [DOI: 10.1542/peds.2011-0359] [PMID: 22065264]">Hammerman 2011</a>). The infants had failed or had contraindications for treatment with ibuprofen. All infants were treated with oral paracetamol 15 mg/kg per dose every six hours. The treatment resulted in ductal closure in all infants within three days. No side effects were observed. The authors suggested that paracetamol could offer important therapeutic advantages over non‐steroidal anti‐inflammatory drugs (indomethacin and ibuprofen) as paracetamol has no peripheral vasoconstrictive effect, can be given to infants with clinical contraindications to NSAIDs, and appears to be effective after ibuprofen treatment failure (<a href="./references#CD010061-bbs2-0074" title="HammermanC , Bin-NunA , MarkovitchE , SchimmelMS , KaplanM , FinkD . Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics2011;128(6):e1618-21. [DOI: 10.1542/peds.2011-0359] [PMID: 22065264]">Hammerman 2011</a>). </p> <p>Unconjugated hyperbilirubinemia impacts upon clearance of paracetamol (<a href="./references#CD010061-bbs2-0097" title="PalmerGM , AtkinsM , AndersonBJ , SmithKR , CulnaneTJ , McNallyCM , et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. British Journal of Anaesthesia2008;101(4):523-30. [DOI: 10.1093/bja/aen208] [PMID: 18628265]">Palmer 2008</a>). Acetaminophen‐induced hepatic failure with encephalopathy has been described in a term newborn who received oral acetaminophen every four hours by the parents following circumcision (<a href="./references#CD010061-bbs2-0113" title="WallsL , BakerCF , SarkarS . Acetaminophen-induced hepatic failure with encephalopathy in a newborn. Journal of Perinatology2007;27(2):133-5. [DOI: 10.1038/sj.jp.7211641] [PMID: 17262050]">Walls 2007</a>). </p> <p>Paracetamol can be given as prophylaxis for a PDA within 24 hours after birth or as early (&lt; 14 days' postnatal age), late (&gt; 14 days' postnatal age), and combination (ibuprofen plus paracetamol) treatment for a PDA diagnosed by echocardiography (ECHO). We include all approaches in this review. </p> </section> <section id="CD010061-sec-0012"> <h3 class="title" id="CD010061-sec-0012">How the intervention might work</h3> <p>Paracetamol is an analgesic, antipyretic derivative of acetanilide with weak anti‐inflammatory properties. It is used as a common analgesic in all age groups, but may cause liver, blood cell, and kidney damage (<a href="./references#CD010061-bbs2-0092" title="US National Library of Medicine. Drug Information Portal. druginfo.nlm.nih.gov/drugportal (accessed 21 March 2018).">NLM 2012</a>). In low concentrations paracetamol stimulates, and in high concentrations inhibits, the synthesis of prostaglandins. In vivo (in adults) 500 mg of paracetamol causes a pronounced reduction of prostacyclin synthesis but has no effect on thromboxane synthesis (<a href="./references#CD010061-bbs2-0072" title="GrèenK , DrvotaV , VesterqvistO . Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins1989;37(3):311-5. [DOI: 10.1016/0090-6980(89)90001-4] [PMID: 2664901]">Grèen 1989</a>). Because in vitro paracetamol is a weak inhibitor of both COX 1 and COX 2, the possibility exists that it inhibits a so far unidentified form of COX, perhaps a COX 3 (<a href="./references#CD010061-bbs2-0063" title="BottingRM . Mechanism of action of acetaminophen: is there a cyclooxgygenase 3?Clinical Infectious Diseases2000;31(Suppl 5):S202-10. [DOI: 10.1086/317520] [PMID: 11113024]">Botting 2000</a>). In a murine model, paracetamol was found to be less potent than indomethacin for constriction of the mouse ductus arteriosus in vitro (<a href="./references#CD010061-bbs2-0069" title="El-KhuffashA , JainA , CorcoranD , ShahPS , HooperCW , BrownN , et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatric Research2014;76(3):238-44. [DOI: 10.1038/pr.2014.82] [PMID: 24941212]">El‐Khuffash 2014</a>). </p> <p>Since the report in 2011 by Hammerman and colleagues (<a href="./references#CD010061-bbs2-0074" title="HammermanC , Bin-NunA , MarkovitchE , SchimmelMS , KaplanM , FinkD . Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics2011;128(6):e1618-21. [DOI: 10.1542/peds.2011-0359] [PMID: 22065264]">Hammerman 2011</a>), there have been many case series of treatment of a PDA with paracetamol in preterm infants. In five case series, a total of 38 infants with different contraindications for the use of ibuprofen or indomethacin were included (<a href="./references#CD010061-bbs2-0082" title="KesselI , WaismanD , Lavie-NevoK , GolzmanM , LorberA , RotschildA . Paracetamol effectiveness, safety and blood level monitoring during patent ductus arteriosus closure: a case series. Journal of Maternal-fetal &amp; Neonatal Medicine2014;27(16):1719-21. [DOI: 10.3109/14767058.2013.871630] [PMID: 24460433]">Kessel 2014</a>; <a href="./references#CD010061-bbs2-0089" title="NadirE , KassemE , FoldiS , HochbergA , FeldmanM . Paracetamol treatment of patent ductus arteriosus in preterm infants. Journal of Perinatology2014;34(10):748-9. [DOI: 10.1038/jp.2014.96] [PMID: 24854626]">Nadir 2014</a>; <a href="./references#CD010061-bbs2-0107" title="SinahR , NegiV , DalalSS . An interesting observation of PDA closure with oral paracetamol in preterm neonates. Journal of Clinical Neonatology2013;2(1):30-2. [DOI: 10.4103/2249-4847.109245] [PMID: 24027742]">Sinah 2013</a>; <a href="./references#CD010061-bbs2-0110" title="TerrinG , ConteF , ScipioneA , BacchioE , ContiMG , FerroR . Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates. Italian Journal of Pediatrics2014;40(1):21. [DOI: 10.1186/1824-7288-40-21] [PMID: 24555510]">Terrin 2014</a>; <a href="./references#CD010061-bbs2-0118" title="YurttutanS , OncelMY , ArayiciS , UrasN , AltugN , ErdeveO , et al. A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. Journal of Maternal-fetal &amp; Neonatal Medicine2013;26(8):825-7. [DOI: 10.3109/14767058.2012.755162] [PMID: 23205872]">Yurttutan 2013</a>). Paracetamol was administered orally, intravenously, or via nasogastric tube, and the dose and duration of treatment varied: orally 15 mg/kg every eight hours for 48 hours (<a href="./references#CD010061-bbs2-0107" title="SinahR , NegiV , DalalSS . An interesting observation of PDA closure with oral paracetamol in preterm neonates. Journal of Clinical Neonatology2013;2(1):30-2. [DOI: 10.4103/2249-4847.109245] [PMID: 24027742]">Sinah 2013</a>); 15 mg/kg every six hours for three days (<a href="./references#CD010061-bbs2-0118" title="YurttutanS , OncelMY , ArayiciS , UrasN , AltugN , ErdeveO , et al. A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. Journal of Maternal-fetal &amp; Neonatal Medicine2013;26(8):825-7. [DOI: 10.3109/14767058.2012.755162] [PMID: 23205872]">Yurttutan 2013</a>); 15 mg/kg every six hours for up to seven days (<a href="./references#CD010061-bbs2-0089" title="NadirE , KassemE , FoldiS , HochbergA , FeldmanM . Paracetamol treatment of patent ductus arteriosus in preterm infants. Journal of Perinatology2014;34(10):748-9. [DOI: 10.1038/jp.2014.96] [PMID: 24854626]">Nadir 2014</a>); via nasogastric tube 15 mg/kg every six hours for three to seven days (<a href="./references#CD010061-bbs2-0082" title="KesselI , WaismanD , Lavie-NevoK , GolzmanM , LorberA , RotschildA . Paracetamol effectiveness, safety and blood level monitoring during patent ductus arteriosus closure: a case series. Journal of Maternal-fetal &amp; Neonatal Medicine2014;27(16):1719-21. [DOI: 10.3109/14767058.2013.871630] [PMID: 24460433]">Kessel 2014</a>); or intravenously 7.5 mg/kg to 15 mg/kg every four to six hours, with a maximum daily dose of 60 mg/kg (duration of treatment three days in five of seven cases) (<a href="./references#CD010061-bbs2-0110" title="TerrinG , ConteF , ScipioneA , BacchioE , ContiMG , FerroR . Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates. Italian Journal of Pediatrics2014;40(1):21. [DOI: 10.1186/1824-7288-40-21] [PMID: 24555510]">Terrin 2014</a>). In these case reports, the PDA closed in 33 of the 38 cases treated with paracetamol (86%). Kessel and colleagues measured plasma paracetamol concentrations before the fifth dose and ninth dose and 24 hours after the last dose (<a href="./references#CD010061-bbs2-0082" title="KesselI , WaismanD , Lavie-NevoK , GolzmanM , LorberA , RotschildA . Paracetamol effectiveness, safety and blood level monitoring during patent ductus arteriosus closure: a case series. Journal of Maternal-fetal &amp; Neonatal Medicine2014;27(16):1719-21. [DOI: 10.3109/14767058.2013.871630] [PMID: 24460433]">Kessel 2014</a>). Most measured paracetamol blood concentrations were comparable to those recommended for pain and fever control (10 mg/mL to 20 mg/mL) (<a href="./references#CD010061-bbs2-0057" title="AranaA , MortonNS , HansenTG . Treatment with paracetamol in infants. Acta Anaesthesiologica Scandinavica2001;45(1):20-9. [DOI: 10.1034/j.1399-6576.2001.450104.x] [PMID: 11152028]">Arana 2001</a>). </p> <p>In another published case series, <a href="./references#CD010061-bbs2-0069" title="El-KhuffashA , JainA , CorcoranD , ShahPS , HooperCW , BrownN , et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatric Research2014;76(3):238-44. [DOI: 10.1038/pr.2014.82] [PMID: 24941212]">El‐Khuffash 2014</a> retrospectively evaluated the clinical effectiveness of paracetamol on the closure of a PDA, and prospectively examined its effect on the in vitro term and preterm murine ductus arteriosus. A total of 21 infants were included in the study from the Mount Sinai Hospital, Toronto, Ontario, Canada and the Rotunda Maternity Hospital, Dublin, Ireland. At the Canadian site, paracetamol was either given orally as a short course (15 mg/kg every six hours for 48 hours) or a long course of 15 mg/kg every six hours for seven days. At the Irish site, paracetamol was given intravenously, 15 mg/kg every six hours for a minimum of 48 hours, until PDA closure was confirmed on echocardiography or up to a maximum of six days. In both centers, the decision to administer paracetamol treatment to neonates with a hemodynamically significant PDA was after failure of two courses of either ibuprofen or indomethacin, or if there were contraindications to medical treatments (<a href="./references#CD010061-bbs2-0069" title="El-KhuffashA , JainA , CorcoranD , ShahPS , HooperCW , BrownN , et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatric Research2014;76(3):238-44. [DOI: 10.1038/pr.2014.82] [PMID: 24941212]">El‐Khuffash 2014</a>). No changes in PDA hemodynamics were seen in the five infants treated with a short course of paracetamol. In six of the seven infants treated with a long course, the PDA closed. In eight of the nine infants treated with intravenous paracetamol, the PDA closed (<a href="./references#CD010061-bbs2-0069" title="El-KhuffashA , JainA , CorcoranD , ShahPS , HooperCW , BrownN , et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatric Research2014;76(3):238-44. [DOI: 10.1038/pr.2014.82] [PMID: 24941212]">El‐Khuffash 2014</a>). Paracetamol drug levels were not ascertained. The authors concluded that the effectiveness of paracetamol on PDA closure may depend on the duration of treatment and the mode of administration (<a href="./references#CD010061-bbs2-0069" title="El-KhuffashA , JainA , CorcoranD , ShahPS , HooperCW , BrownN , et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatric Research2014;76(3):238-44. [DOI: 10.1038/pr.2014.82] [PMID: 24941212]">El‐Khuffash 2014</a>). The inhibitory effect of paracetamol on prostaglandin E₂ (PGE₂) may not be present at lower gestational ages (<a href="./references#CD010061-bbs2-0069" title="El-KhuffashA , JainA , CorcoranD , ShahPS , HooperCW , BrownN , et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatric Research2014;76(3):238-44. [DOI: 10.1038/pr.2014.82] [PMID: 24941212]">El‐Khuffash 2014</a>). </p> <p>Recently, concerns have been raised that prenatal or neonatal exposure, or both, to paracetamol could have adverse effects on brain development. Viberg and colleagues examined whether neonatal paracetamol exposure in mice could affect the development of the brain (<a href="./references#CD010061-bbs2-0112" title="VibergH , ErikssonP , GordhT , FredrikssonA . Paracetamol (acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice. Toxicological Sciences2014;138(1):139-47. [DOI: 10.1093/toxsci/kft329] [PMID: 24361869]">Viberg 2014</a>), manifested as adult behaviour and cognitive deficits, as well as changes in the response to paracetamol. They concluded that exposure to and presence of paracetamol during a critical period of brain development in mice can induce long‐lasting effects on cognitive function and alter the adult response to paracetamol (<a href="./references#CD010061-bbs2-0112" title="VibergH , ErikssonP , GordhT , FredrikssonA . Paracetamol (acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice. Toxicological Sciences2014;138(1):139-47. [DOI: 10.1093/toxsci/kft329] [PMID: 24361869]">Viberg 2014</a>). </p> <p>In an ecological study conducted in humans and using country‐level data for the period 1984 to 2005, prenatal use of paracetamol was correlated with autism or autism spectrum disorder (ASD) (<a href="./references#CD010061-bbs2-0059" title="BauerAZ , KriebelD . Prenatal and perinatal analgesic exposure and autism: an ecological link. Environmental Health2013;12:41. [DOI: 10.1186/1476-069X-12-41] [PMID: 23656698]">Bauer 2013</a>). To explore the relationship of early neonatal paracetamol exposure to autism and ASD, population‐weighted average male autism prevalence rates for all available countries and US states were compared to male circumcision rates, a procedure for which paracetamol has been widely prescribed since the mid‐1990s. For studies including boys born after 1995, there was a strong correlation between country‐level autism and ASD prevalence in males and a country's circumcision rate (r = 0.98) (<a href="./references#CD010061-bbs2-0059" title="BauerAZ , KriebelD . Prenatal and perinatal analgesic exposure and autism: an ecological link. Environmental Health2013;12:41. [DOI: 10.1186/1476-069X-12-41] [PMID: 23656698]">Bauer 2013</a>). In a Spanish birth cohort study, prenatal acetaminophen exposure was associated with a greater number of autism‐spectrum symptoms in males and showed adverse effects on attention‐related outcomes for both genders (<a href="./references#CD010061-bbs2-0058" title="Avella-GarciaCB , JulvezJ , FortunyJ , RebordosaC , García-EstebanR , GalánIR , et al. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms. International Journal of Epidemiology2016;45(6):1987-96. [DOI: 10.1093/ije/dyw115] [PMID: 27353198]">Avella‐Garcia 2016</a>). <a href="./references#CD010061-bbs2-0117" title="YstromE , GustavsonK , BrandlistuenRE , KnudsenGP , MagnusP , SusserE . Prenatal exposure to acetaminophen and risk of ADHD. Pediatrics2017;140(5):e20163840. [DOI: 10.1542/peds.2016-3840] [PMID: 29084830]">Ystrom 2017</a>, in a study based on the Norwegian Mother and Child Cohort study, including 2246 children with attention deficit hyperactivity disorder (ADHD), found that long‐term maternal use of paracetamol during pregnancy was substantially associated with ADHD in offspring. </p> <p>In a study from Sweden, <a href="./references#CD010061-bbs2-0062" title="BornehagCG , ReichenbergA , HallerbackMU , WikstromS , KochHM , JonssonBA , et al. Prenatal exposure to acetaminophen and children's language development at 30 months. European Psychiatry2018;51:98-103. [DOI: 10.1016/j.eurpsy.2017.10.007] [PMID: 29331486]">Bornehag 2017</a> reported on a possible association of prenatal exposure to acetaminophen and language delay in girls at 30 months of age. The same group reviewed nine prospective cohort studies that reported on associations between prenatal use of paracetamol and neurodevelopmental outcomes in the offspring (<a href="./references#CD010061-bbs2-0060" title="BauerAZ , KriebelD , HerbertMR , BornehagCG , SwanSH . Prenatal paracetamol exposure and child neurodevelopment: a review. Hormones and Behavior2018;101:125-47. [DOI: 10.1016/j.yhbeh.2018.01.003] [PMID: 29341895]">Bauer 2018</a>). All included studies suggested an association between prenatal paracetamol exposure and the neurodevelopmental outcomes of ADHD, ASD, or lower intelligence quotient (IQ). Longer duration of paracetamol use was associated with increased risk. Associations were strongest for hyperactivity and attention‐related outcomes (<a href="./references#CD010061-bbs2-0060" title="BauerAZ , KriebelD , HerbertMR , BornehagCG , SwanSH . Prenatal paracetamol exposure and child neurodevelopment: a review. Hormones and Behavior2018;101:125-47. [DOI: 10.1016/j.yhbeh.2018.01.003] [PMID: 29341895]">Bauer 2018</a>). </p> <p>It is therefore of extreme importance that infants enrolled in trials of paracetamol either for pain relief or for closure of a PDA be followed in the long term with conventional developmental tests and tests to diagnose autism and ASD (<a href="./references#CD010061-bbs2-0056" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington, VA: American Psychiatric Association, 2013.">APA 2013</a>). </p> </section> <section id="CD010061-sec-0013"> <h3 class="title" id="CD010061-sec-0013">Why it is important to do this review</h3> <p>There is marked variation in clinical practice as to whether to treat PDA or not, and if the decision is made to treat, with what agent. Combination treatment (ibuprofen plus paracetamol) targeting two separate enzyme sites has recently been evaluated as a management strategy for treatment of PDA in preterm infants with varying results. This strategy was not in clinical practice during the previous version of the review (<a href="./references#CD010061-bbs2-0122" title="OhlssonA , ShahPS . Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD010061. [DOI: 10.1002/14651858.CD010061.pub4]">Ohlsson 2020c</a>). Thus, we felt it was important to perform an up‐to‐date literature search in an attempt to synthesize evidence of this comparison and to present the current evidence to the scientific community. Moreover, we identified a number of ongoing studies (n = 19) in our previous update and we were keen to discover if new study data had since emerged. </p> <p>For the management of PDA, clinicians often use multiple (two to three) courses of pharmacotherapy and, if unsuccessful, proceed to definitive approaches for ductal closure (ligation/transcatheter). Hence, it is important to explore the efficacy of paracetamol on the failure of ductal closure after the second course and after a total of two courses of treatment. In view of findings in mice of adverse effects on brain development following neonatal exposure to paracetamol, and in humans of an association of neonatal exposure to paracetamol and autism or ASD and language delay, it is important that we continually review the efficacy and safety of paracetamol for the management of PDA in preterm and low birth weight neonates.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010061-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010061-sec-0014"></div> <p>To determine the efficacy and safety of paracetamol as monotherapy or as part of combination therapy via any route of administration, compared with placebo, no intervention, or another prostaglandin inhibitor, for prophylaxis or treatment of an echocardiographically‐diagnosed PDA in preterm or low birth weight infants. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010061-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010061-sec-0015"></div> <section id="CD010061-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010061-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomized and quasi‐randomized controlled trials for inclusion.</p> </section> <section id="CD010061-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included infants born preterm (&lt; 37 weeks' postmenstrual age) or with low birth weight (&lt; 2500 g at birth) who had an echocardiographic diagnosis of a PDA regardless of their postnatal age. In the Cochrane Review of ibuprofen for the treatment of a PDA, all 20 included studies made the diagnoses of a PDA by echocardiography (<a href="./references#CD010061-bbs2-0095" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020b</a>), and it is likely that that would be the case in studies of the effectiveness of paracetamol in closing a PDA. For prophylactic administration of paracetamol (orally or intravenously (IV)) versus placebo (IV) or no intervention within 24 hours after birth for a PDA, ECHO confirmation of a PDA was not required. </p> </section> <section id="CD010061-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included paracetamol (given via any route for the purpose of closure of a PDA) administered alone or in combination in any dose versus placebo or no intervention or versus another prostaglandin inhibitor. If the intention for administration of paracetamol was not closure of a PDA, we excluded the study. We included studies that used any therapeutic regimen of paracetamol. We conducted six comparisons for this review, described below in the 'Summary of findings and assessment of the certainty of the evidence' section.  </p> </section> <section id="CD010061-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD010061-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010061-list-0001"> <li> <p>Failure of PDA closure after the first course of paracetamol treatment (closure and failure of closure confirmed by echocardiographic criteria) </p> </li> <li> <p>Neurodevelopmental impairment (neurodevelopmental outcome assessed by a standardized and validated assessment tool or a child developmental specialist, or both) at any age reported (outcome data grouped at 12, 18, 24, 36, and 60 months, if available) </p> </li> <li> <p>Death or disability (outcome data grouped at 12, 18, 24, 36, and 60 months, if available)</p> </li> </ul> </p> </section> <section id="CD010061-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010061-list-0002"> <li> <p>All‐cause mortality during initial hospital stay</p> </li> <li> <p>Neonatal mortality (death during the first 28 days of life)</p> </li> <li> <p>Re‐opening of the ductus arteriosus (defined as echocardiographic evidence of closure followed by re‐opening of the PDA at a later stage) </p> </li> <li> <p>Failure of PDA closure after second course of paracetamol treatment (closure and failure of closure confirmed by echocardiographic criteria) (added as an outcome in 2021) </p> </li> <li> <p>Failure of PDA closure after a total of two courses of paracetamol treatment (closure and failure of closure confirmed by echocardiographic criteria) </p> </li> <li> <p>Surgical closure of the PDA (added as an outcome in 2021)</p> </li> <li> <p>Treatment with indomethacin, ibuprofen, or another prostaglandin inhibitor to close the PDA following treatment failure </p> </li> <li> <p>Duration of ventilator support (days)</p> </li> <li> <p>Duration of need for supplementary oxygen (O₂) (days)</p> </li> <li> <p>Pulmonary hemorrhage (blood‐stained liquid flowing from the trachea of the infant)</p> </li> <li> <p>Pulmonary hypertension (defined as an increased mean pulmonary arterial pressure of 25 mmHg at rest) (<a href="./references#CD010061-bbs2-0111" title="Van LoonRL , RoofthooftMT , HillegeHL , ten HarkelAD , Van Osch-GeversM , DelhaasT , et al. Pediatric pulmonary hypertension in the Netherlands. Epidemiology and characterization during the period 1991 to 2005. Circulation2011;124(16):1755-64. [DOI: 10.1161/CIRCULATIONAHA.110.969584] [PMID: 21947294]">Van Loon 2011</a>) </p> </li> <li> <p>Bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (defined as O₂ requirement at 36 weeks' postmenstrual age in addition to compatible clinical and roentgenographic findings) </p> </li> <li> <p>BPD defined according to the new criteria (i.e. mild BPD defined as a need for supplemental O₂ for ≥ 28 days but not at 36 weeks' postmenstrual age or discharge; moderate BPD as O₂ for ≥ 28 days plus treatment with &lt; 30% O₂ at 36 weeks' postmenstrual age; and severe BPD as O₂ for ≥ 28 days plus ≥ 30% O₂ or positive pressure, or both, at 36 weeks' postmenstrual age (<a href="./references#CD010061-bbs2-0068" title="EhrenkranzRA , WalshMC , VohrBR , JobeAH , WrightLL , FanaroffAA , et al, National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics2005;116(6):1353-60. [DOI: 10.1542/peds.2005-0249] [PMID: 16322158]">Ehrenkranz 2005</a>)) </p> </li> <li> <p>Intraventricular hemorrhage (IVH) (Grade I to IV) (<a href="./references#CD010061-bbs2-0098" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-34. [DOI: 10.1016/s0022-3476(78)80282-0] [PMID: 305471]">Papile 1978</a>) </p> </li> <li> <p>Severe IVH (Grade III to IV)</p> </li> <li> <p>Periventricular leukomalacia (PVL)</p> </li> <li> <p>Necrotizing enterocolitis (NEC) (stage ≥ 2) (<a href="./references#CD010061-bbs2-0061" title="BellMJ , TernbergJL , FeiginRD , KeatingJP , MarshallR , BartonL , et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery1978;187(1):1-7. [DOI: 10.1097/00000658-197801000-00001] [PMID: 413500]">Bell 1978</a>) </p> </li> <li> <p>Intestinal perforation</p> </li> <li> <p>Gastrointestinal bleed or stools positive for occult blood</p> </li> <li> <p>Retinopathy of prematurity (ROP) (according to the international classification of ROP) stage 3 or higher (<a href="./references#CD010061-bbs2-0078" title="International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Archives of Ophthalmology2005;123(7):991-9. [DOI: 10.1001/archopht.123.7.991] [PMID: 16009843]">ICCROP 2005</a>) </p> </li> <li> <p>Oliguria (decreased urine output defined as &lt; 1 mL/kg/h during treatment)</p> </li> <li> <p>Acute kidney injury (defined by authors as there is no consensus definition)</p> </li> <li> <p>Sepsis (clinical symptoms and signs of sepsis and a positive blood bacterial culture); this outcome was added at the full review stage </p> </li> <li> <p>Post‐pre treatment difference in serum or plasma levels of creatinine (mg/dL) (added as an outcome in 2021) </p> </li> <li> <p>Post‐pre treatment difference in serum or plasma levels of aspartate transaminase (AST) (U/L) (added as an outcome in 2021) </p> </li> <li> <p>Post‐pre treatment difference in serum or plasma levels of alanine transaminase (ALT) (U/L) (added as an outcome in 2021) </p> </li> <li> <p>Number of infants with AST or ALT levels greater than 100 U/L</p> </li> <li> <p>Serum bilirubin (μmol/L) following treatment</p> </li> <li> <p>Hyperbilirubinemia (serum bilirubin level higher than the exchange level according to the postnatal age and body weight) </p> </li> <li> <p>Incidence of liver failure; evidence of acute liver injury combined with either severe coagulopathy (International Normalized Ratio (INR) &gt; 2.0 or prothrombin time (PT) &gt; 20 seconds) or encephalopathy with moderate coagulopathy (INR ≥ 1.5 or PT ≥ 15 seconds) (<a href="./references#CD010061-bbs2-0108" title="SundaramSS , AlonsoEM , NarkewiczMR , ZhangS , SquiresRH , Pediatric Acute Liver Failure Study Group. Characterization and outcomes of young infants with acute liver failure. Journal of Pediatrics2011;159(5):813-8.e1. [DOI: 10.1016/j.jpeds.2011.04.016] [PMID: 21621221]">Sundaram 2011</a>) </p> </li> <li> <p>Duration of hospitalization (total length of hospitalization from birth to discharge home or death) (days) </p> </li> <li> <p>Autism or autism spectrum disorder (ASD) in childhood (<a href="./references#CD010061-bbs2-0056" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington, VA: American Psychiatric Association, 2013.">APA 2013</a>); this outcome was added at the full review stage </p> </li> <li> <p>Language delay; this outcome was added in 2017</p> </li> <li> <p>Other adverse effects as reported by the study authors (i.e. not prespecified)</p> </li> <li> <p>Other neurodevelopmental outcomes: Severity of cerebral palsy (CP), attention deficit hyperactivity disorder (ADHD), pervasive developmental disorder, blindness, deafness (added as an outcome in 2021) </p> </li> </ul> </p> </section> </section> </section> <section id="CD010061-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>The Neonatal Group Information Specialist developed new search strategies to increase the sensitivity of the search. The Information Specialist developed the strategies in consultation with the review authors.  </p> <section id="CD010061-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 13 October 2021 without date, language, or publication status restrictions (<a href="./references#CD010061-bbs2-0096" title="OvelmanC , EckertC , FriesenC . Validating Cochrane Neonatal’s standard search databases: is it okay to stop searching Embase?In: Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews 2020; (9 Suppl 1): [320] www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD202001/full.">Ovelman 2020</a>): </p> <p> <ul id="CD010061-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2021, Issue 10) (<a href="./appendices#CD010061-sec-0163">Appendix 1</a>); </p> </li> <li> <p>Ovid MEDLINE and Epub Ahead of Print, In‐Process, In‐Data‐Review &amp; Other Non‐Indexed Citations, Daily and Versions 1946 to 13 October 2021 (<a href="./appendices#CD010061-sec-0165">Appendix 2</a>); </p> </li> <li> <p>OVID Embase 1974 to 13 October 2021 (<a href="./appendices#CD010061-sec-0167">Appendix 3</a>). </p> </li> </ul> </p> <p>We searched the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCO) on 1 March 2022 (<a href="./appendices#CD010061-sec-0169">Appendix 4</a>). We used methodological filters based on those developed by Cochrane (<a href="./references#CD010061-bbs2-0066" title="Cochrane. How CENTRAL is created: identifying RCTs for inclusion in CENTRAL. www.cochranelibrary.com/central/central-creation (accessed prior to 4 August 2022).">Cochrane 2021</a>; <a href="./references#CD010061-bbs2-0084" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Lefebvre 2011</a>), and the Canadian Agency for Drugs and Technologies in Health (<a href="./references#CD010061-bbs2-0064" title="Canadian Agency for Drugs and Technologies in Health (CADTH). Strings attached: CADTH database search filters. Ottawa: CADTH; 2016. Available from: /resources/finding-evidence (accessed prior to 4 August 2022).">CADTH 2016</a>), to limit retrieval to randomized controlled trials, quasi‐randomized trials, and systematic reviews. </p> <p>This is the third update of this review. Previous search details are listed in <a href="./appendices#CD010061-sec-0170">Appendix 5</a> and <a href="./appendices#CD010061-sec-0171">Appendix 6</a>. </p> </section> <section id="CD010061-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the following clinical trials registries for ongoing or recently completed trials up to October 2021 (<a href="./appendices#CD010061-sec-0172">Appendix 7</a>): </p> <p> <ul id="CD010061-list-0004"> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) search portal (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>); </p> </li> <li> <p>U.S. National Library of Medicine’s ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>ISRCTN Registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>). </p> </li> </ul> </p> <p>We also searched the reference lists of related systematic reviews and trials selected for inclusion in this review in order to identify additional relevant articles. </p> </section> </section> <section id="CD010061-sec-0026"> <h3 class="title" id="CD010061-sec-0026">Data collection and analysis</h3> <p>We used standard methods recommended by Cochrane (<a href="./references#CD010061-bbs2-0077" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>) and Cochrane Neonatal. </p> <section id="CD010061-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BJ, SM) independently assessed study eligibility for inclusion in this review according to the prespecified selection criteria. Consensus was achieved by involving a third review author (PS). </p> </section> <section id="CD010061-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (BJ, SM) independently extracted data from the new full‐text articles using a specifically designed spreadsheet and customized form to manage information. We used these forms to decide trial inclusion and exclusion, extract data from eligible trials, and for requesting additional published information from authors of the original reports. We entered and cross‐checked data using Review Manager 5 (RevMan 5) software (<a href="./references#CD010061-bbs2-0101" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We compared the extracted data for any differences. If noted, we resolved differences by mutual discussion and consensus and involving a third review author (PS). We contacted the authors of three identified trials, and we obtained unpublished data from the Oncel group (<a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>), the Dang group (<a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>), and the Dash group (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>). In the previous version, PS and AO collected data using a similar process. PS resolved any differences. </p> </section> <section id="CD010061-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BJ, SM) independently assessed the risk of bias (low, high, or unclear) of all included trials using the Cochrane risk of bias tool for the following domains (<a href="./references#CD010061-bbs2-0076" title="HigginsJP , AltmanDG , SterneJA , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>): </p> <p> <ul id="CD010061-list-0005"> <li> <p>sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>any other bias.</p> </li> </ul> </p> <p>We resolved any disagreements through discussion or by involving a third assessor to reach consensus. In the previous version of the review, PS and AO assessed risk of bias using a similar process. PS resolved any differences. See <a href="./appendices#CD010061-sec-0173">Appendix 8</a> for a more detailed description of risk of bias for each domain.  </p> </section> <section id="CD010061-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analyzed treatment effects in the individual trials using RevMan 5 (<a href="./references#CD010061-bbs2-0101" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <section id="CD010061-sec-0031"> <h5 class="title">Dichotomous data</h5> <p>We reported dichotomous data using risk ratio (RR) and risk difference (RD) with respective 95% confidence intervals (CI). For those outcomes with a statistically significant RD for the pooled estimate from the meta‐analysis, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) and respective 95% CI. </p> </section> <section id="CD010061-sec-0032"> <h5 class="title">Continuous data</h5> <p>We reported continuous data using mean difference (MD) with 95% CI.</p> </section> </section> <section id="CD010061-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomization was the individual infant. We did not include cross‐over or cluster‐randomized trials as those trial designs are unlikely for the intervention studied in this review — indeed, we identified no cross‐over or cluster‐randomized trials. We only considered an infant once, even though the infant might have been randomized twice by investigators. We planned to contact the authors in order to provide data resulting from the first randomization. If we could not separate data from the first randomization, we planned to exclude the study. We included studies with multiple arms in meta‐analysis by making multiple pair‐wise comparisons between all possible pairs of intervention groups and ensuring that study arms were not counted multiple times in the same meta‐analyses. </p> </section> <section id="CD010061-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We requested additional data from the authors of each included trial when data on important outcomes were missing or needed clarification. We did receive clarifying information from the authors of the following included trials: <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; and <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>. The authors clarified that all the published analyses, and those they provided to us, were intention‐to‐treat analyses. </p> </section> <section id="CD010061-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used RevMan 5 software to assess the heterogeneity of treatment effects between trials (<a href="./references#CD010061-bbs2-0101" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used the two formal statistics described below. </p> <p> <ul id="CD010061-list-0006"> <li> <p>The Chi² test, to assess whether observed variability in effect sizes between studies was greater than would be expected by chance. Since this test has low power when the number of studies included in the meta‐analysis is small, we set the alpha probability at the 10% level of significance. </p> </li> <li> <p>The I² statistic to ensure that pooling of data was valid. We graded the degree of heterogeneity as: none, low, moderate, and high for values of less than 25%, 25% to 49%, 50% to 74%, and 75% or higher, respectively (<a href="./references#CD010061-bbs2-0075" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] [PMID: 12958120]">Higgins 2003</a>). </p> </li> </ul> </p> </section> <section id="CD010061-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to identify the study protocols for the trials we selected for inclusion (see the <a href="./references#CD010061-sec-0190" title="">Characteristics of included studies</a> table). We planned to assess reporting and publication bias by examining the degree of asymmetry of a funnel plot in RevMan 5 provided that a sufficient number of studies (n = 10) were available (<a href="./references#CD010061-bbs2-0101" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD010061-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analyses according to the recommendations of Cochrane Neonatal (<a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">neonatal.cochrane.org/resources-review-authors</a>). We analyzed all infants randomized on an intention‐to‐treat basis. We analyzed treatment effects in the individual trials. We used a fixed‐effect model in the meta‐analysis to combine the data. Where substantial heterogeneity existed, we examined the potential cause of heterogeneity in subgroup and sensitivity analyses. When we judged meta‐analysis to be inappropriate, we planned to analyze and interpret individual trials separately. For estimates of RR and RD, we used the Mantel‐Haenszel method. For measured quantities, we used the inverse‐variance method. We would have used the standardized mean difference (SMD) to combine trials that measured the same outcome but used different scales. </p> </section> <section id="CD010061-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We considered 'gestational age (&lt; 32 weeks)' for subgroup analysis in the current update by restricting studies that reported outcomes in preterm infants of less than 32 weeks' gestational age for the comparison of paracetamol versus ibuprofen or paracetamol versus indomethacin. We selected this subgroup as infants of this age group have a high risk of developing PDA with short‐ and long‐term clinical implications (<a href="./references#CD010061-bbs2-0091" title="NielsenMR , AldenrydAE , HagstrømS , PedersenLM , BrixN . The chance of spontaneous patent ductus arteriosus closure in preterm infants born before 32 weeks of gestation is high and continues to increase until 5 years of follow-up. Acta Paediatrica2022;111(12):2322-2330.">Nielsen 2022</a>).  </p> <p>For this update, we were unable to consider the previously defined subgroups (<a href="./references#CD010061-bbs2-0122" title="OhlssonA , ShahPS . Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD010061. [DOI: 10.1002/14651858.CD010061.pub4]">Ohlsson 2020c</a>): gestational age of less than 28 weeks, 28 to 32 weeks, 33 to 36 weeks; and birth weight (&lt; 1000 g, 1001 g to 1500 g, 1501 g to 2500 g) as there were insufficient data to draw clinically relevant, meaningful conclusions. </p> </section> <section id="CD010061-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis to determine if the findings were affected by including only studies of adequate methodology, defined as adequate randomization and allocation concealment, blinding of intervention and measurement, and less than 10% losses to follow‐up.   </p> </section> <section id="CD010061-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD010061-bbs2-0104" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), to assess the certainty of the evidence for the following comparisons: </p> <p> <ul id="CD010061-list-0007"> <li> <p>paracetamol versus ibuprofen;</p> </li> <li> <p>paracetamol versus indomethacin;</p> </li> <li> <p>prophylactic paracetamol versus placebo or no intervention;</p> </li> <li> <p>early paracetamol (&lt; 14 days' postnatal age) versus placebo or no intervention;</p> </li> <li> <p>late paracetamol (≥ 14 days' postnatal age) versus placebo or no intervention;</p> </li> <li> <p>combination treatment (paracetamol plus ibuprofen versus ibuprofen plus placebo or no intervention). </p> </li> </ul> </p> <p>We chose three critical outcomes: failure of PDA closure after the first course of treatment; all‐cause mortality during initial hospital stay; and necrotizing enterocolitis. These outcomes (the former a primary outcome, the latter two secondary outcomes) were deemed critical after discussion amongst all the review authors.  </p> <p>Two authors (BJ, PS) independently assessed the certainty of the evidence for each of the outcomes above. We considered evidence from RCTs as high certainty but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used the <a href="./references#CD010061-bbs2-0071" title="GRADEpro GDT. Version accessed 21 March 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2013. Available at gradepro.org.">GRADEpro GDT</a> Guideline Development Tool to create <a href="./full#CD010061-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD010061-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD010061-tbl-0003">summary of findings Table 3</a>, <a href="./full#CD010061-tbl-0004">summary of findings Table 4</a>, <a href="./full#CD010061-tbl-0005">summary of findings Table 5</a>, and <a href="./full#CD010061-tbl-0006">summary of findings Table 6</a> to report the certainty of the evidence. We resolved any differences in GRADE assessment by consensus and involving a third review author. </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence in one of four grades: </p> <p> <ul id="CD010061-list-0008"> <li> <p>high certainty: further research is very unlikely to change our confidence in the estimate of effect; </p> </li> <li> <p>moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; </p> </li> <li> <p>low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; </p> </li> <li> <p>very low certainty: we are very uncertain about the estimate.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010061-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010061-sec-0041"></div> <section id="CD010061-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD010061-sec-0043"> <h4 class="title">Results of the search</h4> <p>For this 2022 update, our electronic database search yielded 493 records and our search of trials registers retrieved 120 records. After removing 199 duplicates, we screened a total of 414 records. After excluding 366 clearly irrelevant records, we assessed 48 full‐text articles for eligibility. Of these, we excluded four studies (see <a href="#CD010061-sec-0051">Excluded studies</a>) and 24 ongoing studies (25 reports). Thus, this 2022 update search included 19 new studies (<a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a>;<a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>). Overall, a total of 27 RCTs (19 new studies plus eight studies from previous review version) involving 2278 infants are included in the current review. For details see <a href="#CD010061-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010061-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for 2022 review update" data-id="CD010061-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for 2022 review update</p> </div> </div> </div> <p>We also identified 24 ongoing studies (25 reports) (<a href="./references#CD010061-bbs2-0032" title="ACTRN12613000289718. Paracetamol for patent ductus arteriosus treatment: comparison between oral and intravenous administration. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363736&amp;isReview=true (first received 8 March 2013). ">ACTRN12613000289718</a>; <a href="./references#CD010061-bbs2-0033" title="ChiCTR-TRC-13003912. Comparison of oral paracetamol versus ibuprofen in premature infants &lt; 1500g with patent ductus arteriosus: a randomized controlled trial. www.chictr.org.cn/hvshowproject.aspx?id=8209 (first received 7 December 2013). ">ChiCTR‐TRC‐13003912</a>; <a href="./references#CD010061-bbs2-0034" title="CTRI/2017/10/009989. Paracetamol versus ibuprofen for closure of patent ductus arteriosus [Efficacy and safety of oral paracetamol versus oral ibuprofen in management of patent ductus arteriosus in preterm neonates less than or equal to 34 Weeks or less than or equal to 1800 gms: a randomized control trial - BAP trial]. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2017/10/009989 (first received 10 October 2017). ">CTRI/2017/10/009989</a>; <a href="./references#CD010061-bbs2-0035" title="CTRI/2017/10/010012. A clinical trial comparing low dose versus standard dose of intravenous paracetamol for PDA closure in very premature babies [Randomized controlled trial of two different doses of intravenous paracetamol for PDA closure in preterm infants less than 30 weeks]. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=20401&amp;EncHid=&amp;modid=&amp;compid=%27,%2720401det%27 (first received 05 October 2017). ">CTRI/2017/10/010012</a>; <a href="./references#CD010061-bbs2-0036" title="CTRI/2018/02/011942. To study the efficacy and safety of oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomised controlled trial [Paracetamol versus ibuprofen in the management of patent ductus arteriosus (congenital heart disease) in preterm infants]. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/02/011942 (first received 19 February 2018). ">CTRI/2018/02/011942</a>; <a href="./references#CD010061-bbs2-0037" title="EUCTR2015-003177-14-ES. Paracetamol versus ibuprofen in preterm infants with a hemodynamically significant patent ductus arteriosus: a randomized clinical trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-003177-14-ES (first received 20 April 2016). ">EUCTR2015‐003177‐14‐ES</a>; <a href="./references#CD010061-bbs2-0038" title="EUCTR2019-004297-26-FR. Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen - TREOCAPA. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004297-26 (first received 28 February 2020). ">EUCTR2019‐004297‐26‐FR</a>; <a href="./references#CD010061-bbs2-0040" title="IRCT20111011007763N2. Clinical trial of the effect of intravenous acetaminophen in patent ductus arteriosus prophylaxis of preterm infants with gestational age less than 32 weeks. en.irct.ir/trial/8223 (first received 3 March 2018). ">IRCT20111011007763N2</a>; <a href="./references#CD010061-bbs2-0041" title="IRCT20120215009014N321. Effect of intravenous ibuprofen versus intravenous paracetamol on the occlusion of patent ductus arteriosus in preterm infants: a single-blind randomized clinical trial. en.irct.ir/trial/43951 (first received 10 December 2019). ">IRCT20120215009014N321</a>; <a href="./references#CD010061-bbs2-0042" title="IRCT20130812014333N118. Comparison of the therapeutic and safety effect of oral and rectal acetaminophen for treatment and safety on the closure of ductus arteriosus in preterm neonates under 35 weeks and 6 days gestational old. en.irct.ir/trial/38155 (first received 11 April 2019). ">IRCT20130812014333N118</a>; <a href="./references#CD010061-bbs2-0043" title="IRCT20171227038102N1. Investigation effect of oral acetaminophen and ibuprofen on patent ductus arteriosus in preterm neonates. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20171227038102N1 (first received 3 July 2018). ">IRCT20171227038102N1</a>; <a href="./references#CD010061-bbs2-0044" title="IRCT20190505043478N1. Comparison of the efficacy of oral acetaminophen and intravenous acetaminophen for closure of patent ductus arteriosus in preterm neonates. www.irct.ir/trial/39364 (first received 10 May 2019). ">IRCT20190505043478N1</a>; <a href="./references#CD010061-bbs2-0045" title="IRCT20200218046538N1. Effect of prophylactic oral administration of acetaminophen on patent ductus arteriosus (PDA) closure in preterm neonate admitted in NICU section of Ali ibn Abitaleb Hospital in Zahedan in 2019-2020. en.irct.ir/trial/45975 (first received 10 March 2020). ">IRCT20200218046538N1</a>; <a href="./references#CD010061-bbs2-0046" title="NCT01291654. Paracetamol and patent ductus arteriosus (PDA) [Paracetamol in the treatment of patent ductus arteriosus in the premature neonate]. Clinicaltrials.gov/show/NCT01291654 (first received 6 February 2011). ">NCT01291654</a>; <a href="./references#CD010061-bbs2-0047" title="NCT02056223. Paracetamol vs ibuprofen for PDA closure in preterm infants (PARIDA) [Paracetamol versus ibuprofen for patent ductus arteriosus closure in preterm infants. A prospective, randomized, controlled, double blind, multicenter clinical trial]. clinicaltrials.gov/show/NCT02056223 (first received 10 August 2005). ">NCT02056223</a>; <a href="./references#CD010061-bbs2-0048" title="NCT02819414. Paracetamol treatment of the borderline significant PDA [Time to re-evaluate the kinder gentler approach to patent ductus arteriosus (PDA) in the preterm neonate]. clinicaltrials.gov/show/NCT02819414 (first received 30 June 2016). ">NCT02819414</a>; <a href="./references#CD010061-bbs2-0049" title="NCT03604796. Alternative acetaminophen treatment of the hemodynamically significant patent ductus arteriosus in preterm neonates who are not candidates for enteral administration: a pilot study. clinicaltrials.gov/show/NCT03604796 (first received 30 July 2018). ">NCT03604796</a>; <a href="./references#CD010061-bbs2-0050" title="NCT03641209. Extremely low gestational age infants' paracetamol study: a randomized trial. clinicaltrials.gov/show/NCT03641209 (first received 21 August 2018). ">NCT03641209</a>; <a href="./references#CD010061-bbs2-0051" title="NCT03648437. Paracetamol and ibuprofen/indomethacin in closing patent ductus arteriosus (PAI). clinicaltrials.gov/show/NCT03648437 (first received 27 August 2018). ">NCT03648437</a>; <a href="./references#CD010061-bbs2-0052" title="García-RoblesA , Gimeno NavarroA , Serrano MartínMD , Párraga QuilesMJ , Parra LlorcaA , Poveda-AndrésJL , et al. Paracetamol vs. ibuprofen in preterm infants with hemodynamically significant patent ductus arteriosus: a non-inferiority randomized clinical trial protocol. Frontiers in Pediatrics2020;8:372. [DOI: 10.3389/fped.2020.00372] [PMID: 32766181]NCT04037514. Paracetamol versus ibuprofen in premature infants with hemodynamically significant patent ductus arteriosus (IBUPAR). clinicaltrials.gov/ct2/show/NCT04037514 (first received 30 July 2019). ">NCT04037514</a>; <a href="./references#CD010061-bbs2-0053" title="NCT04459117. Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen. clinicaltrials.gov/show/NCT04459117 (first received 7 July 2020). ">NCT04459117</a>; <a href="./references#CD010061-bbs2-0054" title="NCT04986839. PAIR (Paracetamol and Ibuprofen Research) Study: a randomised controlled trial comparing IV paracetamol with IV ibuprofen in the management of haemodynamically significant patent ductus arteriosus. clinicaltrials.gov/show/NCT04986839 (first registered on 19 July 2021). ">NCT04986839</a>; <a href="./references#CD010061-bbs2-0055" title="TCTR20201104001. Paracetamol administration within the first 72 hours of life in early preterm infants with hemodynamically significant patent ductus arteriosus for prevention of bronchopulmonary dysplasia. www.thaiclinicaltrials.org/show/TCTR20201104001 (first received 30 August 2021). ">TCTR20201104001</a>). </p> </section> <section id="CD010061-sec-0044"> <h4 class="title">Included studies</h4> <p>We included a total of 27 studies with 2278 participants. Individual study characteristics, inclusion criteria, treatment details, and outcomes can be found the <a href="./references#CD010061-sec-0190" title="">Characteristics of included studies</a> table.  </p> <section id="CD010061-sec-0045"> <h5 class="title">Studies comparing oral/intravenous (IV) paracetamol and oral/IV ibuprofen</h5> <p>Eighteen studies that enrolled 1535 infants compared oral/IV paracetamol to oral/IV ibuprofen. The following section provides a brief description of the included studies. </p> <p><a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a> was a single‐center study in the neonatal intensive care unit (NICU) of Jordan University Hospital, Amman, Jordan. It aimed to evaluate the effectiveness and safety profiles of oral paracetamol versus oral ibuprofen for PDA closure in preterm infants up to and including 32 weeks' gestational age, or birth weight of up to 1500 g, with a hemodynamically significant PDA. Infants were randomised to either oral paracetamol (10 mg/kg every six hours for three days; n = 11) or oral ibuprofen (10‐5‐5 mg/kg/dose; n = 11) for PDA treatment. The study's primary outcomes included mortality and primary PDA closure rate. The baseline characteristics were similar between the two groups. The authors found no significant difference in the mortality or primary closure rates between the two groups. </p> <p><a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a> was a single‐center, randomized controlled trial (RCT) at Hajar Hospital in Shahrekord, Iran, from 2016 to 2017. It aimed to compare the efficacy of oral paracetamol and oral Ibuprofen for the closure of PDA in preterm infants under 37 weeks' gestational age with PDA. Infants were randomised to either oral paracetamol (10 mg/kg every six hours for three days; n = 25) or oral ibuprofen (10‐5‐5 mg/kg/dose; n = 25) for PDA treatment. The study's outcomes included PDA closure rate, bilirubin, serum creatinine, blood urea nitrogen, aspartate transaminase (AST), alanine transaminase (ALT) pre‐post treatment in both groups and gastrointestinal complications, mortality, and primary PDA closure. The baseline characteristics were similar between the two groups. The authors found no significant difference in the PDA closure rates between the two groups. Of note, infants who received paracetamol had higher post‐treatment ALT levels compared to the ibuprofen group but no infant had overt hepatotoxicity. In addition, infants who received ibuprofen had higher gastrointestinal complications compared to the paracetamol group (0/25 in the paracetamol group versus 5/25 in the ibuprofen group; P = 0.05).  </p> <p><a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a> was a single‐center RCT in the NICU of Afzalipour Hospital, Kerman, Iran, from July 2014 to November 2014. It aimed to compare the efficacy of oral paracetamol and oral Ibuprofen for the closure of PDA in preterm infants under 37 weeks' gestational age and postnatal age of 14 days or less, with a hemodynamically significant PDA. Infants were randomised to either oral paracetamol (15 mg/kg every six hours for three days; n = 67) or oral ibuprofen (20‐10‐10 mg/kg/dose; n = 62) for PDA treatment. The study's outcomes included failure of ductal closure after the first and second course of treatment. The baseline characteristics were similar between the two groups. The authors found no significant difference in the PDA closure rates after the first and second course of treatment between the two groups. </p> <p><a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a> was a single‐center RCT in the NICU in Pondicherry, India, from October 2014 to January 2016. It aimed to compare the efficacy of oral paracetamol and oral ibuprofen for PDA closure confirmed by echocardiography in preterm infants up to and including 37 weeks' gestational age with a hemodynamically significant PDA. Infants were randomised to either oral paracetamol (15 mg/kg every six hours for two days; n = 55) or oral ibuprofen (10‐5‐5 mg/kg/dose; n = 55) for PDA treatment. The study's outcomes included PDA closure rates, mortality, cardiorespiratory morbidity, and adverse effects. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to PDA closure, mortality, or cardiorespiratory morbidity. The infants who received ibuprofen had a significantly higher occurrence of acute kidney injury (AKI) compared to the paracetamol group (27.3% in the ibuprofen group versus 9.1% in the paracetamol group, P = 0.02).  </p> <p><a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a> was a single‐center study in Changchun, China. It aimed to compare the effectiveness and safety profiles of oral paracetamol and oral ibuprofen for PDA closure in preterm infants up to and including 34 weeks' gestational age and postnatal age of 14 days or less, with an echocardiographically confirmed hemodynamically significant PDA. Infants were randomised to either oral paracetamol (15 mg/kg every six hours for three days; n = 80) or oral ibuprofen (10‐5‐5 mg/kg/dose; n = 80) for PDA treatment. The study's outcomes included PDA closure rates, mortality, oliguria, AKI, intraventricular hemorrhage (IVH), gastrointestinal bleeding, necrotizing enterocolitis (NEC), hyperbilirubinemia, bronchopulmonary dysplasia (BPD), periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), sepsis, and serum creatinine. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to PDA closure. The infants who received paracetamol had significantly lower hyperbilirubinemia (20% in the paracetamol group versus 35% in the ibuprofen group, P = 0.03) and gastrointestinal bleeding (2.5% in the paracetamol group versus 10% in the ibuprofen group, P = 0.03) compared to the ibuprofen group.  </p> <p><a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a> was a multi‐center RCT in five NICUs in Italy. It aimed to assess the efficacy and safety of IV paracetamol versus IV ibuprofen for the treatment of hemodynamically significant PDAs in preterm infants with a gestational age of 25to31 weeks, and echocardiographic evidence of a hemodynamically significant PDA between 24 and 72 hours of life. Infants were randomised to either IV paracetamol (15 mg/kg every six hours for three days; n = 52) or IV ibuprofen (10‐5‐5 mg/kg/dose; n = 49) for PDA treatment. The study's outcomes included failure to close the PDA after the first and second course of treatment, failure to constrict the PDA after the first and second course of treatment, re‐opening rate, and incidence of surgical closure 30 days after enrolment. The baseline characteristics were similar between the two groups. Paracetamol was less effective in closing hemodynamically significant PDAs than ibuprofen (52% in the paracetamol group versus 78% in the ibuprofen group; P = 0.026) after the first course of treatment. The constriction rate of the PDA, re‐opening rate, the need for surgical closure, and the occurrence of adverse effects were similar between the two groups. </p> <p><a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a> was a double‐blind RCT in the NICU of an obstetrics and gynaecology hospital, at Ain Shams University in Cairo, Egypt, from June 2015 to June 2017. It aimed to evaluate the efficacy and safety of oral paracetamol versus oral ibuprofen in preterm infants of up to and including 34 weeks' gestational age and a postnatal age of two to seven days with a hemodynamically significant PDA. Infants were randomised to either oral paracetamol (15 mg/kg every six hours for three days; n = 30) oral ibuprofen (10‐5‐5 mg/kg/dose; n = 30) for PDA treatment. The study's outcomes included PDA closure after the first and second course of treatment, surgical ligation, mortality, IVH, NEC, gastrointestinal bleeding, intestinal perforation, AKI, hepatotoxicity, and BPD. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and other prespecified secondary outcomes, including rates of adverse effects.  </p> <p><a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a> was a three‐arm, single‐center RCT in the NICU of Tanta University Hospital Pediatric Department, Tanta, Egypt. It compared the effectiveness and side effects of paracetamol, indomethacin, and ibuprofen in the closure of hemodynamically significant PDAs in preterm infants under 28 weeks' gestational age or a birth weight of less than 1500 g in the first two weeks of life with a hemodynamically significant PDA diagnosed with echocardiography. Infants were randomised to IV paracetamol (15 mg/kg every six hours for three days; n = 100), IV ibuprofen (10‐5‐5 mg/kg/dose; n = 100), or IV indomethacin (0.2 mg/kg for three doses 12 hours apart; n = 100) for PDA treatment. The study's outcomes included PDA closure after the first and second course of treatment and adverse effects. The baseline characteristics were similar between the three groups. The authors found no significant difference between the three groups with regards to ductal closure rates after the first and second course of treatment. There was a significant increase in serum creatinine levels and serum blood urea nitrogen (BUN) and a significant reduction in platelet count and urine output in the ibuprofen and indomethacin groups compared to the paracetamol group. There was a significant increase in bilirubin levels in the ibuprofen group compared to the indomethacin or paracetamol group. </p> <p><a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a> was a multi‐center, non‐inferiority, randomized, double‐blind clinical trial in the Al‑Zahra and Shahid Beheshti Hospitals at the Isfahan University of Medical Sciences, Iran. It compared the effectiveness of oral ibuprofen and a low dose of IV paracetamol in the management of PDA in preterm infants up to and including 34 weeks' gestational age and a weight of 1000 g or more with echocardiographic evidence of PDA. Infants were randomised to IV paracetamol (15 mg/kg/dose every six hours for two days; n = 20) or oral ibuprofen (10‐5‐5 mg/kg/dose; n = 20) . The study's outcomes included PDA closure rates after the first and second course of treatment. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates after the first and second course of treatment.  </p> <p><a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a> was a multi‐center, parallel‐group, double‐blind, non‐inferiority RCT in the NICUs of the Al‐Zahra and Shahid Beheshti Hospitals, affiliated to the Isfahan University of Medical Sciences, Isfahan, Iran from January 2017 to October 2018. It aimed to compare the efficacy of oral ibuprofen and oral acetaminophen for closure of symptomatic PDA in preterm neonates of less than 32 weeks' gestational age, or a birth weight of less than 1500 g, and less than 14 days' postnatal age, with a hemodynamically significant PDA. Infants were randomised to oral paracetamol (15 mg/kg/dose every six hours for two days; n = 20) or oral ibuprofen (10‐5‐5 mg/kg/dose every 24 hours; n = 20). Outcomes included PDA closure rates after the first and second course of treatment. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates after the first and second course of treatment. </p> <p><a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a><b> </b>was a single‐center RCT in the NICU of Ayatollah Mousavi Hospital in Zanjan, Iran, from 21 March 2017 to 21 March 2018. It compared the safety and efficacy of IV paracetamol and IV ibuprofen for treatment of PDA in low birth weight infants at a postnatal age of 48 to 72 hours with echocardiographic diagnosis of a hemodynamically significant PDA. Infants were randomised to IV paracetamol (15 mg/kg/dose every six hours for three days; n = 16) or IV ibuprofen (10‐5‐5 mg/kg/dose every 24 hours; n = 14). The study's outcomes included PDA closure, all‐cause mortality, duration of mechanical ventilation, length of stay, IVH (all grades), ROP, pneumothorax, and BPD. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and other prespecified secondary outcomes.  </p> <p><a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a> was a randomised, two‐arm, active‐controlled, blinded, non‐inferiority RCT in three centers across India from April 2014 to June 2017. It compared the efficacy and safety of ibuprofen and paracetamol in the closure of PDAs in preterm neonates under 32 weeks' gestational age with hemodynamically significant PDAs. A screening echocardiography was performed in asymptomatic neonates to detect hemodynamically significant PDAs (between 48 and 72 hours of age in those at 29 to 31 weeks' gestational age, and in the first 48 hours in those at less than 28 weeks' gestational age). Infants were randomised to oral paracetamol (15 mg/kg every six hours for three consecutive days; n = 81) or oral ibuprofen (10‐5‐5 mg/kg/dose every 24 hours; n = 80). The study's outcomes included closure rate of hemodynamically significant PDA by 24 hours from the last dose of the study drug, irrespective of the course of the drug; rate of hemodynamically significant PDA closure by 24 hours after the first course of the study drug, rate of re‐opening following the first course, need for surgical ligation for hemodynamically significant PDA closure, all‐cause mortality in hospital, and adverse events, including azotemia, oliguria, hepatitis with deranged liver transaminase values, deranged coagulation, severe IVH (grade 3 and intraparenchymal extension), PVL, NEC (definite and advanced stage per modified Bell staging), BPD, and ROP necessitating therapy. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and other prespecified secondary outcomes. </p> <p><a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a> was a single‐center study in Ankara, Turkey. It compared the effectiveness and safety of oral paracetamol and oral ibuprofen for the closure of PDA in preterm infants up to and including 30 weeks' gestational age, birth weight of 1250 g or less, postnatal age of 48 to 96 hours with echocardiographic diagnosis of hemodynamically significant PDA. Infants were randomised to oral paracetamol (15 mg/kg/dose every six hours for three days; n = 40) or oral ibuprofen (10‐5‐5 mg/kg/dose every 24 hours; n = 40). The study's outcomes included rates of ductal closure, all‐cause mortality during initial hospital stay, neonatal mortality (first 28 days of life), infant mortality, re‐opening of the ductus arteriosus, surgical closure of the PDA, duration of ventilatory support, duration of need for supplementary oxygen, pulmonary hemorrhage, pulmonary hypertension, BPD (at 28 days' and at 36 weeks' postmenstrual age, severe BPD at 36 weeks' postmenstrual age), IVH (all grades and Grade III to IV), PVL, NEC, intestinal perforation, gastrointestinal bleeding, ROP (any stage, stage ≥ 3, ROP requiring laser treatment), oliguria (urine output &lt; 1 mL/kg/h), serum levels after treatment of creatinine, bilirubin, AST, ALT, liver failure, duration of hospital stay, and sepsis. In 2017, the authors published neurodevelopmental outcomes of the infants enrolled in this trial. They reported on 30 children in the paracetamol group and 31 children in the ibuprofen group. They reported on neurodevelopmental impairment, mental development index (MDI) of less than 70, psychomotor developmental index (PDI) of less than 70, moderate to severe cerebral palsy, blindness, deafness, and MDI and PDI at 18 to 24 months' corrected age. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and other prespecified secondary short‐ and long‐term outcomes. </p> <p><a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a> was a single‐center study at Amiralmomenin Hospital, Semnan, Iran between May 2018 and May 2019. It evaluated the efficacy and gastrointestinal complications of IV paracetamol and oral ibuprofen for the closure of PDA in preterm infants born at less than 37 weeks' gestational age, less than 14 days' postnatal age, and diagnosis of PDA. Infants were randomised to IV paracetamol (15 mg/kg/dose every six hours for two days; n = 23) or oral ibuprofen (10‐5‐5 mg/kg/dose every 24 hours; n = 17). The study's outcomes included failure of ductal closure after treatment, NEC, gastrointestinal bleeding, and feeding intolerance. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and prespecified secondary outcomes.   </p> <p><a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a> was a prospective RCT between January 2017 and May 2019. It compared the efficacy of IV paracetamol and IV ibuprofen for closure of PDA in preterm infants at 23 to 29weeks' gestational age at birth with a hemodynamically significant PDA diagnosed by echocardiogram within the first two weeks of life. Infants were randomised to IV paracetamol (15 mg/kg/dose every six hours for three days; n = 5) or IV ibuprofen (10‐5‐5 mg/kg/dose every 24 hours; n = 5). The study's outcomes included PDA closure rates and safety outcomes. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and prespecified secondary outcomes. </p> <p><a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a> was a single‐center study in Xuzhou, Jiangsu, China. It aimed to understand the effect of paracetamol treatment on preterm infants of less than 37 weeks' gestational age with a hemodynamically significant PDA between 15 hours and 10 days postnatal age, aiming to utilise and develop plasma and urinary prostaglandin E2 (PGE₂) levels as indicators of progress of PDA closure in a non‐invasive manner. Infants were randomised to oral paracetamol (15 mg/kg/dose every six hours for three days; n = 44) or oral ibuprofen (10‐5‐5 mg/kg/dose every 24 hours; n = 43). The study's outcomes included failure of primary ductal closure, oliguria (&lt; 1 mL/kg/h), stools positive for occult blood, IVH, NEC, BPD, plasma PGE₂ (ng/L), urine PGE₂ (ng/L), platelet count (x10⁹/L), serum creatinine (µmol/L) and ALT (U/L) after treatment. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and prespecified secondary outcomes. </p> </section> <section id="CD010061-sec-0046"> <h5 class="title">Studies comparing oral/IV paracetamol and oral/IV indomethacin</h5> <p>Four studies that enrolled 380 infants compared oral/IV paracetamol to oral/IV indomethacin. The following section provides a brief description of the included studies. </p> <p><a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a> was a single‐center study in Mumbai, India. It compared the effectiveness of oral paracetamol and IV indomethacin for closure of a PDA in preterm neonates with a birth weight of 1500 g or less and echocardiographic diagnosis of hemodynamically significant PDA within the first 48 hours of life. Infants were randomised to oral paracetamol (15 mg/kg/dose every six hours for seven days; n = 38) or IV indomethacin (0.2 mg/kg/dose once daily for three days; n = 39). The study's outcomes included failure to close the PDA, surgical ligation, ROP, gastrointestinal bleeding, NEC, pulmonary hemorrhage, IVH, sepsis, daily urine output, serum creatinine, serum bilirubin, and platelet count. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and prespecified secondary outcomes. </p> <p><a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a> was a multi‐center, non‐inferiority RCT at two level 3 NICUs and one level 4 NICU in Memphis, Tennessee, USA, from June 2016 to September 2018. It compared the rate of successful treatment of a hemodynamically significant PDA after use of IV acetaminophen or IV indomethacin in preterm infants of 22 to 32 weeks' gestational age, birth weight of less than 1500 g, up to and including 21 days' postnatal age, platelet count greater than 50 × 10<sup>9</sup>/L, no previous pharmacological treatment for PDA, and strict echocardiogram criteria for ascertaining the hemodynamic significance of PDA. Infants were randomised to IV paracetamol (15 mg/kg/dose every six hours for three days; n = 17) or IV indomethacin (postnatal age‐adjusted dosing every 12 hours; n = 20). The study's outcomes included rate of successful PDA treatment, additional PDA treatment, surgical or transcatheter closure, duration of invasive mechanical ventilation, respiratory support at 36 weeks' postmenstrual age, NEC, IVH (Grade 3 or 4), ROP, days to full feeds (150 cc/kg/d), gastrointestinal perforation, length of stay, renal dysfunction, creatinine elevation greater than 1.5 mg/dL during treatment, and discharge disposition. The baseline characteristics were similar between the two groups except for left atrial size to aortic root ratio (LA:Ao ratio), which was higher in the indomethacin group. The authors found a significant difference between the two groups with regards to ductal closure rates favouring the indomethacin group (11/20 in the indomethacin group versus 1/17 in the paracetamol group; P = 0.002). There were no differences between the two groups for other prespecified secondary outcomes.  </p> <p><a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a> was a single‐center, three‐arm RCT in the Division of Pediatric Cardiology, Department of Pediatrics, MDM and Umaid Hospital, Dr SN Medical College, Jodhpur, India. It compared the efficacy and safety of ibuprofen, indomethacin, and paracetamol in the closure of PDA in preterm neonates of less than 37 weeks' gestational age, in the first 28 days of life, with hemodynamically significant PDA. Infants were randomised to IV paracetamol (15 mg/kg/dose every six hours for three days; n = 35), oral ibuprofen (10‐5‐5 mg/kg/dose; n = 35), or oral indomethacin (postnatal age‐adjusted dosing at 12‐hourly intervals; n = 35) for PDA treatment. The study's outcomes included PDA closure after the first and second course of treatment and adverse effects in each group. The baseline characteristics were similar between the three groups. The authors found no significant difference between the groups with regards to ductal closure rates after the first and second course of treatment. There was significant increase in BUN and serum creatinine post‐treatment in the ibuprofen and indomethacin groups. There were no significant differences for other prespecified secondary outcomes between the three groups.  </p> </section> <section id="CD010061-sec-0047"> <h5 class="title">Studies comparing prophylactic oral/IV paracetamol versus placebo/no intervention</h5> <p>Three studies that enrolled 240 infants compared oral/IV paracetamol to oral/IV indomethacin. The following section provides a brief description of the included studies. </p> <p><a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a> was a single‐center study in Tehran, Iran, from March 2012 to March 2013. It aimed to determine the effectiveness of prophylactic treatment with oral paracetamol for PDA in preterm infants of 32 weeks' gestational age or less, birth weight of 1500 g or less, and a postnatal age of less than 24 hours. Infants were randomised to prophylactic oral paracetamol (15 mg/kg/dose every six hours for 48 hours; n = 16) or no intervention (n = 16). The study's outcomes included failure to close a PDA by four to five days, death, and needing treatment with ibuprofen. The baseline characteristics were similar between the two groups. The authors found no significant difference between the two groups with regards to ductal closure rates and prespecified secondary outcomes.  </p> <p><a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a> was a single‐center RCT in the NICU of the Afzalipour tertiary hospital, Kerman, Iran, between November 2015 and 2016. It aimed to assess the efficacy of prophylactic IV paracetamol versus no intervention in decreasing the rate of ductal patency in preterm infants of 34 weeks' gestational age or less. Infants were randomised to prophylactic IV paracetamol (20 mg/kg immediately followed by 7.5 mg/kg every six hours during the first three days; n = 80) or no intervention (n = 80). The study's outcomes included frequency of PDA on day four of life, all‐cause mortality, duration of mechanical ventilation, and duration of hospitalization. The baseline characteristics were similar between the two groups. The authors found a significant difference between the two groups with regards to the frequency of PDA favouring the prophylactic paracetamol group (12/80 in prophylactic paracetamol group versus 57/80 in the no‐intervention group; P &lt; 0.001). There were no significant differences between the two groups for other prespecified secondary outcomes.  </p> <p><a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a> was a single‐center study in the NICU of Oulu University Hospital, Oulu, Finland. It studied the biologic effect of prophylactic paracetamol on early closure of PDA in preterm infants of less than 32 weeks' gestational age and of less than 24 hours of age. Infants were randomised to prophylactic IV paracetamol (20 mg/kg followed by 7.5 mg/kg/dose every six hours for four days; n =23) or placebo (0.45% NaCl; n = 25). The study's outcomes included decrease in ductal calibre without side effects and failure to close a PDA by four to five days, permanent closure of PDA, oliguria (&lt; 1 mL/kg/h), polyuria (&gt; 5 mL/kg/h), hypernatremia (&gt; 150 mmol/L), sepsis, supplemental oxygen at 28 days, supplemental oxygen at 36 weeks' postmenstrual age, ROP treated, IVH grades 1 to 2, IVH grades 3 to 4, NEC stage 3, death, days of supplemental oxygen, and the highest serum bilirubin (µmol/L). In 2019, the authors published growth, cardiac, and neurodevelopmental outcomes of the infants enrolled in this trial at two years' corrected age. They reported on 23 children in the paracetamol group and 21 children in the control group. The baseline characteristics were similar between the two groups. The mean (95% CI) postnatal ages for ductal closure were 177 hours (31.1 to 324) for the paracetamol‐treated group versus 338 hours (118 to 557) for controls (P = 0.045). There were no significant differences between the two groups for other prespecified short‐ and long‐term outcomes. </p> </section> <section id="CD010061-sec-0048"> <h5 class="title">Studies comparing early (&lt; 14 days' postnatal age) oral/IV paracetamol versus placebo/no intervention </h5> <p>Two studies that enrolled 127 infants compared early oral/IV paracetamol to placebo or no intervention. The following section provides a brief description of the included studies. </p> <p><a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a> was a single‐center RCT in the NICU of the Imam Reza Hospital in Kermanshah City, Iran in 2015. It aimed to evaluate the effect of oral acetaminophen on closure of PDA in preterm neonates of 34 weeks' gestational age or less, postnatal age of less than 14 days, and with a hemodynamically significant PDA. Infants were randomised to the oral paracetamol group (15 mg/kg/dose every six hours for 72 hours; n = 36) or a control group which received no intervention (n = 33). The study's outcomes included primary and secondary closure rate of PDA and hepatotoxicity. The baseline characteristics were similar between the two groups. The authors found a significant difference between the two groups with regards to overall PDA closure rates favouring the paracetamol group (34/36 in paracetamol group versus 5/33 in the no‐intervention group; P = 0.001). There were no significant differences between the two groups for other prespecified secondary outcomes.  </p> <p><a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a> was a double‐blind, placebo‐controlled, parallel, two‐arm, randomised, phase II, single‐center trial between November 2016 and March 2019. It investigated whether early treatment with paracetamol reduced the number of infants requiring intervention for PDA and assessed the safety profile of paracetamol compared to placebo in preterm infants born at less than 29 weeks' gestational age, less than six hours old, and with a ductus arteriosus of 1.0 mm diameter or greater with less than 30% right to left shunt (implying normal circulatory adaptation). Infants were randomised to IV paracetamol (15 mg/kg followed by 7.5 mg/kg/dose every six hours for five days; n =29) or placebo (IV 5% dextrose 1.5 mL/kg, followed by 0.75 mL every six hours for five days; n = 29). The study's outcomes included any intervention for management of PDA up to five days' postnatal age, closure of ductus arteriosus at five days' postnatal age, size of the ductus arteriosus at 48 hours and at five days' postnatal age, ductal re‐opening during admission, ductus arteriosus parameters, systemic blood flow measurements, adverse events during the treatment period, mortality, pulmonary hemorrhage, NEC, early‐onset sepsis, late‐onset sepsis, IVH, PVL, BPD, and ROP. The baseline characteristics were similar between the two groups. The authors found a significant difference between the two groups with regards to any intervention for PDA up to five days of life favouring the paracetamol group (6/29 in paracetamol group versus 17/29 in placebo group; P = 0.003). There were no significant differences between the two groups for other prespecified secondary outcomes.  </p> </section> <section id="CD010061-sec-0049"> <h5 class="title">Studies comparing late (&gt; 14 days' postnatal age) oral/IV paracetamol versus placebo/no intervention </h5> <p>One study in 55 infants compared late oral/IV paracetamol to placebo or no intervention. The following section provides a brief description of this study. </p> <p><a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a> was a multi‐center, prospective, randomised, blinded, placebo‐controlled pilot trial in three Australian tertiary NICUs from March 2012 to December 2015. It aimed to explore the efficacy and risks of oral paracetamol in late treatment of PDA in preterm infants of less than 33 weeks' gestational age and postnatal age of more than two weeks, with a hemodynamically significant PDA and tolerating at least 50% of enteral feeds. Infants were randomized to oral paracetamol (loading dose of 25 mg/kg/dose followed by 15 mg/kg per dose. The maintenance dosing interval was a 12‐hourly interval in preterm infants of less than 32 weeks' postmenstrual age, an 8‐hourly interval in infants of 32 to 36 weeks' postmenstrual age, and a 6‐hourly interval in term infants, for a total of five days; n = 27) or placebo (same volume and similar to paracetamol in consistency and colour; n = 28). The study's outcomes included PDA closure, significant (&gt; 25%) constriction of ductal diameter, safety of paracetamol assessed by determining serum paracetamol levels and liver function tests, change in respiratory status (pre‐treatment versus post‐treatment), feed intolerance, abdominal distension, mortality, and BPD. The baseline characteristics were similar between the two groups except for a higher number of males in the paracetamol group. There was a significant difference between the two groups favouring the paracetamol group with regards to ductal closure (4/27 in the paracetamol group versus 0/28 in the placebo group; P = 0.03) and significant constriction of PDA (13/23 in the paracetamol group versus 7/28 in the placebo group; P &lt; 0.001). There were no differences between the two groups for other prespecified secondary outcomes. </p> </section> <section id="CD010061-sec-0050"> <h5 class="title">Studies comparing combination treatment (ibuprofen plus paracetamol) versus ibuprofen plus placebo/no intervention </h5> <p>Two studies that enrolled 111 infants compared oral/IV ibuprofen plus paracetamol to oral/IV ibuprofen plus placebo or no intervention. The following section provides a brief description of these two studies. </p> <p><a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a> was a randomised, double‐blind, prospective pilot study in the NICU of Rambam Medical Center in Haifa, Israel, between 2014 and 2016. It compared the closure rate of hemodynamically significant PDA for IV ibuprofen plus paracetamol versus ibuprofen plus placebo in preterm infants of 24 to 31 weeks' gestational age with a hemodynamically significant PDA. Infants were randomised to IV paracetamol plus ibuprofen (ibuprofen 10‐5‐5 mg/kg/dose and paracetamol: loading dose of 20 mg/kg followed by 10 mg/kg every six hours for three days; n = 12) or ibuprofen plus placebo (10‐5‐5 mg/kg/dose and placebo [0.9% normal saline]; n =12). The study's outcomes included failure of ductal closure after one or two courses, need for a second course, need for surgical ligation, rates of ductal re‐opening, duration of ventilation, pneumothorax, pulmonary hemorrhage, BPD, IVH, NEC, gastrointestinal bleeding, ROP, sepsis, and death. Safety parameters included an increase in serum creatinine, decrease in urine output to less than 1 mL/kg/h, AST or ALT levels, as well as paracetamol levels. The baseline characteristics were similar between the two groups. There were no differences between the two groups for ductal closure rates and prespecified secondary outcomes. </p> <p><a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a> was a three‐arm, multi‐center RCT in the NICUs of two hospitals (Nemazee Hospital and Hafez Hospital) affiliated with the Shiraz University of Medical Science, Iran from March 2016 to March 2017. It evaluated the efficacy and safety of ibuprofen plus paracetamol, ibuprofen alone, and paracetamol alone for PDA closure in preterm infants with a hemodynamically significant PDA and a postnatal age up to 14 days. Infants were randomised to oral ibuprofen plus IV paracetamol (ibuprofen 10‐5‐5 mg/kg/dose for three doses 24 hours apart and paracetamol: 15 mg/kg every six hours for three days; n = 19) or oral ibuprofen (10‐5‐5 mg/kg/dose for three doses 24 hours apart; n = 68) or IV paracetamol (15 mg/kg every six hours for three days; n = 67). The study's outcomes included ductal closure rates after first and second course of treatment, platelet count, blood urea nitrogen, bilirubin, serum creatinine, AST and ALT pre‐ and post‐treatment course, NEC, renal or liver dysfunction, bleeding tendency, IVH grade 3 or 4, and intestinal perforation. The baseline characteristics were similar between the two groups. There were no differences between the two groups for ductal closure rates and prespecified secondary outcomes. </p> </section> </section> <section id="CD010061-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded four studies, which were all observational in nature (<a href="./references#CD010061-bbs2-0028" title="CakirU , TaymanC , KaracaglarNB , BeserE , CeranB , UnsalH . Comparison of the effect of continuous and standard intermittent bolus paracetamol infusion on patent ductus arteriosus. European Journal of Pediatrics2021;180(2):433-40. [DOI: 10.1007/s00431-020-03822-1] [PMID: 32995919]">Cakir 2021</a>; <a href="./references#CD010061-bbs2-0029" title="HöckM , BrunnerB , RierV , ThöniS , TrawögerR , GeigerR , et al. Prophylactic low-dose paracetamol administration associated with lowered rate of patent ductus arteriosus in preterm infants - impact on outcome and pain perception. Pediatrics and Neonatology2020;61(1):84-91. [DOI: 10.1016/j.pedneo.2019.06.011] [PMID: 31345732]">Höck 2020</a>; <a href="./references#CD010061-bbs2-0030" title="KingR , ColonM , StanfelL , TauberKA . Late acetaminophen therapy for patent ductus arteriosus in the preterm neonate. Journal of Pediatric Pharmacology and Therapeutics2020;25(6):507-13. [DOI: 10.5863/1551-6776-25.6.507] [PMID: 32839654]">King 2020</a>; <a href="./references#CD010061-bbs2-0031" title="ShahSD , MakkerK , NandulaP , SmothermanC , KropfA , HudakML . Effectiveness of dual medication therapy (oral acetaminophen and oral ibuprofen) for the management of patent ductus arteriosus in extremely premature infants: a feasibility trial. American Journal of Perinatology 2021 Jan 17 [Epub ahead of print]. [DOI: 10.1055/s-0040-1722329] [PMID: 33454945]">Shah 2021</a>). See <a href="./references#CD010061-sec-0191" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD010061-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias in included studies is shown in <a href="#CD010061-fig-0002">Figure 2</a> and <a href="#CD010061-fig-0003">Figure 3</a>. Fourteen of the 27 included studies had high risk of bias in the blinding of participants and personnel domain. We assessed five studies to be of low risk of bias across all domains (<a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>; <a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; see <a href="#CD010061-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD010061-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010061-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010061-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010061-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010061-sec-0053"> <h4 class="title">Allocation</h4> <p>We assessed the risk of selection bias regarding random sequence generation to be high in two studies (<a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>), unclear in three studies (<a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>), and low in the remaining 22 studies (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>; <a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). <a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a> reported that infants were "[randomly] allocated in 1:1 ratio by convenient sampling method". <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a> reported that "[neonates] were allocated in either group based on even or odd hospital registration number". </p> <p>Fifteen studies used sequentially‐numbered, sealed, opaque envelopes for allocation to the two treatment groups and thus we judged these to be of low risk of selection bias due to allocation concealment (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>; <a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a>). The risk of selection bias regarding allocation concealment was unclear in 11 studies (<a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a> reported that the "[control] group didn't receive any medication" so we deemed this study as being at high risk of bias for allocation concealment. </p> </section> <section id="CD010061-sec-0054"> <h4 class="title">Blinding</h4> <section id="CD010061-sec-0055"> <h5 class="title">Performance bias</h5> <p>Fourteen studies had high risk of bias in the domain of blinding of participants and personnel (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). Six studies had low risk of bias in the domain of blinding of participants and personnel (<a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>; <a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a>), and the remaining seven studies were unclear (<a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>). </p> </section> <section id="CD010061-sec-0056"> <h5 class="title">Detection bias</h5> <p>In the domain of blinding of outcome assessment, 13 studies had low risk of bias (<a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>; <a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>). Three studies had high risk of bias (<a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>) and the remaining 11 studies had unclear risk of bias (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>).  </p> </section> </section> <section id="CD010061-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>With the exception of <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>, we assessed all included studies as having a low risk of attrition bias as they reported outcome data for all prespecified outcomes and for all enrolled infants. We assessed <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a> as having a high risk of bias in this domain as not all infants randomized were subsequently analyzed. </p> </section> <section id="CD010061-sec-0058"> <h4 class="title">Selective reporting</h4> <p>The protocols for 14 studies were available to us as the trials were registered prospectively (<a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>; <a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>). We assessed these as having a low risk of reporting bias as there did not seem to be any deviations from the protocols for these studies. We judged the remaining 13 studies to have an unclear risk of bias in this domain: five studies were registered retrospectively (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a>; <a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>); eight studies were not registered (<a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>).  </p> </section> <section id="CD010061-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential sources of bias in the 27 included studies.</p> </section> </section> <section id="CD010061-sec-0060"> <h3 class="title" id="CD010061-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD010061-tbl-0001"><b>Summary of findings 1</b> Paracetamol versus ibuprofen for PDA in preterm or low birth weight infants</a>; <a href="./full#CD010061-tbl-0002"><b>Summary of findings 2</b> Paracetamol versus indomethacin for PDA in preterm or low birth weight infants </a>; <a href="./full#CD010061-tbl-0003"><b>Summary of findings 3</b> Prophylactic administration of paracetamol versus placebo or no intervention for PDA in preterm or low birth weight infants</a>; <a href="./full#CD010061-tbl-0004"><b>Summary of findings 4</b> Early paracetamol versus placebo/no intervention for PDA in preterm or low birth weight infants</a>; <a href="./full#CD010061-tbl-0005"><b>Summary of findings 5</b> Late paracetamol versus placebo/no intervention for PDA in preterm or low birth weight infants</a>; <a href="./full#CD010061-tbl-0006"><b>Summary of findings 6</b> Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</a> </p> <section id="CD010061-sec-0061"> <h4 class="title">Comparison 1. Paracetamol (oral or IV) versus ibuprofen (oral or IV)</h4> <p>See <a href="./full#CD010061-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD010061-sec-0062"> <h5 class="title">Primary outcomes</h5> <section id="CD010061-sec-0063"> <h6 class="title">Failure of PDA closure after first course of paracetamol treatment</h6> <p>Eighteen studies (1535 infants) reported this outcome (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). There was probably little to no difference between the paracetamol and the ibuprofen groups in failure of PDA closure after the first course of treatment (RR 1.02, 95% 0.88 to 1.18; I<sup>2</sup> = 16%. RD 0.01, 95% CI −0.04 to 0.05; I<sup>2</sup>= 29%; moderate‐certainty evidence; <a href="./references#CD010061-fig-0006" title="">Analysis 1.1</a>). Visual inspection of the funnel plot did not reveal publication bias (<a href="#CD010061-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD010061-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot: failure of PDA closure after first course of treatment for comparison 'Paracetamol (oral or IV) versus ibuprofen (oral or IV)'" data-id="CD010061-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot: failure of PDA closure after first course of treatment for comparison 'Paracetamol (oral or IV) versus ibuprofen (oral or IV)' </p> </div> </div> </div> </section> <section id="CD010061-sec-0064"> <h6 class="title">Neurodevelopmental impairment at 18 to 24 months (corrected age)</h6> <p>One study reported this outcome in 61 children (<a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was little to no difference between the paracetamol and the ibuprofen groups in the incidence of neurodevelopmental impairment (RR 0.93, 95% CI 0.44 to 1.96. RD −0.02, 95% CI −0.25 to 0.21; low‐certainty evidence; <a href="./references#CD010061-fig-0007" title="">Analysis 1.2</a>). Tests for heterogeneity were not applicable.  </p> <p>There were little to no differences between the groups for the following outcomes in the follow‐up report by <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>: mental development index (MDI) of less than 70, <a href="./references#CD010061-fig-0036" title="">Analysis 1.31</a>; psychomotor developmental index (PDI) of less than 70, <a href="./references#CD010061-fig-0037" title="">Analysis 1.32</a>; moderate to severe cerebral palsy, <a href="./references#CD010061-fig-0038" title="">Analysis 1.33</a>; deafness, <a href="./references#CD010061-fig-0039" title="">Analysis 1.34</a>; blindness, <a href="./references#CD010061-fig-0040" title="">Analysis 1.35</a>; MDI, <a href="./references#CD010061-fig-0041" title="">Analysis 1.36</a>; or PDI, <a href="./references#CD010061-fig-0042" title="">Analysis 1.37</a>. As there was only one study included in these analyses, tests for heterogeneity were not applicable. </p> </section> <section id="CD010061-sec-0065"> <h6 class="title">Death or disability at 18 to 24 months</h6> <p>No studies reported this outcome (including the follow‐up study of <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). </p> </section> </section> <section id="CD010061-sec-0066"> <h5 class="title">Secondary outcomes</h5> <section id="CD010061-sec-0067"> <h6 class="title">All‐cause mortality during initial hospital stay </h6> <p>Eight studies (734 infants) reported this outcome (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was probably little to no difference between the paracetamol and the ibuprofen groups for all‐cause mortality during the initial hospital stay (RR 1.09, 95% CI 0.80 to 1.48; I² = 0%. RD 0.01, 95% CI −0.04 to 0.07; I² = 0%; moderate‐certainty evidence; <a href="./references#CD010061-fig-0008" title="">Analysis 1.3</a>).  </p> </section> <section id="CD010061-sec-0068"> <h6 class="title">Re‐opening of the ductus arteriosus</h6> <p>Defined as echocardiographic evidence of closure followed by re‐opening of PDA at a later stage.  </p> <p>Five studies (458 infants) reported this outcome (<a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was little to no difference between the paracetamol and the ibuprofen groups in the risk of re‐opening of the ductus arteriosus (RR 1.35, 95% CI 0.85 to 2.12, I² = 0%. RD 0.04, 95% CI ‐0.02 to 0.1; I² = 2%; <a href="./references#CD010061-fig-0010" title="">Analysis 1.5</a>). </p> </section> <section id="CD010061-sec-0069"> <h6 class="title">Failure of PDA closure after second course of treatment</h6> <p>Thirteen studies reported this outcome in 393 infants (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was little to no difference in failure of PDA closure after the second course of treatment (RR 0.97, 95% CI 0.78 to 1.21; I² = 0%. RD −0.01, 95% CI −0.11 to 0.08; I² = 0%; <a href="./references#CD010061-fig-0011" title="">Analysis 1.6</a>). Visual inspection of the funnel plot did not reveal publication bias (<a href="#CD010061-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD010061-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot: failure of PDA closure after second course of treatment for comparison 'Paracetamol (oral or IV) versus ibuprofen (oral or IV)'" data-id="CD010061-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot: failure of PDA closure after second course of treatment for comparison 'Paracetamol (oral or IV) versus ibuprofen (oral or IV)' </p> </div> </div> </div> </section> <section id="CD010061-sec-0070"> <h6 class="title">Surgical closure of the PDA</h6> <p>Six studies (603 infants) reported this outcome (<a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>). There was little to no difference between the paracetamol and the ibuprofen groups in surgical closure of the PDA (RR 0.61, 95% CI 0.34 to 1.08, I² = 0%. RD −0.04, 95% CI −0.08 to 0.00; I² = 0%; <a href="./references#CD010061-fig-0012" title="">Analysis 1.7</a>). </p> </section> <section id="CD010061-sec-0071"> <h6 class="title">Duration of need for supplementary oxygen (days)</h6> <p>One study (90 infants) reported this outcome (<a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was little to no difference between the paracetamol and the ibuprofen groups in the duration of need for supplementary oxygen (O₂) favouring the paracetamol group (mean difference (MD) −12.40 days, 95% CI −22.97 to −1.83; <a href="./references#CD010061-fig-0014" title="">Analysis 1.9</a>). The test for heterogeneity was not applicable. </p> </section> <section id="CD010061-sec-0072"> <h6 class="title">Pulmonary hemorrhage</h6> <p>Defined as blood‐stained liquid flowing from the trachea of the infant. </p> <p>Five studies (442 infants) reported this outcome (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was little to no difference between the paracetamol and the ibuprofen groups in the risk of pulmonary hemorrhage (RR 0.87, 95% CI 0.36 to 2.09, I² = 0%. RD −0.01, 95% CI −0.04 to 0.03; I² = 0%; <a href="./references#CD010061-fig-0015" title="">Analysis 1.10</a>). </p> </section> <section id="CD010061-sec-0073"> <h6 class="title">Intraventricular hemorrhage (IVH) (Grade I‐IV)</h6> <p>Eight studies reported this outcome, in 800 infants (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). There was probably little to no difference between the paracetamol and the ibuprofen groups in the risk of IVH (RR 0.97, 95% CI 0.77 to 1.22; I² = 0%. RD −0.01, 95% CI −0.05 to 0.04; I² = 0%; <a href="./references#CD010061-fig-0020" title="">Analysis 1.15</a>). </p> </section> <section id="CD010061-sec-0074"> <h6 class="title">Severe IVH (Grade III‐IV) </h6> <p>Six studies reported this outcome, in 544 infants (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was probably little to no difference between the paracetamol and the ibuprofen groups in the risk of severe IVH (RR 0.63, 95% CI 0.28 to 1.43; I² = 0%. RD −0.02, 95% CI −0.05 to 0.02; I² = 0%; <a href="./references#CD010061-fig-0021" title="">Analysis 1.16</a>). </p> </section> <section id="CD010061-sec-0075"> <h6 class="title">Periventricular leukomalacia (PVL)</h6> <p>Four studies reported this outcome, in 421 infants (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was little to no difference between the paracetamol and the ibuprofen groups in the risk of PVL (RR 1.40, 95% CI 0.56 to 3.50; I² = 0%. RD 0.01, 95% CI −0.03 to 0.05; I² = 0%; <a href="./references#CD010061-fig-0022" title="">Analysis 1.17</a>). </p> </section> <section id="CD010061-sec-0076"> <h6 class="title">Necrotizing enterocolitis (NEC)</h6> <p>Ten studies (1015 infants) reported this outcome (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). There was probably little to no difference between the paracetamol and the ibuprofen groups for NEC (RR 1.30, 95% CI 0.87 to 1.94; I² = 0%. RD 0.02, 95% CI −0.01 to 0.05, I² = 17%; moderate‐certainty evidence; <a href="./references#CD010061-fig-0023" title="">Analysis 1.18</a>).  </p> </section> <section id="CD010061-sec-0077"> <h6 class="title">Gastrointestinal bleed</h6> <p>Seven studies (693 infants) reported gastrointestinal bleeding (<a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). There may be a reduction in the incidence of gastrointestinal bleeding in the paracetamol group compared to the ibuprofen group (RR 0.37, 95% CI 0.19 to 0.73; I² = 10%. RD −0.05, 95% CI −0.09 to −0.02; I² = 25%; <a href="./references#CD010061-fig-0025" title="">Analysis 1.20</a>). The NNTB was 20, 95% CI 12 to 54.  </p> </section> <section id="CD010061-sec-0078"> <h6 class="title">Oliguria</h6> <p>Decreased urine output defined as &lt; 1 mL/kg/h during treatment. </p> <p>Five studies (608 infants) reported this outcome (<a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). Oliguria did not occur in any infant in the study by <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>. There was likely a reduction in oliguria favouring the paracetamol group, in the comparison between paracetamol and ibuprofen (RR 0.47, 95% CI 0.30 to 0.76; I<sup>2</sup> = 0%. RD −0.08, 95% CI −0.13 to ‐0.03; I<sup>2</sup>= 76%; <a href="./references#CD010061-fig-0028" title="">Analysis 1.23</a>). </p> </section> <section id="CD010061-sec-0079"> <h6 class="title">Sepsis</h6> <p>Clinical symptoms and signs of sepsis and a positive blood bacterial culture. </p> <p>Seven studies (844 infants) reported this outcome (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was little to no difference between the paracetamol and the ibuprofen groups in the risk for sepsis (RR 0.93, 95% CI 0.72 to 1.22; I² = 0%. RD −0.01, 95% CI −0.07 to 0.04; I<sup>2</sup>=15%; <a href="./references#CD010061-fig-0029" title="">Analysis 1.24</a>). </p> </section> <section id="CD010061-sec-0080"> <h6 class="title">Post‐pre difference in serum or plasma levels of creatinine (mg/dL) </h6> <p>Six studies (557 infants) reported this outcome (<a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). There was likely a reduction, favouring the paracetamol group, in post‐pre treatment difference in serum creatinine levels in the comparison between paracetamol and ibuprofen (MD −0.12 mg/dL, 95% CI −0.13 to −0.10; I² = 88%; <a href="./references#CD010061-fig-0030" title="">Analysis 1.25</a>). This result indicates that creatinine levels were probably higher post‐treatment with ibuprofen compared with paracetamol. </p> </section> <section id="CD010061-sec-0081"> <h6 class="title">Serum bilirubin (μmol/L) following treatment</h6> <p>Four studies reported this outcome, in 400 infants (<a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). There was likely a reduction in serum bilirubin (μmol/L) following treatment in both the paracetamol and the ibuprofen groups, with lower serum bilirubin levels in the paracetamol group (MD −10.56 µmol/L, 95% CI −13.16 to −7.96; I² = 82%; <a href="./references#CD010061-fig-0033" title="">Analysis 1.28</a>). </p> </section> <section id="CD010061-sec-0082"> <h6 class="title">Hyperbilirubinemia</h6> <p>Defined as a serum bilirubin level higher than the exchange level according to the postnatal age and body weight.  </p> <p>One study reported this outcome in 160 infants (<a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>). There was likely a reduction in hyperbilirubinemia favouring the paracetamol group compared to the ibuprofen group (RR 0.57, 95% CI 0.34 to 0.97; RD −0.15, −0.29 to −0.01; NNTB 7, 95% CI 3 to 100; <a href="./references#CD010061-fig-0034" title="">Analysis 1.29</a>). </p> </section> </section> <section id="CD010061-sec-0083"> <h5 class="title">Other secondary outcomes</h5> <p>There were little to no differences between the paracetamol (oral or IV) group compared to the ibuprofen group (oral or IV) for the following outcomes. </p> <p> <ul id="CD010061-list-0009"> <li> <p>Neonatal mortality (death during the first 28 days of life), as illustrated in <a href="./references#CD010061-fig-0009" title="">Analysis 1.4</a>. </p> </li> <li> <p>Duration of ventilator support (days) (<a href="./references#CD010061-fig-0013" title="">Analysis 1.8</a>). </p> </li> <li> <p>Pulmonary hypertension (defined as an increased mean pulmonary arterial pressure of 25 mmHg at rest) (<a href="./references#CD010061-fig-0016" title="">Analysis 1.11</a>).  </p> </li> <li> <p>BPD at 36 weeks' postmenstrual age (defined as O₂ requirement at 36 weeks' postmenstrual age in addition to compatible clinical and roentgenographic findings) (<a href="./references#CD010061-fig-0017" title="">Analysis 1.12</a>).  </p> </li> <li> <p>Moderate to severe BPD according to the new criteria (i.e. moderate BPD defined as O₂ for ≥ 28 days plus treatment with &lt; 30% O₂ at 36 weeks' postmenstrual age; and severe BPD as O₂ for ≥ 28 days plus ≥ 30% O₂ or positive pressure at 36 weeks' postmenstrual age, or both) (<a href="./references#CD010061-fig-0018" title="">Analysis 1.13</a>).  </p> </li> <li> <p>Severe BPD defined according to the new criteria (i.e. severe BPD defined as O₂ for ≥ 28 days plus ≥ 30% O₂ or positive pressure at 36 weeks' postmenstrual age, or both (<a href="./references#CD010061-fig-0019" title="">Analysis 1.14</a>)).  </p> </li> <li> <p>Intestinal perforation (<a href="./references#CD010061-fig-0024" title="">Analysis 1.19</a>). </p> </li> <li> <p>ROP stage 3 or higher (according to the international classification of ROP) (<a href="./references#CD010061-fig-0026" title="">Analysis 1.21</a>).  </p> </li> <li> <p>ROP requiring treatment (<a href="./references#CD010061-fig-0027" title="">Analysis 1.22</a>).  </p> </li> <li> <p>Serum or plasma levels of aspartate transaminase (AST) (U/L) following treatment (<a href="./references#CD010061-fig-0031" title="">Analysis 1.26</a>).  </p> </li> <li> <p>Post‐pre difference in serum or plasma levels of ALT (U/L) (<a href="./references#CD010061-fig-0032" title="">Analysis 1.27</a>). </p> </li> <li> <p>Duration of hospitalization (total length of hospitalization from birth to discharge home or death, in days) (<a href="./references#CD010061-fig-0035" title="">Analysis 1.30</a>). </p> </li> </ul> </p> <section id="CD010061-sec-0084"> <h6 class="title">Incidence of liver failure</h6> <p>Defined as evidence of acute liver injury combined with either severe coagulopathy (international normalized ratio (INR) &gt; 2.0 or prothrombin time (PT) &gt; 20 seconds) or encephalopathy with moderate coagulopathy (INR ≥ 1.5 or PT ≥ 15 seconds). </p> <p>One study (90 infants) reported this outcome (<a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>). Liver failure did not occur in any infant enrolled in the study. </p> </section> <section id="CD010061-sec-0085"> <h6 class="title">Autism or autism spectrum disorder (ASD) in childhood</h6> <p>As defined by the American Psychiatric Association (<a href="./references#CD010061-bbs2-0056" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington, VA: American Psychiatric Association, 2013.">APA 2013</a>). </p> <p>No study has reported on this outcome, but <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a> indicates in his follow‐up study that the authors plan to re‐evaluate their cohort in terms of autism spectrum disorders in the future. </p> </section> <section id="CD010061-sec-0086"> <h6 class="title">Other side effects reported by the authors (not prespecified)</h6> <p><a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a> found no other side effects. </p> <p>The following outcomes were not reported: treatment with indomethacin, ibuprofen or another prostaglandin inhibitor to close the PDA, acute kidney injury, number of infants with AST or ALT greater than 100 U/L, and language delay. </p> </section> </section> <section id="CD010061-sec-0087"> <h5 class="title">Comparison 1 subgroup analysis: paracetamol (oral or IV) versus ibuprofen (oral or IV) in infants of less than 32 weeks' gestational age </h5> <section id="CD010061-sec-0088"> <h6 class="title">Primary outcomes</h6> <section id="CD010061-sec-0089"> <p><b>Failure of PDA closure after first course of paracetamol treatment</b></p> <p>Six studies reported this outcome in 584 infants (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>). There was little to no difference between the paracetamol and ibuprofen groups for failure of PDA closure after one course of treatment (RR 1.29, 95% CI 1.00 to 1.66; I<sup>2</sup> = 47%. RD 0.07, 95% CI 0.00 to 0.15; I<sup>2</sup>= 59%; <a href="./references#CD010061-fig-0091" title="">Analysis 7.1</a>). </p> </section> <section id="CD010061-sec-0090"> <p><b>Neurodevelopmental impairment at 18 to 24 months corrected age</b></p> <p>No studies reported on this outcome.</p> </section> <section id="CD010061-sec-0091"> <p><b>Death or disability at 18 to 24 months</b></p> <p>No studies reported on this combined outcome.</p> </section> </section> <section id="CD010061-sec-0092"> <h6 class="title">Secondary outcomes</h6> <p>There was little to no difference between the paracetamol (oral or IV) and ibuprofen (oral or IV) groups for the following outcomes: </p> <p> <ul id="CD010061-list-0010"> <li> <p>all‐cause mortality during initial hospital stay (<a href="./references#CD010061-fig-0092" title="">Analysis 7.2</a>); </p> </li> <li> <p>failure of PDA closure after two courses of treatment (<a href="./references#CD010061-fig-0093" title="">Analysis 7.3</a>); </p> </li> <li> <p>surgical ligation of PDA (<a href="./references#CD010061-fig-0094" title="">Analysis 7.4</a>); </p> </li> <li> <p>IVH (all grades) (<a href="./references#CD010061-fig-0095" title="">Analysis 7.5</a>); </p> </li> <li> <p>severe IVH (<a href="./references#CD010061-fig-0096" title="">Analysis 7.6</a>); </p> </li> <li> <p>NEC (<a href="./references#CD010061-fig-0097" title="">Analysis 7.7</a>); </p> </li> <li> <p>gastrointestinal bleed or stools positive for occult blood (<a href="./references#CD010061-fig-0098" title="">Analysis 7.8</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD010061-sec-0093"> <h4 class="title">Comparison 2. Paracetamol (oral or IV) versus indomethacin (oral or IV)</h4> <p>See <a href="./full#CD010061-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD010061-sec-0094"> <h5 class="title">Primary outcomes</h5> <section id="CD010061-sec-0095"> <h6 class="title">Failure of PDA closure after first course of treatment</h6> <p>Four studies reported this outcome in 380 infants (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>). There was little to no difference between the paracetamol and indomethacin groups (RR 1.02, 95% CI 0.78 to 1.33, I² = 76%. RD 0.01, 95% CI −0.07 to 0.08; I² = 85%; low‐certainty evidence; <a href="./references#CD010061-fig-0043" title="">Analysis 2.1</a>).  </p> </section> <section id="CD010061-sec-0096"> <h6 class="title">Neurodevelopmental impairment at 18 to 24 months (corrected age) </h6> <p>No studies reported this outcome.</p> </section> <section id="CD010061-sec-0097"> <h6 class="title">Death or disability at 18 to 24 months</h6> <p>No studies reported this outcome.</p> </section> </section> <section id="CD010061-sec-0098"> <h5 class="title">Secondary outcomes</h5> <section id="CD010061-sec-0099"> <h6 class="title">All‐cause mortality during initial hospital stay</h6> <p>Two studies reported this outcome in 114 infants (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>). There was little to no difference between the paracetamol and indomethacin groups for all‐cause mortality during initial hospital stay (RR 0.86, 95% CI 0.39 to 1.92, I² = 0%. RD −0.03, 95% CI −0.16 to 0.11; I² = 0%; low‐certainty evidence; <a href="./references#CD010061-fig-0044" title="">Analysis 2.2</a>).  </p> </section> <section id="CD010061-sec-0100"> <h6 class="title">Pulmonary hemorrhage</h6> <p>Three studies reported this outcome in 347 infants (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>). There was little to no difference between the paracetamol and indomethacin groups (RR 0.77, 95% CI 0.28 to 2.10; I² = 48%. RD −0.01, 95% CI −0.05 to 0.03; I² = 62%; <a href="./references#CD010061-fig-0047" title="">Analysis 2.5</a>).  </p> </section> <section id="CD010061-sec-0101"> <h6 class="title">IVH (Grade I‐IV)</h6> <p>Two studies reported this outcome in 275 infants (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>). There was little to no difference between the paracetamol and indomethacin groups (RR 0.82, 95% CI 0.42 to 1.63; I² = 49%. RD −0.02, 95% CI −0.09 to 0.05; I² = 29%; <a href="./references#CD010061-fig-0049" title="">Analysis 2.7</a>). </p> </section> <section id="CD010061-sec-0102"> <h6 class="title">NEC</h6> <p>Four studies reported this outcome in 384 infants (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>). There was likely a reduction for risk of NEC in the paracetamol group compared with the indomethacin group (RR 0.42, 95% CI 0.19 to 0.96; I² = 0%. RD −0.05, 95% CI −0.10 to ‐0.01; I² = 0%; low‐certainty evidence; <a href="./references#CD010061-fig-0052" title="">Analysis 2.10</a>).  </p> </section> <section id="CD010061-sec-0103"> <h6 class="title">Gastrointestinal bleed</h6> <p>Three studies reported this outcome in 347 infants (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>). There was little to no difference between the paracetamol and indomethacin groups (RR 0.63, 95% CI 0.32 to 1.25; I² = 71%. RD −0.04, 95% CI −0.10 to 0.02; I² = 54%; <a href="./references#CD010061-fig-0053" title="">Analysis 2.11</a>). </p> </section> <section id="CD010061-sec-0104"> <h6 class="title">Sepsis</h6> <p>Three studies reported this outcome in 314 infants (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>). There was little to no difference between the paracetamol and indomethacin groups (RR 1.04, 95% CI 0.59 to 1.82; I² = 0%. RD 0.01, 95% CI −0.07 to 0.08; I² = 0%; <a href="./references#CD010061-fig-0056" title="">Analysis 2.14</a>). </p> </section> <section id="CD010061-sec-0105"> <h6 class="title">Post‐pre difference in serum creatinine (mg/dL)</h6> <p>Two studies reported this outcome in 270 infants (<a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>). The post‐pre difference in serum creatinine was probably lower in the paracetamol group compared with the indomethacin group (MD −0.37, 95% CI −0.40 to −0.34; I<sup>2</sup>= 95%; <a href="./references#CD010061-fig-0057" title="">Analysis 2.15</a>). This result indicates that creatinine levels were likely higher post‐treatment with indomethacin compared with paracetamol. </p> </section> <section id="CD010061-sec-0106"> <h6 class="title">Serum bilirubin (µmol/L) following treatment</h6> <p>One study reported this outcome in 200 infants (<a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>). The serum bilirubin was likely higher in the paracetamol group compared with the indomethacin group (MD 1.03 µmol/L, 95% CI 0.13 to 1.93; <a href="./references#CD010061-fig-0058" title="">Analysis 2.16</a>). Tests for heterogeneity were not applicable. The increase in serum bilirubin is not clinically relevant. </p> </section> </section> <section id="CD010061-sec-0107"> <h5 class="title">Other secondary outcomes</h5> <p>There were little to no differences between the paracetamol (oral or IV) group compared to the indomethacin group (oral or IV) for the following outcomes: </p> <p> <ul id="CD010061-list-0011"> <li> <p>failure of PDA closure after second course of treatment (<a href="./references#CD010061-fig-0045" title="">Analysis 2.3</a>); </p> </li> <li> <p>surgical closure of PDA (<a href="./references#CD010061-fig-0046" title="">Analysis 2.4</a>); </p> </li> <li> <p>BPD at 36 weeks' postmenstrual age (<a href="./references#CD010061-fig-0048" title="">Analysis 2.6</a>); </p> </li> <li> <p>IVH (Grade III‐IV) (<a href="./references#CD010061-fig-0050" title="">Analysis 2.8</a>);  </p> </li> <li> <p>PVL (<a href="./references#CD010061-fig-0051" title="">Analysis 2.9</a>); </p> </li> <li> <p>severe ROP requiring treatment (<a href="./references#CD010061-fig-0054" title="">Analysis 2.12</a>);  </p> </li> <li> <p>acute kidney injury (<a href="./references#CD010061-fig-0055" title="">Analysis 2.13</a>). </p> </li> </ul> </p> <p>The following outcomes were not reported: neonatal mortality, re‐opening of the ductus arteriosus, failure of PDA closure after two courses, treatment with indomethacin, ibuprofen or another prostaglandin inhibitor to close the PDA, duration of ventilator support, duration of supplementary oxygen, pulmonary hypertension, BPD defined as per new criteria, intestinal perforation, decreased urine output, post‐pre difference in AST (U/L), post‐pre difference in ALT (U/L), number of infants with AST or ALT greater than 100 U/L, hyperbilirubinemia, liver failure, duration of hospitalization, ASD, language delay and other side effects. </p> </section> <section id="CD010061-sec-0108"> <h5 class="title">Comparison 2 subgroup analysis: paracetamol (oral or IV) versus indomethacin (IV) in infants of less than 32 weeks' gestational age </h5> <section id="CD010061-sec-0109"> <h6 class="title">Primary outcome</h6> <section id="CD010061-sec-0110"> <p><b>Failure of PDA closure after first course of treatment</b></p> <p>Three studies reported this outcome in 310 infants (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>). There was little to no difference between the paracetamol and indomethacin groups for failure of PDA closure after the first course of treatment (RR 1.27, 95% CI 0.86 to 1.87; I<sup>2</sup> = 65%. RD 0.05, 95% CI ‐0.03 to 0.13; I<sup>2</sup>= 89%; <a href="./references#CD010061-fig-0099" title="">Analysis 8.1</a>). </p> </section> <section id="CD010061-sec-0111"> <p><b>Neurodevelopmental impairment at 18 to 24 months corrected age</b></p> <p>No studies reported this outcome.</p> </section> <section id="CD010061-sec-0112"> <p><b>Death or disability at 18 to 24 months</b></p> <p>No studies reported this outcome.</p> </section> </section> <section id="CD010061-sec-0113"> <h6 class="title">Secondary outcomes</h6> <p>There were little to no differences between the paracetamol (oral or IV) group compared to the indomethacin group (oral or IV) for the following outcomes: </p> <p> <ul id="CD010061-list-0012"> <li> <p>all‐cause mortality during initial hospital stay (<a href="./references#CD010061-fig-0100" title="">Analysis 8.2</a>); </p> </li> <li> <p>failure of PDA closure after two courses of treatment (<a href="./references#CD010061-fig-0101" title="">Analysis 8.3</a>); </p> </li> <li> <p>surgical closure of PDA (<a href="./references#CD010061-fig-0102" title="">Analysis 8.4</a>); </p> </li> <li> <p>IVH (Grade I‐IV) (<a href="./references#CD010061-fig-0103" title="">Analysis 8.5</a>); </p> </li> <li> <p>severe IVH (Grade III‐IV) (<a href="./references#CD010061-fig-0104" title="">Analysis 8.6</a>); </p> </li> <li> <p>NEC (<a href="./references#CD010061-fig-0105" title="">Analysis 8.7</a>); </p> </li> <li> <p>gastrointestinal bleed (<a href="./references#CD010061-fig-0106" title="">Analysis 8.8</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD010061-sec-0114"> <h4 class="title">Comparison 3. Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention</h4> <p>See <a href="./full#CD010061-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD010061-sec-0115"> <h5 class="title">Primary outcomes </h5> <section id="CD010061-sec-0116"> <h6 class="title">Failure of PDA closure after first course of prophylaxis</h6> <p>Three studies reported this outcome in 240 infants (<a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>). Paracetamol likely reduced the rate of failure of PDA closure after one course of prophylaxis compared to placebo or no intervention (RR 0.27, 95% CI 0.18 to 0.42; I² = 43%. RD −0.45, 95% CI −0.55 to −0.34; I² = 78%; NNTB 3, 95% CI 1.8 to 3; low‐certainty evidence; <a href="./references#CD010061-fig-0059" title="">Analysis 3.1</a>).  </p> </section> <section id="CD010061-sec-0117"> <h6 class="title">Neurodevelopmental impairment at 18 to 24 months (corrected age) </h6> <p><a href="./references#CD010061-bbs2-0080" title="JuujärviS , KallankariH , PätsiP , LeskinenM , SaarelaT , HallmanM , et al. Follow-up study of the early, randomised paracetamol trial to preterm infants, found no adverse reactions at the two-years corrected age. Acta Paediatrica2019;108(3):452-8. [DOI: 10.1111/apa.14614] [PMID: 30325529]">Juujärvi 2019</a> and <a href="./references#CD010061-bbs2-0081" title="JuujärviS , SaarelaT , HallmanM , AikioO . Trial of paracetamol for premature newborns: five-year follow-up. Journal of Maternal-fetal &amp; Neonatal Medicine 2021 Jan 21 [Epub ahead of print]. [DOI: 10.1080/14767058.2021.1875444] [PMID: 33478294]">Juujärvi 2021</a> reported two‐ (n = 44) and five‐year (n = 39) follow‐up of the prophylactic paracetamol trial conducted by <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>. They concluded that exposure to prophylactic paracetamol in very preterm infants was probably not associated with increased neurodevelopmental impairment or other adverse consequences compared to placebo both at two‐ and five‐year follow‐up visits (cerebral palsy, <a href="./references#CD010061-fig-0069" title="">Analysis 3.11</a>; autism spectrum disorder, <a href="./references#CD010061-fig-0070" title="">Analysis 3.12</a>; ADHD, <a href="./references#CD010061-fig-0071" title="">Analysis 3.13</a>; and pervasive developmental disorder, <a href="./references#CD010061-fig-0072" title="">Analysis 3.14</a> at five‐year follow‐up). </p> </section> <section id="CD010061-sec-0118"> <h6 class="title">Death or disability at 18 to 24 months</h6> <p>No studies reported on this combined outcome.</p> </section> </section> <section id="CD010061-sec-0119"> <h5 class="title">Secondary outcomes</h5> <section id="CD010061-sec-0120"> <h6 class="title">All‐cause mortality during initial hospital stay</h6> <p>Three studies reported this outcome in 240 infants (<a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>). There was little to no difference between the paracetamol group and the placebo or no intervention group (RR 0.59, 95% CI 0.24 to 1.44; I² = 0%. RD −0.04, 95% CI −0.11 to 0.03; I² = 0%; low‐certainty evidence; <a href="./references#CD010061-fig-0060" title="">Analysis 3.2</a>).  </p> </section> </section> <section id="CD010061-sec-0121"> <h5 class="title">Other secondary outcomes</h5> <p>For the following outcomes, one study reported on 48 infants (<a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>). As only one study was included in the different analyses, tests for heterogeneity were not applicable. There was probably little to no difference between the paracetamol and placebo groups for the following outcomes: </p> <p> <ul id="CD010061-list-0013"> <li> <p>Duration of need for supplementary oxygen (<a href="./references#CD010061-fig-0061" title="">Analysis 3.3</a>);  </p> </li> <li> <p>BPD at 36 weeks' postmenstrual age (<a href="./references#CD010061-fig-0062" title="">Analysis 3.4</a>);  </p> </li> <li> <p>IVH grades (Grade I‐IV) (<a href="./references#CD010061-fig-0063" title="">Analysis 3.5</a>);  </p> </li> <li> <p>Severe IVH (Grade III‐IV) (<a href="./references#CD010061-fig-0064" title="">Analysis 3.6</a>);  </p> </li> <li> <p>Intestinal perforation (<a href="./references#CD010061-fig-0065" title="">Analysis 3.7</a>);  </p> </li> <li> <p>ROP requiring treatment (<a href="./references#CD010061-fig-0066" title="">Analysis 3.8</a>);  </p> </li> <li> <p>Oliguria (<a href="./references#CD010061-fig-0067" title="">Analysis 3.9</a>);  </p> </li> <li> <p>Sepsis (<a href="./references#CD010061-fig-0068" title="">Analysis 3.10</a>). </p> </li> </ul> </p> <p>The following outcomes were not reported: neonatal mortality, re‐opening of the ductus arteriosus, failure of PDA closure after second course, failure of PDA closure after two courses, surgical closure of the PDA, treatment with indomethacin, ibuprofen or another prostaglandin inhibitor to close the PDA, duration of ventilator support, pulmonary hemorrhage, pulmonary hypertension, BPD defined as per new criteria, PVL, NEC, intestinal perforation, gastrointestinal bleed, acute kidney injury, post‐pre treatment difference in creatinine, post‐pre treatment difference in AST (U/L), post‐pre treatment difference in ALT (U/L), number of infants with AST or ALT greater than 100 U/L, hyperbilirubinemia, liver failure, duration of hospitalization, ASD, language delay, and other side effects. </p> </section> </section> <section id="CD010061-sec-0122"> <h4 class="title">Comparison 4. Early paracetamol (oral or IV) versus placebo (oral or IV) or no intervention</h4> <p>See <a href="./full#CD010061-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD010061-sec-0123"> <h5 class="title">Primary outcomes</h5> <section id="CD010061-sec-0124"> <h6 class="title">Failure of PDA closure after first course of treatment</h6> <p>Two studies reported this outcome in 127 infants (<a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a>). There was likely a reduction in the early paracetamol group compared to the placebo or no intervention group in the failure of PDA closure after one course of treatment, favouring the paracetamol group (RR 0.35, 95% CI 0.23 to 0.53; I<sup>2</sup> = 0%. RD −0.51, 95% CI −0.66 to ‐0.37; I<sup>2</sup>= 33%; low‐certainty evidence; <a href="./references#CD010061-fig-0073" title="">Analysis 4.1</a>).  </p> </section> <section id="CD010061-sec-0125"> <h6 class="title">Neurodevelopmental impairment at 18 to 24 months (corrected age) </h6> <p>Neither study reported this outcome.</p> </section> <section id="CD010061-sec-0126"> <h6 class="title">Death or disability at 18 to 24 months</h6> <p>Neither study reported this outcome.</p> </section> </section> <section id="CD010061-sec-0127"> <h5 class="title">Secondary outcomes</h5> <section id="CD010061-sec-0128"> <h6 class="title">All‐cause mortality during initial hospital stay</h6> <p>Neither study reported this outcome.</p> </section> <section id="CD010061-sec-0129"> <h6 class="title">Failure of PDA closure after two courses of treatment</h6> <p>One study reported this outcome in 69 infants (<a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>). There was likely a reduction in the early paracetamol group compared to the placebo or no intervention group for failure of PDA closure after two courses of treatment, favouring the paracetamol group (RR 0.07, 95% CI 0.02 to 0.25; RD −0.79, 95% CI −0.94 to ‐0.65; <a href="./references#CD010061-fig-0074" title="">Analysis 4.2</a>). Tests for heterogeneity were not applicable.  </p> </section> <section id="CD010061-sec-0130"> <h6 class="title">NEC</h6> <p>Neither study reported this outcome.</p> <p>The following outcomes were not reported: neonatal mortality, re‐opening of the ductus arteriosus, failure of PDA closure after second course, surgical closure of the PDA, treatment with indomethacin, ibuprofen or another prostaglandin inhibitor to close the PDA, duration of ventilator support, duration of supplementary oxygen, pulmonary hemorrhage, pulmonary hypertension, BPD at 36 weeks' postmenstrual age, BPD defined as per new criteria, IVH grade (I to IV), severe IVH (grade III to IV), PVL, intestinal perforation, gastrointestinal bleed, ROP stage 3 or greater, decreased urine output, acute kidney injury, sepsis, post‐pre treatment difference in creatinine, post‐pre treatment difference in AST (U/L), post‐pre treatment difference in ALT (U/L), number of infants with AST or ALT greater than 100 U/L, serum bilirubin, hyperbilirubinemia, liver failure, duration of hospitalization, ASD, language delay and other side effects. </p> </section> </section> </section> <section id="CD010061-sec-0131"> <h4 class="title">Comparison 5. Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention</h4> <p>See <a href="./full#CD010061-tbl-0005">summary of findings Table 5</a>. <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a> was the only included study that examined this comparison, in 55 infants. As only one study was included in the different analyses, tests for heterogeneity were not applicable. </p> <section id="CD010061-sec-0132"> <h5 class="title">Primary outcomes</h5> <section id="CD010061-sec-0133"> <h6 class="title">Failure of PDA closure after first course of treatment</h6> <p>One study reported this outcome in 55 infants (<a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>). There was little to no difference between the late paracetamol and placebo groups for failure of PDA closure after one course of treatment (RR 0.85, 95% CI 0.72 to 1.01; RD −0.15, 95% CI −0.29 to ‐0.00; low‐certainty evidence; <a href="./references#CD010061-fig-0075" title="">Analysis 5.1</a>).  </p> </section> <section id="CD010061-sec-0134"> <h6 class="title">Neurodevelopmental impairment at 18 to 24 months (corrected age) </h6> <p><a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a> did not report this outcome. </p> </section> <section id="CD010061-sec-0135"> <h6 class="title">Death or disability at 18 to 24 months</h6> <p><a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a> did not report this outcome. </p> </section> </section> <section id="CD010061-sec-0136"> <h5 class="title">Secondary outcomes</h5> <section id="CD010061-sec-0137"> <h6 class="title">All‐cause mortality during initial hospital stay</h6> <p><a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a> did not report this outcome. </p> </section> <section id="CD010061-sec-0138"> <h6 class="title">NEC</h6> <p>One study reported this outcome in 55 infants (<a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>). There was little to no difference between the late paracetamol and placebo groups for NEC (RR 1.04, 95% CI 0.07 to 15.76; RD 0.00, 95% CI −0.10 to 0.10; low‐certainty evidence; <a href="./references#CD010061-fig-0079" title="">Analysis 5.5</a>).  </p> </section> </section> <section id="CD010061-sec-0139"> <h5 class="title">Other secondary outcomes</h5> <p>For the following outcomes, <a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a> reported on 55 infants. There was probably little to no difference between the late paracetamol and placebo groups for the following outcomes:  </p> <p> <ul id="CD010061-list-0014"> <li> <p>Surgical closure of PDA (<a href="./references#CD010061-fig-0076" title="">Analysis 5.2</a>);  </p> </li> <li> <p>Pulmonary hemorrhage (<a href="./references#CD010061-fig-0077" title="">Analysis 5.3</a>);  </p> </li> <li> <p>BPD at 36 weeks' postmenstrual age (<a href="./references#CD010061-fig-0078" title="">Analysis 5.4</a>);  </p> </li> <li> <p>ROP requiring treatment (<a href="./references#CD010061-fig-0080" title="">Analysis 5.6</a>); </p> </li> <li> <p>Acute kidney injury (<a href="./references#CD010061-fig-0081" title="">Analysis 5.7</a>). </p> </li> </ul> </p> <section id="CD010061-sec-0140"> <h6 class="title">Failure of PDA closure/non‐significant PDA after treatment</h6> <p>There was probably a reduction in failure of PDA closure/non‐significant PDA after treatment, favouring the late paracetamol group compared to the placebo group (RR 0.49, 95% CI 0.29 to 0.84; RD −0.38, 95% CI −0.62 to ‐0.14; <a href="./references#CD010061-fig-0082" title="">Analysis 5.8</a>). </p> <p>The following outcomes were not reported: neonatal mortality, re‐opening of the ductus arteriosus, failure of PDA closure after second course, treatment with indomethacin, ibuprofen or another prostaglandin inhibitor to close the PDA, duration of ventilator support, duration of supplementary oxygen, pulmonary hypertension, BPD defined as per new criteria, IVH grade (I to IV), severe IVH (grade III to IV), PVL, intestinal perforation, gastrointestinal bleed, decreased urine output, sepsis, post‐pre treatment difference in creatinine, post‐pre treatment difference in AST (U/L), post‐pre treatment difference in ALT (U/L), number of infants with AST or ALT greater than 100 U/L, serum bilirubin, hyperbilirubinemia, liver failure, duration of hospitalization, ASD, language delay and other side effects. </p> </section> </section> </section> <section id="CD010061-sec-0141"> <h4 class="title">Comparison 6. Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention </h4> <p>See <a href="./full#CD010061-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD010061-sec-0142"> <h5 class="title">Primary outcomes</h5> <section id="CD010061-sec-0143"> <h6 class="title">Failure of PDA closure after first course of treatment</h6> <p>Two studies reported this outcome in 111 infants (<a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>). There was little to no difference between the ibuprofen plus paracetamol group and the ibuprofen plus placebo or no intervention group for failure of PDA closure after one course of treatment (RR 0.77, 95% CI 0.43 to 1.36; I² = 0%. RD −0.09, 95% CI −0.27 to 0.09; I<sup>2</sup>= 7%; low‐certainty evidence; <a href="./references#CD010061-fig-0083" title="">Analysis 6.1</a>).  </p> </section> <section id="CD010061-sec-0144"> <h6 class="title">Neurodevelopmental impairment at 18 to 24 months (corrected age) </h6> <p>Neither study reported this outcome.</p> </section> <section id="CD010061-sec-0145"> <h6 class="title">Death or disability at 18 to 24 months</h6> <p>Neither study reported this outcome.</p> </section> </section> <section id="CD010061-sec-0146"> <h5 class="title">Secondary outcomes</h5> <section id="CD010061-sec-0147"> <h6 class="title">All‐cause mortality during initial hospital stay</h6> <p>Neither study reported this outcome.</p> </section> <section id="CD010061-sec-0148"> <h6 class="title">Failure of PDA closure after two courses of treatment</h6> <p>Two studies reported this outcome in 111 infants (<a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>). There was likely a reduction for failure of PDA closure after two courses of treatment favouring the ibuprofen plus paracetamol group compared to the ibuprofen plus placebo or no intervention group (RR 0.28, 95% CI 0.08 to 0.99; I<sup>2</sup> = 0%. RD −0.18, 95% CI −0.31 to ‐0.06; I<sup>2</sup>= 81%; <a href="./references#CD010061-fig-0084" title="">Analysis 6.2</a>).  </p> </section> <section id="CD010061-sec-0149"> <h6 class="title">NEC</h6> <p>One study reported this outcome in 24 infants (<a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>). There was little to no difference between the ibuprofen plus paracetamol group compared to the ibuprofen plus placebo group for risk of NEC (RR 0.33, 95% CI 0.01 to 7.45; RD −0.08, 95% CI −0.29 to 0.12; low‐certainty evidence; <a href="./references#CD010061-fig-0089" title="">Analysis 6.7</a>).  </p> </section> </section> <section id="CD010061-sec-0150"> <h5 class="title">Other secondary outcomes</h5> <p>For the following outcomes, one study reported on 24 infants (<a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>). As only one study was included in the different analyses, tests for heterogeneity were not applicable. There was probably little to no difference between the ibuprofen plus paracetamol group versus the ibuprofen plus placebo group for the following outcomes:  </p> <p> <ul id="CD010061-list-0015"> <li> <p>BPD at 36 weeks (<a href="./references#CD010061-fig-0085" title="">Analysis 6.3</a>);  </p> </li> <li> <p>IVH (Grade I‐IV) (<a href="./references#CD010061-fig-0086" title="">Analysis 6.4</a>);  </p> </li> <li> <p>Severe IVH (Grade III‐IV) (<a href="./references#CD010061-fig-0087" title="">Analysis 6.5</a>);  </p> </li> <li> <p>PVL (<a href="./references#CD010061-fig-0088" title="">Analysis 6.6</a>);  </p> </li> <li> <p>Oliguria (<a href="./references#CD010061-fig-0090" title="">Analysis 6.8</a>). </p> </li> </ul> </p> <p>The following outcomes were not reported: neonatal mortality, re‐opening of the ductus arteriosus, failure of PDA closure after second course, surgical closure of the PDA, treatment with indomethacin, ibuprofen or another prostaglandin inhibitor to close the PDA, duration of ventilator support, duration of supplementary oxygen, pulmonary hemorrhage, pulmonary hypertension, BPD defined as per new criteria, intestinal perforation, gastrointestinal bleed, ROP stage 3 or above, acute kidney injury, sepsis, post‐pre treatment difference in creatinine, post‐pre treatment difference in AST (U/L), post‐pre treatment difference in ALT (U/L), number of infants with AST or ALT greater than 100 U/L, serum bilirubin, hyperbilirubinemia, liver failure, duration of hospitalization, ASD, language delay and other side effects. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010061-sec-0151" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010061-sec-0151"></div> <section id="CD010061-sec-0152"> <h3 class="title" id="CD010061-sec-0152">Summary of main results</h3> <p>Evidence from 27 studies in 2278 preterm infants contributing data to the primary outcomes of this review showed that there is probably little or no difference in effectiveness between paracetamol and non‐selective COX inhibitors for PDA treatment. From the safety standpoint, paracetamol has a favourable adverse effect profile compared to non‐selective COX inhibitors. The certainty of the evidence was moderate for the primary outcome. The comparisons included paracetamol to ibuprofen (eighteen studies) (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0002" title="AsadpourN , HarandiPS , HamidiM , Malek AhmadiMR , Malekpour-TehraniA . Comparison of the effect of oral acetaminophen and ibuprofen on patent ductus arteriosus closure in premature infants referred to Hajar hospital in Shahrekord in 2016-2017. Journal of Clinical Neonatology2018;7(4):224-30. [DOI: 10.4103/jcn.JCN_47_18]">Asadpour 2018</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0015" title="GhaderianM , BarekatainB , DardashtyAB . Comparison of oral acetaminophen with oral ibuprofen on closure of symptomatic patent ductus arteriosus in preterm neonates. Journal of Research in Medical Sciences2019;24:96. [DOI: 10.4103/jrms.JRMS_197_19] [PMID: 31850085]">Ghaderian 2019b</a>; <a href="./references#CD010061-bbs2-0018" title="JafariN , Mahdian JouibariR , EbadiA , KamaliK , AbdolahzadehS , HosseiniM . Comparison between the safety and efficacy of iv paracetamol (acetaminophen) and iv ibuprofen in treating premature neonates with patent ductus arteriosus (PDA). Journal of Iranian Medical Council2019;2(4):66-73. [http://www.jimc.ir/article_96268_032a52ab47502ad6c9ff75d3c6e5b3eb.pdf]">Jafari 2019</a>; <a href="./references#CD010061-bbs2-0020" title="KumarA , GosaviRS , SundaramV , OletiTP , KrishnanA , KiranS , et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: a randomized, controlled, noninferiority trial. Journal of Pediatrics2020;222:79-84.e2. [DOI: 10.1016/j.jpeds.2020.01.058] [PMID: 32336479]">Kumar 2020</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0025" title="ShahmirzadiG , NooripourS , ZiariA , DanaeiN . Comparison of gastrointestinal complications of paracetamol and ibuprofen in the management of infants with patent ductus arteriosus: a randomized clinical trial study. International Journal of Preventive Medicine2021;12:48. [PMID: 34211679]">Shahmirzadi 2021</a>; <a href="./references#CD010061-bbs2-0026" title="TauberKA , KingR , ColonM . Intravenous acetaminophen vs intravenous ibuprofen to close a patent ductus arteriosus closure: a pilot randomized controlled trial. Health Science Reports2020;3(3):e183. [DOI: 10.1002/hsr2.183] [PMID: 32775700]">Tauber 2020</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>); prophylactic paracetamol to placebo or no intervention (three studies) (<a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0006" title="BagheriM , Bahman-BijariB , Torabi-NejadM , NiknafsP , MousaviH , FatemehS , et al. Is prophylactic parenteral paracetamol effective to diminish incidence of PDA in preterm neonates? A randomized trial. Iranian Journal of Pediatrics2018;28(4):e11735. [DOI: 10.5812/ijp.11735]">Bagheri 2018</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>); paracetamol to indomethacin (four studies) (<a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>); early paracetamol to placebo or no intervention (two studies) (<a href="./references#CD010061-bbs2-0004" title="BabaeiH , NematiR , DaryoshiH . Closure of patent ductus arteriosus with oral acetaminophen in preterm neonates: a randomized trial. Biomedical Research and Therapy2018;5(2):2034-44. [DOI: 10.15419/bmrat.v5i02.418]">Babaei 2018</a>; <a href="./references#CD010061-bbs2-0024" title="SchindlerT , SmythJ , BolisettyS , MichalowskiJ , MallittKA , SinglaA , et al. Early PARacetamol (EPAR) trial: a randomized controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants. Neonatology2021;118(3):274-82. [DOI: 10.1159/000515415] [PMID: 33845473]">Schindler 2021</a>); late paracetamol to placebo (one study) (<a href="./references#CD010061-bbs2-0019" title="KluckowM , CarlisleH , BroomM , WoodsP , JefferyM , DesaiD , et al. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of Perinatology2019;39(1):102-7. [DOI: 10.1038/s41372-018-0265-x] [PMID: 30429580]">Kluckow 2019</a>); and the combination of paracetamol and ibuprofen to ibuprofen plus placebo or no intervention (two studies) (<a href="./references#CD010061-bbs2-0017" title="HochwaldO , MainzerG , Borenstein-LevinL , JubranH , DinurG , ZuckerM , et al. Adding paracetamol to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a double-blind, randomized, placebo-controlled pilot study. American Journal of Perinatology2018;35(13):1319-25. [DOI: 10.1055/s-0038-1653946] [PMID: 29783269]">Hochwald 2018</a>; <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a>). There were two three‐arm studies, comparing paracetamol to ibuprofen as well as indomethacin (<a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0021" title="MeenaV , MeenaDS , RathorePS , ChaudharyS , SoniJP . Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - a randomized controlled trial. Annals of Pediatric Cardiology2020;13(2):130-5. [DOI: 10.4103/apc.APC_115_19] [PMID: 32641884]">Meena 2020</a>). The <a href="./references#CD010061-bbs2-0022" title="OboodiR , NajibKS , AmoozgarH , PourarianS , MoghtaderiM , MehdizadeganN , et al. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Türk Kardiyoloji Derneği Arşivi2020;48(6):605-12. [DOI: 10.5543/tkda.2020.03902] [PMID: 32955023]">Oboodi 2020</a> study compared paracetamol to ibuprofen and to paracetamol plus ibuprofen in a three‐arm study.  </p> <p>In the current version of the review, we added new outcomes, including failure of PDA closure after second course and after a total of two courses of paracetamol treatment; these were not planned a priori in the first version of the protocol (<a href="./references#CD010061-bbs2-0119" title="OhlssonA , ShahPS . Paracetamol (acetaminophen) for patent ductus arteriosus in preterm and/or low‐birth‐weight infants. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD010061. [DOI: 10.1002/14651858.CD010061]">Ohlsson 2012</a>). We deemed these outcomes important as clinicians often use multiple courses of pharmacotherapy (two to three) and, if unsuccessful, proceed to definitive approaches for PDA closure (ligation/transcatheter). Thus, it is important to know the efficacy after the second course and after a total of two courses to guide ongoing management. </p> <p>There is probably little or no difference in effectiveness between paracetamol and ibuprofen or indomethacin in closing a PDA after the first course (closure and failure of closure confirmed by echocardiographic criteria). Adverse effects and morbidities were less common in the paracetamol groups compared with the ibuprofen or the indomethacin groups. Gastrointestinal bleed or stools positive for occult blood may be less likely to occur in the paracetamol versus the ibuprofen group. Necrotizing enterocolitis was probably less likely to occur in infants given paracetamol compared to those given indomethacin. Post‐pre difference in serum or plasma creatinine were probably lower in the paracetamol versus the ibuprofen and versus the indomethacin groups. Urine output was probably higher in infants given paracetamol versus those given ibuprofen and versus indomethacin. The serum bilirubin levels were probably higher in the paracetamol group compared to the ibuprofen and the indomethacin groups after treatment. </p> <p>In the current version of the review, we added three comparisons which were not planned a priori in the first version of the protocol (<a href="./references#CD010061-bbs2-0119" title="OhlssonA , ShahPS . Paracetamol (acetaminophen) for patent ductus arteriosus in preterm and/or low‐birth‐weight infants. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD010061. [DOI: 10.1002/14651858.CD010061]">Ohlsson 2012</a>): early paracetamol, late paracetamol and combination (ibuprofen plus paracetamol) approaches for PDA treatment in preterm infants. Combination treatment (ibuprofen plus paracetamol) targeting two separate enzyme sites has recently been evaluated as a management strategy for treatment of PDA in preterm infants with varying results. Low‐certainty evidence suggest that early paracetamol treatment may be more efficacious than placebo/no intervention in closing a PDA after the first course. Late paracetamol treatment was probably similar to placebo in closing a PDA after the first course. It may have benefit in constriction of a PDA not needing additional treatment compared to placebo; however, the certainty of the evidence is low. There is probably little or no difference in effectiveness between combination treatment (ibuprofen plus paracetamol) and ibuprofen plus placebo/no intervention in closing a PDA after the first course. Combination treatment (ibuprofen plus paracetamol) may be more effective than ibuprofen plus placebo/no intervention after two treatment courses; however, the certainty of evidence is low. It would be important to present the current evidence pertaining to combination treatment to the scientific community before incorporation as a routine practice across neonatal units. </p> <p>Subgroup analysis in infants of less than 32 weeks' gestation revealed that there is probably little or no difference in effectiveness between paracetamol and ibuprofen and indomethacin for PDA closure after the first course of treatment. Adverse effects and morbidities were similar in the paracetamol group compared with the ibuprofen or the indomethacin groups. </p> </section> <section id="CD010061-sec-0153"> <h3 class="title" id="CD010061-sec-0153">Overall completeness and applicability of evidence</h3> <p>In this review, we have included data on 2278 infants enrolled in 27 trials that compared the efficacy and safety of paracetamol with ibuprofen, indomethacin, and placebo/no intervention for PDA closure in preterm infants. Larger trials are required in extremely preterm infants to confirm the current promising evidence on efficacy as well as safety. Viberg and colleagues reported that paracetamol administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice (<a href="./references#CD010061-bbs2-0112" title="VibergH , ErikssonP , GordhT , FredrikssonA . Paracetamol (acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice. Toxicological Sciences2014;138(1):139-47. [DOI: 10.1093/toxsci/kft329] [PMID: 24361869]">Viberg 2014</a>). The dose of paracetamol used in mice was similar to that used in the two studies included in this review. In view of the possible negative impact of paracetamol on the developing brain reported in mice (<a href="./references#CD010061-bbs2-0112" title="VibergH , ErikssonP , GordhT , FredrikssonA . Paracetamol (acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice. Toxicological Sciences2014;138(1):139-47. [DOI: 10.1093/toxsci/kft329] [PMID: 24361869]">Viberg 2014</a>), the long‐term effects of paracetamol used for PDA closure or prevention and treatment of pain need to be studied carefully. In addition, in an ecological study conducted in humans and using country‐level data for the period 1984 to 2005, postnatal use of paracetamol was associated with autism or ASD (<a href="./references#CD010061-bbs2-0059" title="BauerAZ , KriebelD . Prenatal and perinatal analgesic exposure and autism: an ecological link. Environmental Health2013;12:41. [DOI: 10.1186/1476-069X-12-41] [PMID: 23656698]">Bauer 2013</a>). In 2017, <a href="./references#CD010061-bbs2-0062" title="BornehagCG , ReichenbergA , HallerbackMU , WikstromS , KochHM , JonssonBA , et al. Prenatal exposure to acetaminophen and children's language development at 30 months. European Psychiatry2018;51:98-103. [DOI: 10.1016/j.eurpsy.2017.10.007] [PMID: 29331486]">Bornehag 2017</a> reported in a study from Sweden of a possible association between maternal prenatal exposure to paracetamol and language delay in 30‐month‐old girls (parental report of use of fewer than 50 words). </p> <p>There is an increasing body of evidence demonstrating that the high efficacy (about 68%) of treatment reported in clinical trials has not translated to effective treatment in clinical practice among extremely low gestational age neonates (ELGANs &lt; 28 weeks' gestational age) with PDA. Initial observational studies (<a href="./references#CD010061-bbs2-0102" title="RoofthooftDW , Van BeynumIM , De KlerkJC , Van DijkM , Van den AnkerJN , ReissIK , et al. Limited effects of intravenous paracetamol on patent ductus arteriosus in very low birth weight infants with contraindications for ibuprofen or after ibuprofen failure. European Journal of Pediatrics2015;174(11):1433-40. [DOI: 10.1007/s00431-015-2541-5] [PMID: 25922139]">Roofthooft 2015</a>), and more recently, RCTs have reported less than 25% treatment success when acetaminophen is administered to ELGANs (<a href="./references#CD010061-bbs2-0009" title="DaniC , ListaG , BianchiS , MoscaF , SchenaF , RamenghiL , et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. European Journal of Pediatrics2021;180(3):807-16. [DOI: 10.1007/s00431-020-03780-8] [PMID: 32888085]">Dani 2021</a>; <a href="./references#CD010061-bbs2-0011" title="DavidsonJM , FergusonJ , IveyE , PhilipR , WeemsMF , TalatiAJ . A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants. Journal of Perinatology2021;41(1):93-9. [DOI: 10.1038/s41372-020-0694-1] [PMID: 32439957]">Davidson 2021</a>; <a href="./references#CD010061-bbs2-0085" title="LiebowitzM , KaempfJ , ErdeveO , BulbulA , HåkanssonS , LindqvistJ , et al. Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). Journal of Perinatology2019;39(5):599-607. [DOI: 10.1038/s41372-019-0347-4] [PMID: 30850756]">Liebowitz 2019</a>). There are several potential reasons for this poor translation. First, while ELGANs are the patients being treated for PDA in contemporary practice, they were underrepresented in clinical trials which almost exclusively enrolled moderately preterm neonates (79% of RCTs enrolled neonates with mean gestational age at birth &gt; 30 weeks). Most importantly, the acetaminophen dose and administration frequency evaluated in clinical trials was selected based on extrapolation from studies of pediatric analgesia. True pharmacokinetic studies of proper dose and duration of paracetamol for PDA treatment are lacking. </p> <p>There are at least 24 ongoing trials that would provide additional evidence regarding this topic. The researchers should be encouraged to include pharmacokinetic data to determine optimal dosing regimen, have ELGANs as a population of interest, and study various durations of treatment and mode of administration (<a href="./references#CD010061-bbs2-0069" title="El-KhuffashA , JainA , CorcoranD , ShahPS , HooperCW , BrownN , et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatric Research2014;76(3):238-44. [DOI: 10.1038/pr.2014.82] [PMID: 24941212]">El‐Khuffash 2014</a>). Long‐term follow‐up should be planned to at least 18 to 24 months and preferably to school age. </p> <p>Applicability of current evidence regarding similar effectiveness of paracetamol should be appropriately evaluated considering local context. Cost of oral paracetamol is very low compared to intravenous indomethacin or intravenous ibuprofen. Oral paracetamol has a favourable side effect profile and thus a unit may decide to use paracetamol as primary agent. However, we strongly recommend that neonates should be followed for neurodevelopmental assessment and further information should be gathered about paracetamol's impact. </p> </section> <section id="CD010061-sec-0154"> <h3 class="title" id="CD010061-sec-0154">Certainty of the evidence</h3> <p>Although healthcare providers and researchers were aware of group assignment in many studies, we considered the included trials to be of good quality because, in most studies, the random sequence was computer‐generated and allocation to study groups was by opaque, sequentially‐numbered, and sealed envelopes. The certainty of the evidence, using GRADE, was moderate for the primary outcome 'failure of PDA closure after the first course of treatment' in the comparison of paracetamol versus ibuprofen and moderate for other important outcomes — all‐cause mortality and NEC. We downgraded evidence by one level due to concerns about blinding of personnel and outcome assessment. For prophylactic paracetamol versus placebo or no intervention, the certainty of the evidence was low for 'failure of PDA closure after the first course of treatment' and all‐cause mortality. We downgraded evidence due to concerns about selection bias, blinding of personnel, and high heterogeneity. For the paracetamol versus indomethacin comparison, we assessed the certainty of the evidence for the outcomes 'failure of PDA closure after the first course of treatment', all‐cause mortality, and NEC as low due to concerns about blinding of personnel, outcome assessment, and imprecision. For early, late, and combination treatment, the overall certainty of the evidence was low for the three key outcomes. For early and combination treatment, the reasons for downgrading the evidence were concerns about selection bias, blinding of personnel, outcome assessment, imprecision, and high heterogeneity. For late treatment, we downgraded the evidence due to concerns about indirectness and imprecision. Overall, in order to improve the certainty of the evidence, future trials need to include the features indicated above and in the <a href="#CD010061-sec-0159">Implications for research</a> section. </p> </section> <section id="CD010061-sec-0155"> <h3 class="title" id="CD010061-sec-0155">Potential biases in the review process</h3> <p>We deviated from the original protocol (e.g. decisions to amend the types of subgroup analyses) to minimize multiple subgroups to be able to draw meaningful, clinically relevant conclusions. Departures from the protocol were primarily related to clarification of inclusion criteria and relevant outcomes. None of the review authors are involved in any of the trials included in the review. </p> </section> <section id="CD010061-sec-0156"> <h3 class="title" id="CD010061-sec-0156">Agreements and disagreements with other studies or reviews</h3> <p>We are aware of three recent systematic reviews with meta‐analyses on the topic (<a href="./references#CD010061-bbs2-0087" title="MarconiE , BettiolA , AmbrosioG , PerducaV , VannacciA , TroianiS , et al. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies. Pharmacological Research2019;148:104418. [DOI: 10.1016/j.phrs.2019.104418] [PMID: 31479749]">Marconi 2019</a>; <a href="./references#CD010061-bbs2-0100" title="PranataR , YonasE , VaniaR , PrakosoR . The efficacy and safety of oral paracetamol versus oral ibuprofen for patent ductus arteriosus closure in preterm neonates - a systematic review and meta-analysis. Indian Heart Journal2020;72(3):151-9. [DOI: 10.1016/j.ihj.2020.05.012] [PMID: 32768013]">Pranata 2020</a>; <a href="./references#CD010061-bbs2-0116" title="XiaoY , LiuH , HuR , YouQ , ZengM , JiangX . Efficacy and safety of paracetamol for patent ductus arteriosus closure in preterm infants: an updated systematic review and meta-analysis. Frontiers in Pediatrics2020;7:568. [DOI: 10.3389/fped.2019.00568] [PMID: 32133328]">Xiao 2020</a>). In the previous version of this review (<a href="./references#CD010061-bbs2-0122" title="OhlssonA , ShahPS . Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD010061. [DOI: 10.1002/14651858.CD010061.pub4]">Ohlsson 2020c</a>), we included eight trials (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0003" title="AsbaghPA , ZarkeshMR , NiliF , Sadat NayeriFS , NaeemAT . Prophylactic treatment with oral paracetamol for patent ductus arteriosus in preterm infants: a randomized clinical trial. Tehran University Medical Journal2015;73(2):86-92. [http://tumj.tums.ac.ir/article-1-6603-en.html]">Asbagh 2015</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0010" title="DashSK , KabraNS , AvasthiBS , SharmaSR , PadhiP , AhmedJ . Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatrics2015;52(7):573-8. [DOI: 10.1007/s13312-015-0677-z] [PMID: 26244949]KabraNS , DashSK . Comparison of enteral paracetamol and intravenous indomethacin in closure of patent ductus arteriosus (PDA) in preterm newborns: a randomized controlled trial. In: Pediatric Academic Societies Annual Meeting; 2014 July 17-18; Vienna, Austria. 2014. ">Dash 2015</a>; <a href="./references#CD010061-bbs2-0013" title="El-MashadAE , El-MahdyH , El AmrousyDE , ElgendyM . Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates. European Journal of Pediatrics2017;176(2):233-40. [DOI: 10.1007/s00431-016-2830-7] [PMID: 28004188]">El Mashad 2017</a>; <a href="./references#CD010061-bbs2-0016" title="HärkinP , HärmäA , AikioO , ValkamaM , LeskinenM , SaarelaT , et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. Journal of Pediatrics2016;177:72-7. [DOI: 10.1016/j.jpeds.2016.04.066] [PMID: 27215779]">Härkin 2016</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). </p> <p><a href="./references#CD010061-bbs2-0100" title="PranataR , YonasE , VaniaR , PrakosoR . The efficacy and safety of oral paracetamol versus oral ibuprofen for patent ductus arteriosus closure in preterm neonates - a systematic review and meta-analysis. Indian Heart Journal2020;72(3):151-9. [DOI: 10.1016/j.ihj.2020.05.012] [PMID: 32768013]">Pranata 2020</a> included eight trials (N = 1290) comparing oral paracetamol and oral ibuprofen for PDA treatment in preterm infants (<a href="./references#CD010061-bbs2-0001" title="Al-LawamaM , AlammoriI , AbdelghaniT , BadranE . Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus. Journal of International Medical Research2017;46(2):811-8. [DOI: 10.1177/0300060517722698] [PMID: 29239259]">Al‐Lawama 2017</a>; <a href="./references#CD010061-bbs2-0005" title="BagheriMM , NiknafsP , SabsevariF , TorabiMH , Bahman BijariB , NorooziE , et al. Comparison of oral acetaminophen versus ibuprofen in premature infants with patent ductus arteriosus. Iranian Journal of Pediatrics2016;26(4):e3975. [DOI: 10.5812/ijp.3975] [PMID: 27713809]">Bagheri 2016</a>; <a href="./references#CD010061-bbs2-0007" title="BalachanderB , MondalN , BhatV , AdhisivamB , KumarM , SatheeshS , et al. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial. Journal of Maternal-fetal &amp; Neonatal Medicine2020;33(9):1587-92. [DOI: 10.1080/14767058.2018.1525354] [PMID: 30227731]">Balachander 2020</a>; <a href="./references#CD010061-bbs2-0008" title="DangD , WangD , ZhangC , ZhouW , ZhouQ , WuH . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PloS One2013;8(11):e77888. [DOI: 10.1371/journal.pone.0077888] [PMID: 24223740]">Dang 2013</a>; <a href="./references#CD010061-bbs2-0012" title="El-FarrashRA , El ShimyMS , El-SakkaAS , AhmedMG , Abdel-MoezDG . Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(21):3647-54. [DOI: 10.1080/14767058.2018.1470235] [PMID: 29695206]">El‐Farrash 2019</a>; <a href="./references#CD010061-bbs2-0014" title="GhaderianM , ArmanianAM , SabriMR , MontaseriM . Low-dose intravenous acetaminophen versus oral ibuprofen for the closure of patent ductus arteriosus in premature neonates. Journal of Research in Medical Sciences2019;24:13. [DOI: 10.4103/jrms.JRMS_631_17] [PMID: 30988681]">Ghaderian 2019a</a>; <a href="./references#CD010061-bbs2-0023" title="OncelMY , ErasZ , UrasN , CanpolatFC , ErdeveO , OguzSS . Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. American Journal of Perinatology2017;34(12):1185–9. [DOI: 10.1055/s-0037-1601564] [PMID: 28395364]OncelMY , YurttutanS , ErdeveO , UrasN , AltugN , OguzSS , et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;164(3):510-4.e1. [DOI: 10.1016/j.jpeds.2013.11.008] [PMID: 24359938]">Oncel 2014</a>; <a href="./references#CD010061-bbs2-0027" title="YangB , GaoX , RenY , WangY , ZhangQ . Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: a randomized controlled trial. Experimental and Therapeutic Medicine2016;12(4):2531-6. [DOI: 10.3892/etm.2016.3676] [PMID: 27698754]">Yang 2016</a>). They concluded that there "was no significant difference between the efficacy of oral paracetamol and oral ibuprofen. However, the rate of renal dysfunction and gastrointestinal bleeding were higher in oral ibuprofen.” </p> <p><a href="./references#CD010061-bbs2-0087" title="MarconiE , BettiolA , AmbrosioG , PerducaV , VannacciA , TroianiS , et al. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies. Pharmacological Research2019;148:104418. [DOI: 10.1016/j.phrs.2019.104418] [PMID: 31479749]">Marconi 2019</a> conducted a systematic review and network meta‐analysis of 64 RCTs and 24 observational studies, including 14,568 participants, evaluating all pharmacological agents used for PDA treatment. They concluded that “active pharmacological treatment, with indomethacin, ibuprofen, or paracetamol, is inversely associated with failure to close the PDA compared to non‐treatment. Ibuprofen should be preferred to indomethacin to avoid occurrence of IVH or oliguria, paracetamol should be preferred to indomethacin to avoid oliguria.” </p> <p><a href="./references#CD010061-bbs2-0116" title="XiaoY , LiuH , HuR , YouQ , ZengM , JiangX . Efficacy and safety of paracetamol for patent ductus arteriosus closure in preterm infants: an updated systematic review and meta-analysis. Frontiers in Pediatrics2020;7:568. [DOI: 10.3389/fped.2019.00568] [PMID: 32133328]">Xiao 2020</a> conducted a meta‐analysis including 15 trials (N = 1313). They concluded that “paracetamol can induce early patent ductus arteriosus closure without significant side effects”. </p> <p>This updated review contains the most comprehensive analyses of existing studies, considers all methods of administering paracetamol for PDA treatment, and includes all comparators tested in randomized trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010061-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for 2022 review update" data-id="CD010061-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for 2022 review update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010061-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010061-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot: failure of PDA closure after first course of treatment for comparison 'Paracetamol (oral or IV) versus ibuprofen (oral or IV)'" data-id="CD010061-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot: failure of PDA closure after first course of treatment for comparison 'Paracetamol (oral or IV) versus ibuprofen (oral or IV)' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot: failure of PDA closure after second course of treatment for comparison 'Paracetamol (oral or IV) versus ibuprofen (oral or IV)'" data-id="CD010061-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot: failure of PDA closure after second course of treatment for comparison 'Paracetamol (oral or IV) versus ibuprofen (oral or IV)' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 1: Failure of PDA closure after first course of treatment" data-id="CD010061-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 1: Failure of PDA closure after first course of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 2: Neurodevelopmental impairment" data-id="CD010061-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.02.svg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 2: Neurodevelopmental impairment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 3: All‐cause mortality during initial hospital stay" data-id="CD010061-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 3: All‐cause mortality during initial hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 4: Neonatal mortality (deaths during the first 28 days of life)" data-id="CD010061-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 4: Neonatal mortality (deaths during the first 28 days of life) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 5: Re‐opening of the ductus arteriosus" data-id="CD010061-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 5: Re‐opening of the ductus arteriosus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 6: Failure of PDA closure after second course of treatment" data-id="CD010061-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 6: Failure of PDA closure after second course of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 7: Surgical closure of the PDA" data-id="CD010061-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 7: Surgical closure of the PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 8: Duration of ventilator support (days)" data-id="CD010061-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 8: Duration of ventilator support (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 9: Duration of need for supplementary oxygen (days)" data-id="CD010061-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 9: Duration of need for supplementary oxygen (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 10: Pulmonary hemorrhage" data-id="CD010061-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 10: Pulmonary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 11: Pulmonary hypertension" data-id="CD010061-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 11: Pulmonary hypertension </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 12: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA" data-id="CD010061-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 12: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 13: Moderate to severe BPD (according to the new criteria)" data-id="CD010061-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 13: Moderate to severe BPD (according to the new criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 14: Severe BPD (according to the new criteria)" data-id="CD010061-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 14: Severe BPD (according to the new criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 15: Intraventricular hemorrhage (IVH, Grade I‐IV)" data-id="CD010061-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 15: Intraventricular hemorrhage (IVH, Grade I‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 16: Severe IVH (Grade III‐IV)" data-id="CD010061-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 16: Severe IVH (Grade III‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 17: Periventricular leukomalacia" data-id="CD010061-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 17: Periventricular leukomalacia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 18: Necrotizing enterocolitis (NEC)" data-id="CD010061-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 18: Necrotizing enterocolitis (NEC) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 19: Intestinal perforation" data-id="CD010061-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 19: Intestinal perforation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 20: Gastrointestinal bleed" data-id="CD010061-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 20: Gastrointestinal bleed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 21: Retinopathy of prematurity stage ≥ 3" data-id="CD010061-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 21: Retinopathy of prematurity stage ≥ 3 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 22: Retinopathy of prematurity requiring treatment" data-id="CD010061-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 22: Retinopathy of prematurity requiring treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 23: Oliguria (&lt; 1 mL/kg/h)" data-id="CD010061-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 23: Oliguria (&lt; 1 mL/kg/h) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 24: Sepsis" data-id="CD010061-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 24: Sepsis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 25: Post‐pre difference in serum or plasma levels of creatinine (mg/dL)" data-id="CD010061-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 25: Post‐pre difference in serum or plasma levels of creatinine (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 26: Serum levels of aspartate transaminase (AST) IU/L" data-id="CD010061-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 26: Serum levels of aspartate transaminase (AST) IU/L </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 27: Post‐pre difference in serum levels of alanine aminotransferase (ALT) (IU/L)" data-id="CD010061-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 27: Post‐pre difference in serum levels of alanine aminotransferase (ALT) (IU/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 28: Serum bilirubin following treatment (µmol/L)" data-id="CD010061-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 28: Serum bilirubin following treatment (µmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 29: Hyperbilirubinemia (serum bilirubin level higher than the exchange level according to the postnatal age and BW)" data-id="CD010061-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 29: Hyperbilirubinemia (serum bilirubin level higher than the exchange level according to the postnatal age and BW) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 30: Duration of hospitalization (days)" data-id="CD010061-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 30: Duration of hospitalization (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 31: Mental developmental index (MDI) &lt; 70" data-id="CD010061-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 31: Mental developmental index (MDI) &lt; 70 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 32: Psychomotor developmental index (PDI) &lt; 70" data-id="CD010061-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 32: Psychomotor developmental index (PDI) &lt; 70 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 33: Moderate to severe cerebral palsy" data-id="CD010061-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 33: Moderate to severe cerebral palsy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 34: Deafness" data-id="CD010061-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 34: Deafness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 35: Blindness" data-id="CD010061-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 35: Blindness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 36: Mental developmental index" data-id="CD010061-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 36: Mental developmental index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-001.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 37: Psychomotor developmental index" data-id="CD010061-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-001.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1: Paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 37: Psychomotor developmental index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-001.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 1: Failure of PDA closure after first course of treatment " data-id="CD010061-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 1: Failure of PDA closure after first course of treatment  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 2: All‐cause mortality during initial hospital stay" data-id="CD010061-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 2: All‐cause mortality during initial hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 3: Failure of PDA closure after second course of treatment " data-id="CD010061-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 3: Failure of PDA closure after second course of treatment  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 4: Surgical closure of the PDA" data-id="CD010061-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 4: Surgical closure of the PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 5: Pulmonary hemorrhage" data-id="CD010061-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 5: Pulmonary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 6: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA" data-id="CD010061-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 6: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 7: Intraventricular hemorrhage (IVH, Grade I‐IV)" data-id="CD010061-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 7: Intraventricular hemorrhage (IVH, Grade I‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 8: IVH (Grade III‐IV)" data-id="CD010061-fig-0050" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 8: IVH (Grade III‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 9: Periventricular leukomalacia" data-id="CD010061-fig-0051" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 9: Periventricular leukomalacia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 10: Necrotizing enterocolitis (NEC)" data-id="CD010061-fig-0052" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 10: Necrotizing enterocolitis (NEC) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 11: Gastrointestinal bleed" data-id="CD010061-fig-0053" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 11: Gastrointestinal bleed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 12: Retinopathy of prematurity requiring treatment " data-id="CD010061-fig-0054" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 12: Retinopathy of prematurity requiring treatment  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 13: Acute kidney injury" data-id="CD010061-fig-0055" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 13: Acute kidney injury </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 14: Sepsis" data-id="CD010061-fig-0056" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 14: Sepsis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 15: Post‐pre difference in serum creatinine (mg/dL)" data-id="CD010061-fig-0057" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 15: Post‐pre difference in serum creatinine (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 16: Serum bilirubin following treatment (µmol/L)" data-id="CD010061-fig-0058" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 16: Serum bilirubin following treatment (µmol/L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 1: Failure of PDA closure after first course of prophylaxis" data-id="CD010061-fig-0059" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 1: Failure of PDA closure after first course of prophylaxis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 2: All‐cause mortality during initial hospital stay" data-id="CD010061-fig-0060" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 2: All‐cause mortality during initial hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 3: Duration of need for supplementary oxygen (days)" data-id="CD010061-fig-0061" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 3: Duration of need for supplementary oxygen (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 4: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA" data-id="CD010061-fig-0062" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 4: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 5: Intraventricular hemorrhage (IVH, Grade I‐IV)" data-id="CD010061-fig-0063" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 5: Intraventricular hemorrhage (IVH, Grade I‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 6: Severe IVH (Grade III‐IV) " data-id="CD010061-fig-0064" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 6: Severe IVH (Grade III‐IV)  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 7: Intestinal perforation" data-id="CD010061-fig-0065" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 7: Intestinal perforation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 8: Retinopathy of prematurity requiring treatment " data-id="CD010061-fig-0066" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 8: Retinopathy of prematurity requiring treatment  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 9: Oliguria (&lt; 1 mL/kg/h)" data-id="CD010061-fig-0067" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 9: Oliguria (&lt; 1 mL/kg/h) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 10: Sepsis" data-id="CD010061-fig-0068" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 10: Sepsis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 11: Cerebral palsy (5 years' follow‐up)" data-id="CD010061-fig-0069" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 11: Cerebral palsy (5 years' follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 12: Autism spectrum disorder (5 years' follow‐up)" data-id="CD010061-fig-0070" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 12: Autism spectrum disorder (5 years' follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 13: Attention deficit hyperactivity disorder (5 years' follow‐up)" data-id="CD010061-fig-0071" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 13: Attention deficit hyperactivity disorder (5 years' follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 14: Pervasive developmental disorder (5 years' follow‐up)" data-id="CD010061-fig-0072" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention, Outcome 14: Pervasive developmental disorder (5 years' follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Early paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 1: Failure of PDA closure after first course of treatment" data-id="CD010061-fig-0073" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Early paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 1: Failure of PDA closure after first course of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Early paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 2: Failure of PDA closure after two courses of treatment" data-id="CD010061-fig-0074" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Early paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 2: Failure of PDA closure after two courses of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 1: Failure of PDA closure after one course of treatment" data-id="CD010061-fig-0075" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 1: Failure of PDA closure after one course of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 2: Surgical closure of PDA" data-id="CD010061-fig-0076" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 2: Surgical closure of PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 3: Pulmonary hemorrhage" data-id="CD010061-fig-0077" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 3: Pulmonary hemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 4: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA" data-id="CD010061-fig-0078" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 4: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 5: Necrotizing enterocolitis (NEC)" data-id="CD010061-fig-0079" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 5: Necrotizing enterocolitis (NEC) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 6: Retinopathy of prematurity requiring treatment" data-id="CD010061-fig-0080" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 6: Retinopathy of prematurity requiring treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 7: Acute kidney injury" data-id="CD010061-fig-0081" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 7: Acute kidney injury </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 8: Failure of PDA closure/non‐significant PDA after treatment" data-id="CD010061-fig-0082" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention, Outcome 8: Failure of PDA closure/non‐significant PDA after treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 1: Failure of PDA closure after first course of treatment" data-id="CD010061-fig-0083" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 1: Failure of PDA closure after first course of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 2: Failure of PDA closure after two courses of treatment" data-id="CD010061-fig-0084" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 2: Failure of PDA closure after two courses of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 3: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA" data-id="CD010061-fig-0085" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 3: Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 4: Intraventricular hemorrhage (IVH, Grade I‐IV)" data-id="CD010061-fig-0086" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 4: Intraventricular hemorrhage (IVH, Grade I‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 5: Severe IVH (Grade III‐IV)" data-id="CD010061-fig-0087" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 5: Severe IVH (Grade III‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 6: Periventricular leukomalacia" data-id="CD010061-fig-0088" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 6: Periventricular leukomalacia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 7: Necrotizing enterocolitis (NEC)" data-id="CD010061-fig-0089" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 7: Necrotizing enterocolitis (NEC) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 8: Oliguria (&lt; 1 mL/kg/h)" data-id="CD010061-fig-0090" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention, Outcome 8: Oliguria (&lt; 1 mL/kg/h) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 1: Failure of PDA closure after first course of treatment" data-id="CD010061-fig-0091" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 1: Failure of PDA closure after first course of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 2: All‐cause mortality during initial hospital stay" data-id="CD010061-fig-0092" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 2: All‐cause mortality during initial hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 3: Failure of PDA closure after two courses of treatment" data-id="CD010061-fig-0093" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 3: Failure of PDA closure after two courses of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 4: Surgical closure of PDA" data-id="CD010061-fig-0094" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 4: Surgical closure of PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 5: Intraventricular hemorrhage (IVH, Grade I‐IV)" data-id="CD010061-fig-0095" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 5: Intraventricular hemorrhage (IVH, Grade I‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 6: Severe IVH (Grade III‐IV)" data-id="CD010061-fig-0096" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 6: Severe IVH (Grade III‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 7: Necrotizing enterocolitis (NEC)" data-id="CD010061-fig-0097" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 7: Necrotizing enterocolitis (NEC) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 8: Gastrointestinal bleed" data-id="CD010061-fig-0098" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV), Outcome 8: Gastrointestinal bleed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 1: Failure of PDA closure after first course of treatment" data-id="CD010061-fig-0099" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 1: Failure of PDA closure after first course of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 2: All‐cause mortality during initial hospital stay" data-id="CD010061-fig-0100" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 2: All‐cause mortality during initial hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 3: Failure of PDA closure after two courses of treatment" data-id="CD010061-fig-0101" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 3: Failure of PDA closure after two courses of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 4: Surgical closure of PDA" data-id="CD010061-fig-0102" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 4: Surgical closure of PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 5: Intraventricular hemorrhage (IVH, Grade I‐IV)" data-id="CD010061-fig-0103" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 5: Intraventricular hemorrhage (IVH, Grade I‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 6: Severe IVH (Grade III‐IV)" data-id="CD010061-fig-0104" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 6: Severe IVH (Grade III‐IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 7: Necrotizing enterocolitis (NEC)" data-id="CD010061-fig-0105" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 7: Necrotizing enterocolitis (NEC) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010061-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/urn:x-wiley:14651858:media:CD010061:CD010061-CMP-008.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 8: Gastrointestinal bleed" data-id="CD010061-fig-0106" src="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_t/tCD010061-CMP-008.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV), Outcome 8: Gastrointestinal bleed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/media/CDSR/CD010061/image_n/nCD010061-CMP-008.08.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010061-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paracetamol versus ibuprofen for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol (oral or IV) versus ibuprofen (oral or IV) for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm or low birth weight infants with PDA<br/><b>Settings:</b> hospitals in China, Egypt, Jordan, Iran, India, Italy, and Turkey<br/><b>Intervention:</b> paracetamol<br/><b>Comparison:</b> ibuprofen </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty  of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral/IV ibuprofen</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral/IV paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(assessed by post‐treatment ECHO)<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b><br/>(0.88 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1535<br/>(18 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>299 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b><br/>(266 to 355) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality during initial hospital stay</b><br/>(by clinical assessment) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.09</b><br/>(0.80 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>734<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>166 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b><br/>(133 to 245) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Necrotizing enterocolitis</b> <b>during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> <p>(61 to 136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.30</b><br/>(0.87 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1015<br/>(10 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>For all three key critical outcomes, we downgraded the evidence by one level to moderate certainty, due to concerns regarding blinding of personnel and outcome assessment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Paracetamol versus ibuprofen for PDA in preterm or low birth weight infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010061-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Paracetamol versus indomethacin for PDA in preterm or low birth weight infants </span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol (oral or IV) versus indomethacin (IV) for PDA in preterm or low birth weight infants </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with PDA </p> <p><b>Settings:</b> neonatal intensive care unit in India, Egypt, and the USA  </p> <p><b>Intervention:</b> paracetamol </p> <p><b>Comparison:</b> indomethacin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Indomethacin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(assessed by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b> (0.78 to 1.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>380<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>297 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>303 per 1000</b><br/>(232 to 395) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> <p>(73 to 358)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> (0.39 to 1.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>93 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> </p> <p>(18 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.42</b> (0.19 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>384</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded evidence by two levels to low certainty due to concerns regarding blinding of personnel and outcome assessment, and high heterogeneity.<br/><sup>b</sup>We downgraded evidence by two levels to low certainty due to concerns regarding blinding of personnel and outcome assessment, and imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Paracetamol versus indomethacin for PDA in preterm or low birth weight infants </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010061-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prophylactic administration of paracetamol versus placebo or no intervention for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylactic administration of paracetamol (oral or IV) versus placebo (IV) or no intervention for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with PDA </p> <p><b>Settings:</b> neonatal intensive care units in Finland and Iran </p> <p><b>Intervention:</b> paracetamol </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Failure of PDA closure after first course </b> </p> <p>(assessed by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.27</b> (0.18 to 0.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>612 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>165 per 1000</b><br/>(110 to 257) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.59</b> (0.24 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>240<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b><br/>(22 to 131) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Data not available</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the evidence by two levels to low certainty due to concerns regarding selection bias, blinding of personnel, and high heterogeneity.<br/><sup>b</sup>We downgraded the evidence by two levels to low certainty due to concerns regarding selection bias, blinding of personnel, and imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prophylactic administration of paracetamol versus placebo or no intervention for PDA in preterm or low birth weight infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010061-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Early paracetamol versus placebo/no intervention for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Early paracetamol (oral or IV, &lt; 14 days postnatal age) versus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm or low birth weight infants with PDA<br/><b>Settings:</b> hospitals in Iran and Australia<br/><b>Intervention:</b> paracetamol<br/><b>Comparison:</b> placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty  of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral/IV paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.35</b> </p> <p>(0.23 TO 0.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>790 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>277 per 1000 </b> </p> <p>(182 to 419)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the evidence by two levels to low certainty due to concerns regarding selection bias, blinding of personnel and outcome assessors, and high heterogeneity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Early paracetamol versus placebo/no intervention for PDA in preterm or low birth weight infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010061-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Late paracetamol versus placebo/no intervention for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Late paracetamol (oral or IV, ≥ 14 days postnatal age) versus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm or low birth weight infants with PDA<br/><b>Settings:</b> hospital in Australia<br/><b>Intervention:</b> paracetamol<br/><b>Comparison:</b> placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty  of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo/no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oral/IV paracetamol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(assessed by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.85</b> </p> <p>(0.72 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>850 per 1000</b> </p> <p>(720 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(by radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> <p>(3 to 563)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> </p> <p>(0.07 to 15.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the evidence for both failure of PDA closure after first course of treatment and NEC by two levels to low certainty due to concerns regarding indirectness and imprecision.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Late paracetamol versus placebo/no intervention for PDA in preterm or low birth weight infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010061-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm or low birth weight infants with PDA<br/><b>Settings:</b> hospitals in Israel and Iran<br/><b>Intervention:</b> paracetamol plus ibuprofen<br/><b>Comparison:</b> ibuprofen plus placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Ibuprofen plus placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Paracetamol plus ibuprofen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure of PDA closure after first course of treatment</b> </p> <p>(assessed by post‐treatment ECHO)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> </p> <p>(134 to 425)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77</p> <p>(0.43 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause mortality during initial hospital stay</b> </p> <p>(by clinical assessment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Necrotizing enterocolitis during initial hospital stay</b> </p> <p>(radiological diagnosis)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> <p>(1 to 621)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.33</p> <p>(0.01 to 7.45)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>ECHO:</b> echocardiography; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the evidence for both failure of PDA closure after first course of treatment and NEC by two levels to low certainty due to concerns regarding selection bias, blinding of personnel, outcome assessment, and imprecision.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention for PDA in preterm or low birth weight infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/full#CD010061-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010061-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Paracetamol (oral or IV) versus ibuprofen (oral or IV)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Failure of PDA closure after first course of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.88, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Neurodevelopmental impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.44, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality during initial hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.80, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Neonatal mortality (deaths during the first 28 days of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.43, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Re‐opening of the ductus arteriosus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.85, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Failure of PDA closure after second course of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.78, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Surgical closure of the PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.34, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Duration of ventilator support (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.19, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Duration of need for supplementary oxygen (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.40 [‐22.97, ‐1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Pulmonary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.36, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Pulmonary hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.45, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Moderate to severe BPD (according to the new criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.22, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Severe BPD (according to the new criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.32, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Intraventricular hemorrhage (IVH, Grade I‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Severe IVH (Grade III‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.28, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.56, 3.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Necrotizing enterocolitis (NEC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [0.12, 67.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Gastrointestinal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.09, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Retinopathy of prematurity stage ≥ 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.12, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Retinopathy of prematurity requiring treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.48, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Oliguria (&lt; 1 mL/kg/h) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.30, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Post‐pre difference in serum or plasma levels of creatinine (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.13, ‐0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Serum levels of aspartate transaminase (AST) IU/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [‐0.16, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Post‐pre difference in serum levels of alanine aminotransferase (ALT) (IU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.00, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Serum bilirubin following treatment (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.56 [‐13.16, ‐7.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Hyperbilirubinemia (serum bilirubin level higher than the exchange level according to the postnatal age and BW) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.34, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Duration of hospitalization (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [0.34, 5.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Mental developmental index (MDI) &lt; 70 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.41, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Psychomotor developmental index (PDI) &lt; 70 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.33, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Moderate to severe cerebral palsy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.41, 10.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Deafness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Blindness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 Mental developmental index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐8.19, 7.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.37 Psychomotor developmental index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐7.44, 7.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Paracetamol (oral or IV) versus ibuprofen (oral or IV)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010061-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Paracetamol (oral or IV) versus indomethacin (oral or IV)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Failure of PDA closure after first course of treatment  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.78, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause mortality during initial hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.39, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Failure of PDA closure after second course of treatment  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.70, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Surgical closure of the PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.72, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Pulmonary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.28, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.77, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Intraventricular hemorrhage (IVH, Grade I‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.42, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 IVH (Grade III‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.28, 4.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Necrotizing enterocolitis (NEC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.19, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Gastrointestinal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.32, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Retinopathy of prematurity requiring treatment  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.58, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Acute kidney injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [0.13, 73.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Post‐pre difference in serum creatinine (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.40, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Serum bilirubin following treatment (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.13, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Paracetamol (oral or IV) versus indomethacin (oral or IV)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010061-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Failure of PDA closure after first course of prophylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.18, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 All‐cause mortality during initial hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.24, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Duration of need for supplementary oxygen (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐16.41, 11.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Intraventricular hemorrhage (IVH, Grade I‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.28, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Severe IVH (Grade III‐IV)  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.07, 16.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.02, 8.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Retinopathy of prematurity requiring treatment  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [0.14, 76.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Oliguria (&lt; 1 mL/kg/h) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.29, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.36, 5.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Cerebral palsy (5 years' follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.07, 15.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Autism spectrum disorder (5 years' follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Attention deficit hyperactivity disorder (5 years' follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.02, 8.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Pervasive developmental disorder (5 years' follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.02, 8.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Prophylactic paracetamol (oral or IV) versus placebo (IV) or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010061-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Early paracetamol (oral or IV) versus placebo (oral or IV) or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Failure of PDA closure after first course of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.23, 0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Failure of PDA closure after two courses of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Early paracetamol (oral or IV) versus placebo (oral or IV) or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010061-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Failure of PDA closure after one course of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Surgical closure of PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.13, 73.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Pulmonary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.20, 21.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.61, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Necrotizing enterocolitis (NEC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.07, 15.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Retinopathy of prematurity requiring treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [0.34, 28.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Acute kidney injury <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Failure of PDA closure/non‐significant PDA after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.29, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Late paracetamol (oral or IV) versus placebo (oral or IV) or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010061-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Failure of PDA closure after first course of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.43, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Failure of PDA closure after two courses of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.08, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Bronchopulmonary dysplasia (BPD) at 36 weeks' PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.28, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Intraventricular hemorrhage (IVH, Grade I‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.38, 4.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Severe IVH (Grade III‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.30, 7.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Necrotizing enterocolitis (NEC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Oliguria (&lt; 1 mL/kg/h) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 4.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Paracetamol plus ibuprofen (oral or IV) versus ibuprofen plus placebo (oral or IV) or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010061-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Failure of PDA closure after first course of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.00, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 All‐cause mortality during initial hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.85, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Failure of PDA closure after two courses of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.48, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Surgical closure of PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.36, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Intraventricular hemorrhage (IVH, Grade I‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.75, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Severe IVH (Grade III‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.14, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Necrotizing enterocolitis (NEC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.71, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Gastrointestinal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus ibuprofen (oral or IV)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010061-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Failure of PDA closure after first course of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.86, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 All‐cause mortality during initial hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.39, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Failure of PDA closure after two courses of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.55, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Surgical closure of PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.72, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Intraventricular hemorrhage (IVH, Grade I‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.42, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Severe IVH (Grade III‐IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.28, 4.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 Necrotizing enterocolitis (NEC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.20, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.8 Gastrointestinal bleed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.33, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis (&lt; 32 weeks' GA): paracetamol (oral or IV) versus indomethacin (oral or IV)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010061.pub5/references#CD010061-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010061.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010061-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010061-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010061-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="id#CD010061-note-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD010061-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD010061-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD010061-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD010061-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010061-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010061\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010061\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010061\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010061\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010061\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010061.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010061.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010061.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010061.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010061.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728904969"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010061.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728904972"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010061.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecfdcfe2a9368',t:'MTc0MDcyODkwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 